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ABSTRACT 
Respiratory syncytial virus (RSV) is a negative-strand RNA virus that causes significant 
pneumonia-related morbidity and mortality worldwide. There are currently neither 
vaccines nor effective therapies for RSV. As with other viruses, RSV mRNAs are 
translated using host-cell machinery, rendering the virus subject to cellular factors that 
regulate mRNA homeostasis. Stress granules (SGs) and processing bodies (p-bodies) 
are inter-dependent, stress-response cytoplasmic structures involved in mRNA triage 
and degradation, respectively. We hypothesized that RSV has evolved to manipulate 
cellular stress responses in order to facilitate optimal virus propagation. While wild-type 
(wt) RSV induced SGs in approximately 1% of infected cells, a mutant version of RSV 
whose Tr region was replaced with an inverted LeC sequence (LeC virus) induced SG 
formation in approximately 50% to 70% of infected cells. A 12U to A substitution relative 
to the 5' end of the LeC virus abrogated SG induction. Mixed-infection studies showed 
vii 
that wt RSV was able to prevent LeG-mediated SG induction. Unlike Sendai virus, RSV-
mediated prevention of SG formation was independent of SG-associated t-cell 
intracellular antigen related (TIAR) protein. RSV infection altered neither the number nor 
distribution of p-bodies; however, p-body-associated decapping protein 1 (dcp1) was 
phosphorylated throughout RSV infection via the extracellular signal-regulated kinase 
(ERK) 1/2 pathway. RSV-mediated dcp1 phosphorylation was limited to serine 315, 
serine 319, and threonine 321. Dcp1 phosphorylation occurred in response to some, but 
not all , environmental stresses, and dcp1 was not phosphorylated during infection with 
HIV-1, measles, mumps, or canine distemper virus. Overexpression of dcp1 significantly 
attenuated RSV cytopathic effects, and preliminary data suggested that dcp1 
phosphorylation regulated RSV-induced interleukin-8 production. Finally, an antibody 
toward cellular SG- and p-body-associated , RNA-binding protein p54 was able to 
recognize a subset of RSV nucleoprotein (N). p54 and RSV N contain a similar amino 
acid sequence motif, suggesting that they may have similar or competing activities that 
are important during RSV replication. Taken together, our results demonstrate that RSV 
can manipulate cellular RNA-processing structures and proteins to facilitate viral 
propagation. 
viii 
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Introduction 
Respiratory syncytial virus 
Overview 
Respiratory syncytial virus (RSV) is a member of the family Paramyxovirus and the order 
Mononegavirales. RSV shares many genome, structure, and replication-strategy 
similarities with viruses within the same order, including measles, mumps, Sendai, 
Nipah, Ebola, Marburg, rabies, and vesicular stomatitis (VSV) viruses (263). It is hoped 
that studying the mechanisms by which RSV interacts with host cells will broaden our 
understanding of not only RSV, but also of related viruses. 
RSV epidemiology 
RSV is one of the leading causes of pneumonia-related deaths in infants, the elderly, 
and immune-compromised persons worldwide. It is estimated that over 120,000 infants 
in the United States are hospitalized annually with RSV infection, accounting for 
approximately 25% of pediatric pneumonia and up to 70% of pediatric bronchiolitis 
hospitalizations (262). The global burden of RSV is approximately 64 million cases and 
160,000 deaths per year (3). Unfortunately, there are currently neither vaccines nor 
effective treatments for the virus. 
RSV morphology 
RSV virions can acquire one of two forms: irregular spheres or long filaments. The 
virions are comprised of a nucleocapsid that is packaged in a lipid envelope, which is 
acquired from the cell membrane during virus budding. The envelope has three 
glycoproteins: the attachment glycoprotein (G), the fusion protein (F), and the short, 
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hydrophobic protein (SH). The matrix protein (M) is believed to form a layer on the inner 
surface of the virion . The viral genome is associated with four proteins: the large 
polymerase subunit (L) , nucleoprotein (N) , phosphoprotein (P), and transcription 
processivity factor (M2-1). 
RSV replication cycle 
RSV enters host cells by fusing with the plasma membrane. The virus genome is 
released into the cytoplasm where it undergoes transcription to make viral mRNAs and 
replication to make antigenome and genome using the virus-encoded RNA-dependent, 
RNA polymerase. Viral mRNAs are translated using host-cell machinery, and virus 
particles are packaged and released by budding at the plasma membrane (Figure 1 ). 
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Figure 1. Overview of RSV replication. RSV enters host cells by fusing with the 
plasma membrane, a process mediated by envelope glycoproteins (red circles) . The 
virus genome is released into the cytoplasm where it undergoes transcription to make 
viral mRNAs, which are capped (yellow circles) and polyadenylated (A's), and replication 
to make antigenome and genome, which are encapsidated by the RSV N protein (small 
blue circles) as they are synthesized. Transcription and replication are carried out by the 
virus-encoded RNA-dependent, RNA polymerase (purple ovals), which associates with 
nucleocapsids. Viral mRNAs are translated using host-cell machinery, and virus 
particles are packaged and released by budding at the plasma membrane. 
3 
There are eleven RSV proteins, whose roles in the RSV replication cycle are described 
in Table 1. 
Table 1. RSV proteins and functions 
Apparent 
Protein Molecular Primary Function(s) 
Weight (kDa) 
Binds tightly to RSV genome and 
antigenome as they are being 
Nucleoprotein (N) 45 synthesized to protect from cellular 
nucleases; may be part of polymerase 
complex 
Major phosphoprotein; part of the 
polymerase complex; also forms 
complex with free N to maintain N 
solubility and availability for 
Phosphoprotein 
33 nucleocapsid assembly; 
(P) 
phosphorylation associated with 
polymerase stabilization on the 
template; P association with M2-1 is 
essential for M2-1 function 
M2 ORF 1 Part of the polymerase complex; 
22 
protein (M2-1) essential RSV transcription factor that 
4 
promotes transcription processivity 
RNA-dependent, RNA polymerase; 
contains an active site for 
Large (L) 250 
polymerization, and active sites for 
mRNA capping 
Internal virus component that 
accumulates at the plasma membrane 
Matrix (M) 25 of host cells; important for viron 
morphogenesis and RNA synthesis 
regulation 
Type-1 transmembrane envelope 
50-70* 
glycoprotein that directs viral entry into 
(F1) 
host cells by mediating fusion between 
1 0-16* 
the viral envelope and plasma 
(F2) 
membrane; can mediate fusion with 
Fusion (F) 
neighboring cells to form syncytia, 
*differences due 
synthesized as inactive precursor (F0) 
to variable 
that is activated by cleavage that 
glycosylation 
yields two disulfied-inked subunits (F1 
and F2) plus a 27-nucleotide fragment. 
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Type-11 transmembrane, envelope 
glycoprotein; major virus attachment 
factor that binds host-cell membranes 
Glycoprotein (G) 90 
(receptor unknown); smaller, secreted 
form mimics the chemokine fractalkine 
to impair immune activation 
Envelope protein with unknown 
function, although there is evidence 
Small 
7.5- 60 that it helps form an ion channel of 
hydrophobic (SH) 
unknown significance; reported to 
inhibit TNF-a signaling 
Nonessential accessory protein with 
M2 ORF2 protein unknown function(s); may play role in 
14.5 
(M2-2) shifting balance of RNA synthesis from 
transcription to replication 
Nonstructural protein; inhibits IFN-a/(3 
Nonstructural-1 induction by inhibiting phosphorylation 
13.8 
(NS1) of interferon-regulatory factor 3 (IRF-
3). 
Nonstructural protein; inhibits IFN-a/(3 
induction by inhibiting phosphorylation 
Nonstructural-2 
14.5 of interferon-regulatory factor 3 (IRF-
(NS2) 
3); may target STAT2 for proteasome-
mediated degradation 
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Cell entry 
Cell entry is facilitated by RSV attachment to and fusion with the plasma membrane by 
the RSV glycoprotein (G) and fusion (F) proteins. Unlike other negative-strand viruses, 
G is not a strict requirement for cell entry; however, viral fitness in vivo is impaired in 
mutants lacking G (246). Initial interactions with host cells are thought to occur first via 
weak-affinity binding ofF and G proteins to glycosaminoglycans (GAGs) (99) on the host 
cell surface, followed by a higher-affinity binding step; however, the host-cell receptor(s) 
for the second, higher-affinity attachment step have not been identified. The virus 
penetrates the cell by fusion of the envelope with the host-cell plasma membrane, which 
is mediated by the F protein. 
Transcription and replication 
Once cell entry has occurred, the RSV genome is uncoated and transcription and 
replication are initiated. RSV's 15.2 kb genome is comprised of a single strand of non-
segmented, negative-sense RNA that is tightly associated with virus nucleoprotein (N) in 
a helical nucleocapsid structure (148, 245). The ten RSV genes encode eleven proteins 
(M2-2 via an alternate translation start site in the M2 mRNA) and are flanked with 
transcription gene-start and gene-end sequences (56). As discussed in further detail in 
Chapter 1, the RSV genome includes two extragenic sequences termed leader (Le) and 
trailer (Tr) at the 3' and 5' termini, respectively. Le contains the promoter for both 
transcription of monocistronic mRNAs and for replication to produce the antigenome, 
while TrC (at the 3' end of the antigenome) contains the promoter for replication to 
produce the genome (Figure 2). 
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Figure 2. Schematic diagram of the RSV genome. Green boxes represent genes; 
white boxes represent gene-start signals, and black boxes represent gene-end signals. 
The lines at the 3' terminus, the 5' terminus, and intergenic regions represent putative 
noncoding sequences. The mRNAs are shown as lines that are capped (red circles) and 
polyadenylated (blue triangles). The replication-intermediate antigenome is shown as 
grey boxes. The red arrows indicate the direction of polymerase procession. 
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RSV RNA replication is dependent on the first 36 nts of the Le sequence. Nucleotides 
1-11 recruit the viral polymerase to the template and signal RNA synthesis initiation, 
while nucleotides 12-36 increase transcript-encapsidation efficiency and promote the 
generation of full-length replication products (62, 63, 157). Genome transcription is 
dependent on Le-sequence nucleotides 1-11 and 37-44, in addition to the adjacent 
gene-start signal of the first gene. These sequences are important for the initiation of 
RNA transcription to produce viral monocistronic mRNAs, and replication to produce 
antigenome (60, 162). Initially, more transcription occurs than replication. As with other 
negative-strand viruses, a transcription gradient is established, with genes at the 3' end 
being transcribed in the greatest quantities due to the polymerase falling off the template 
and differences in gene-end signal efficiency (176). RSV mRNA synthesis reaches a 
plateau at around 12-18 hours after infection (29). Some researchers theorize that M2-2 
might affect the shift from transcription to replication (29). As antigenome and genome 
are produced, they are encapsidated with N protein, a process that protects the RNA 
from nucleases and is associated with increased polymerase processivity (157). 
Next, the virus is assembled and packaged at the apical surface of polarized cells (203). 
Both actin (41) and tubulin (110) have demonstrated roles in RSV assembly and release. 
Virus is released by budding from the plasma membrane, a process that appears to be 
the reverse of cell entry (24) and requires the proteolytic activation of the F protein (14). 
RSV pathogenesis and immune-system interactions 
Humans are the only reservoirs for human RSV infection. The virus is spread primarily 
through large droplets from respiratory secretions; however, it is possible that the virus 
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can also be spread by fomites (98). The prodromal period from infection to onset of 
symptoms is approximately four to five days (111). RSV causes b(onchiolitis in infants, 
during which necrosis of bronchiolar epithelial tissue and destruction of ciliated cells 
occurs (3, 183). Inflammatory responses cause a massive influx of immune cells to the 
airways, which results in edema in submucosal tissues, as well as excessive mucus 
production. Not surprisingly, immune-cell infiltratrion, excess fluids, mucus, and cellular 
debri can obstruct the bronchioles and alveoli , causing emphysema or the collapse of 
the airways. This is particularly dangerous in infants, whose bronchiole diameter is very 
small. 
RSVtropism 
RSV primarily infects the airway and lungs, with replication taking place in the superficial 
layer of respiratory epithelial cells. The virus is shed into the lumen from the apical 
surface of the cells. Infection is generally limited to ciliated cells at the luminal face 
(275). RSV can also infect many other cell types; however, infection is generally limited 
in non-epithelial cells. RSV infection in alveolar macrophages induces significant TNF-a, 
IL-8, and IL-6 production (26); however, infection of these cells results in drastically 
reduced virus production compared to infection of epithelial cells, and appears to be 
confined to initially-infected alveolar macrophages (i.e. no cell-to-cell spread) (27). RSV 
infection of monocyte-derived dendritic cells results in suppressed T-cell proliferation 
and cytokine production (70) through unknown mechanisms. 
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Immune responses to RSV 
Both humoral and cellular immunity are important for RSV clearance and illness 
recovery. An underlying theme in RSV biology is that most aspects of the immune 
response that are beneficial in resolving RSV infection also contribute to disease 
development and pathogenesis. For example, decreased virus shedding in respiratory 
secretions is significantly associated with the appearance of RSV-specific lgA antibodies 
in patients with RSV disease (159), and the fact that fetuses do not begin to acquire 
significant levels of transplacental lgG antibodies until around 26-32 weeks of gestation 
likely helps explain why preterm infants are at increased risk for RSV infection. 
However, maternal antibodies have also been shown to suppress humoral immunity via 
unknown mechanisms (64). Th1 and Th2 CD4+ lymphocytes also are involved in RSV 
clearance from infected persons, and it is believed that the balance of these responses 
may play a role in determining whether cell-mediated immunity is protective against RSV 
disease or whether it exacerbates pathology of the virus. Th2 cytokines IL-5 and IL-13 
are associated with hyper-responsiveness and airway eosinophilia in mouse models 
(1 07, 216). On the other hand, overexpression of Th2-cytokine IL-4 suppressed immune 
responses to RSV infection (22) and Th1-cytokine IL-12 has been shown to enhance 
cell-mediated immunity to RSV (244). Mouse models indicate that RSV G protein elicits 
a Th2-biased response, while RSV F protein elicits a Th1-biased response (13); 
however it is unclear if these findings are relevant in the context of infection with whole 
virus in human systems. These results suggest that the balance ofTh1 and Th2 
immune responses could influence disease outcome. RSV-specific CDS+ cytotoxic T-
lymphocytes (CTLs) are generally believed to be important for virus clearance from 
airways (188); however, as with other immune mediators, an equilibrium seems to exist 
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that determines whether the cells contribute to exacerbated disease. Studies in mice 
show that adoptively transferred CTLs are able to improve RSV clearance from airways, 
but that the clearance is associated with severe (and often fatal) pulmonary disease 
(42). Taken together, these studies suggest that there is a delicate balance needed 
among immune mediators in resolving infection without exacerbating pathogenesis. 
Toll-like receptors 
Several Toll-like receptors (TLRs) are known to be activated by RSV infection. RSV F 
protein has been shown to bind TLR4 I CD14, and infection of TLR4-deficient mice 
demonstrated that TLR4-mediated immune responses are important for clearing virus 
from lungs (128). Two single nucleotide polymorphisms in the TLR4 gene have been 
linked to increased susceptibility to RSV infection ih children (23). In addition, RSV 
signals through TLR3 late in infection to induce cytokine and chemokine production . 
Production of CXCL 10 and CCL5 were linked to TLR3 activation. On the other hand, 
IRF3 was dispensable for CXCL8 production, which was dependent on myeloid 
differentiation primary response gene 88 (MyD88)/TLR4 signaling (204). RSV has been 
shown to activate TLR2 and TLR6 in mice (178) via unknown mechanisms. 
Surfactants 
Several studies have implicated a role for pulmonary surfactant proteins in limiting RSV 
infection. Researchers have shown that surfactant A binds RSV F protein to reduce RSV 
infectivity (91 ). RSV disease was more severe in mice with disrupted surfactant proteins 
(138), and reduced surfactant concentration and function has been correlated with 
severe disease in infants (117). Recent studies have shown that RSV decreases 
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surfactant levels in by interfering with surfactant mRNA translation (38). These findings 
suggest that surfactant proteins may be important in host-cell defenses against RSV. 
Inflammation 
As discussed above, inflammation during RSV infection can contribute to disease 
pathogenesis, particularly when bronchioles and airways become clogged with cells , 
debri, and fluids . RSV infection induces several chemokines, including RANTES, MIP-
1 a, Ml P-113, I L-8, and fractal kine (276), which recruit large numbers of immune cells to 
the sites of infection. IL-8 recruits neutrophils, which are the dominant cells found in the 
bronchial lavage and nasopharyngeal secretions of infants hospitalized for RSV disease 
(79). Neutrophils are important for RSV clearance, but they also cause cell damage 
(152, 259), and granulocytes recruited to. airways can directly mediate the destruction of 
infected cells (259). 
RSV immunomodulation 
RSV has co-evolved with host-cell immune mediators. Not surprisingly, the virus is able 
to subvert and manipulate several aspects of the immune system. RSV F protein binds 
TLR4/ CD14 complexes, and thereby may alter trafficking , activation, and function of 
mononuclear cells (97). In addition, RSV has been shown to reduce interferon (IFN)-a 
production by plasmacytoid dendritic cells (214). As mentioned above, soluble RSV G 
protein mimics the chemokine fractalkine (251), and NS1 and NS2 proteins have been 
shown to inhibit interferon responses (58, 234, 250). 
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RNA granules 
Eukaryotic cells display several types of nuclear and cytoplasmic granules containing 
mRNAs in ribonuceloprotein complexes (mRNPs). These granules have roles in mRNA 
triage, regulation, processing, storage, and turnover (202). Two inter-related cytoplamic 
mRNP-aggregate structures, stress granules and processing bodies (p-bodies), are 
highly conserved from yeast to mammals and have been implicated in host innate 
immune responses that are important during viral infections (15, 89, 118, 121, 122, 155, 
205, 213). 
Stress granules 
Stress granules form in cells during environmental stress, including heat shock, 
endoplasmic reticulum (ER) stress, oxidative stress, nutrient deprivation, dehydration, 
cell crowding, and certain types of viral infections (16, 17, 113, 202). They contain 
stalled translation complexes (including translation factors, ribosome subunits, and 
mRNA), and are thought to be sites of mRNA storage and triage (16, 17, 113). The 
following figure shows a comparison of untreated cells with cells treated with sodium 
arsenite, which induces oxidative damage and stress granule formation. The cells are 
stained with an antibody toward eiF3, a stress-granule marker (red). In untreated cells 
(left panel), the eiF3 is diffuse in the cytoplasm. In arsenite-treated cells (right panel) , 
eiF3 has a punctate distribution characteristic of stress-granule formation. Stress 
granules are discussed in further detail in Chapter 1. 
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untreated treated with arsenite 
Figure 3. Cytoplasmic stress granules. HEp-2 cells were untreated (left) or treated 
with sodium arsenite (right). The cells were immunostained for cellular eiF3, which 
condenses into cytoplasmic aggregates called stress granules during environmental 
stress. 
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Processing bodies 
Unlike stress granules, p-bodies are constitutively present in cells. They are sites of 
mRNA degradation, and contain mRNAs, decapping enzymes, and exonucleases. P-
bodies become larger and more numerous during stress conditions. The following 
pictures shows cells under steady-state conditions. The cells are stably transfected with 
red fluorescent protein (RFP)-tagged decapping protein 1 (dcp1 ), which is a protein 
found in p-bodies (red), and stained with DAPI to visualize the nuclei (blue) . P-bodies 
are discussed in further detail in Chapter 2. 
Figure 4. Cytoplasmic processing bodies. U20S cells stably expressing RFP-tagged 
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dcp1 (red) were stained with DAPI to visualize nuclei (blue). Dcp1 is concentrated in p-
bodies. 
Stress granule and p-body associations 
Stress granules and p-bodies are linked both functionally and spatially. Studies have 
demonstrated that during stress, there is an equilibrium among mRNAs undergoing 
active translation on free polysomes, translationally silent mRNAs in stress granules, 
and mRNAs undergoing degradation in p-bodies (48, 67, 169, 222) . Stress granules are 
theorized to be intermediaries between mRNA translation and decay, and studies have 
shown that they can release mRNAs for resumed translation on polysomes (170) and 
they frequently form transient physical interactions with p-bodies whereby they may be 
able to exchange constituents (48, 115). Kedersha et al. proposed a model in which 
mRNA that is released from disrupted polysomes is sorted and remodeled in stress 
granules, and select transcripts are delivered to p-bodies for degradation (113, 115). 
This model is supported by evidence that the composition of both structures is highly 
dynamic, with rapid turnover of both proteins and mRNAs (115), as well as evidence that 
stress granules and p-bodies may exchange proteins and mRNAs (39, 115). 
Stress granule and p-body implications in virus biology 
While the activities of stress granules and p-bodies have not been extensively 
characterized , both structures are associated with stalled translation- a condition that 
could prove deleterious to viruses dependent on host-cell machinery for their own 
translation. An emerging theme in the field of viral pathogenesis is the idea that cellular 
stress responses are involved in antiviral strategies; either by modulating viral RNA 
levels and/or regulating expression of proteins involved in the innate immune response. 
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This idea is given credence by a rapidly growing list of viruses that are able to subvert or 
manipulate RNA granule formation and/or activities as discussed in detail in Chapters 1 
and 2, in addition to reports that stress responses can post-transcriptionally regulate 
cytokine production (15, 206). 
Hypothesis 
At the time this dissertation project commenced, very little was known about virus 
interactions with stress granules and p-bodies, and nothing had been reported with 
regard to RSV and these RNA-processing structures. We wished to investigate the 
. relationships among RSV and stress granules, p-bodies, and their associated proteins. 
We hypothesized that RSV has evolved to manipulate stress responses in order to 
facilitate optimal virus propagation, and that cellular stress granules and p-bodies 
are part of a host antiviral response. We sought to determine whether i) RSV 
infection altered the distribution of stress granules or p-bodies, ii) RSV infection resulted 
in altered stress granule- or p-body-associated proteins, and iii) what impact such 
alterations had on RSV biology. 
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Materials and Methods 
Buffers and reagents 
General buffers and reagents 
Phosphate-buffered saline (PBS): provided as powder (Sigma), dissolved in 1 L 
deionized (DI) H20 to yield 0.01 M phosphate buffered saline (0.138 M NaCI; 0.0027 M 
KCI); pH 7.4, at 25 °C. 
Tris-buffered saline (TBS): provided as powder (Sigma), dissolved in Dl H20 to yield 
0.05 M Tris buffered saline (NaCI- 0.138 M; KCI- 0.0027 M); pH 8.0, at 25 °C. 
RIPA buffer. 1X solution acquired from Boston Bioproducts. 50 mM Tris-HCL, pH 7.4, 
150 mM NaCL, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS. 
Cell culture buffers and reagents 
Opti-MEM (Invitrogen) 
Kaighn's Modification of Ham's F-12 Medium (F-12K) (ATCC) 
Dulbecco's Modified Eagle's Medium (DMEM) containing high glucose: 4.5 g/L D-
glucose and L-glutamine (GIBCO-Invitrogen catalog #11965-092) 
Glasgow Minimum Essential Medium (GMEM) (Invitrogen) 
RPMI1640 medium containing L-glutamine (GIBCO-Invitrogen) 
Fetal Bovine Serum (FBS) Qualified (GIBCO- Invitrogen); thawed at 3rC, heat 
inactivated for 30 min at 56°C; 25 ml aliquots stored at -20°C. 
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Newborn Calf Serum (NCS) heat inactivated (GIBCO- Invitrogen); thawed at 3rC, 50 ml 
aliquots stored at -20°C. 
Penicillin-Streptomycin-L-glutamine (PS/G), 100x (GIBCO-Invitrogen); 5 ml added per 
500 ml of media for a final concentration of 1 OOU/ml penicillin, 100 f.lg/ml streptomycin, 
and 0.29 mg/ml L-glutamine; 5 ml aliquots PS/G stored at -20°C. 
Phosphate-buffered saline (PBS) pH 7.4 (GIBCO-Invitrogen) 
Hank's balanced salt solution (HBSS) (GIBCO-Invitrogen) 
0.25% Trypsin , 1x (GIBCO-Invitrogen catalog) 
Dimethyl sulphoxide (DMSO) (Sigma-Aldrich) 
Fico/1-Paque PLUS (GE Healthcare) 
Hygomycin B solution (GIBCO-Invitrogen); 50 mg/ml in PBS stored at 4°C 
Gentamycin sulfate (G418) (GIBCO-Invitrogen): reconstituted in water to 500 mg/ml. 
Sterile filtered through 0.2 f.lm syringe filter. Aliquoted and stored at -20°C. 
Puromycin (Sigma-Aldrich): reconstituted in water to 100 f.lg/ml. Sterile filtered through 
0.2 f.lm syringe filter. Aliquoted and stored at -20°C. 
Northern blot buffers and reagents 
1.5% agarose gel: Gels were made by dissolving 1.5 g agarose (Sigma) in 86.5 ml Dl 
H20 and then immediately adding 10 mi10X 3-(N-morpholino)propanesulfonic acid 
(MOPS) buffer and 3.6 ml 36.7% formaldehyde. 
Running buffer. Made by diluting 1 OX MOPS buffer (Sigma) with Dl H20. 
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Loading buffer. 50% glycerol, 1mM EDTA, and bromophenol blue tracking dye. 
Transfer buffer. 175.32 g Nael, 4 mi2M NaOH, Dl H20 to 1 L, filter sterilized . 
Neutralization buffer: 6X saline-sodium citrate (SSe), diluted in Dl H20 from 20X SSe 
(American Bioanalytical). 
Prehybridization buffer. Used 20 ml/ membrane. For 20 ml, added 6 ml 20X SSe, 0.8 
ml 2X Denhart's reagent (diluted from SOX solution provided by Sigma), 0.2 ml10% 
SDS, and 13 ml Dl H20. 
Wash buffer. 2X SSe, 0.1% SDS. For 250 ml, add 25 ml 20X SSe and 2.5 ml 10% 
SDS to 222.5 ml Dl H20. 
Stringent wash buffer. 0.1X SSe, 0.1% SDS. For 150 ml, added 0.75 mi20X SSe, 1.5 
ml10% SDS to 146.75 ml Dl H20. 
Film. Kodak BioMax MR 8" by 10". 
Immunofluorescence buffers and reagents 
~ 
Fixative: 5% formaldehyde with 2% sucrose in PBS. 
Permeablilization buffer. 0.5% IGEPAL with 10% sucrose in PBS. 
Wash buffer. 2% FBS in PBS. 
Antibody diluent: 2% FBS in PBS. 
Western blot buffers and reagents 
Loading buffer. 2X Laemmli sample buffer (BioRad) with dithiothreitol (OTT) added to a 
final concentration of 0.1 M immediately before use. 
21 
Molecular-weight markers: Thermo Scientific* PageRuler* Plus Prestained Protein 
Ladder 10-250kDa (Fisher) (chemiluminescence) or Odyssey Protein Molecular Weight 
Marker (1 0-250 kDa) (0.5 mL) (Licor) 
10% polyacrylamide gel: For 10 ml (2 gels), 2.82 ml H20, 3.75 ml1 M Tris buffer pH 8.8, 
100 1JI10% SDS, 3.33 ml 30% (w/v) acrylamide (37.5:1) 0.8% bis-acrylamide (National 
Diagnostics), 50 IJI 10% ammonium persulfate (APS), and 10 IJI 1 ,2-
Bis(dimethylamino)ethane; N,N,N',N'-Tetramethyl-1 ,2-diaminoethane (TEMED). 
4% polyacrylamide stacking gel: For 10 ml (4 gels): 7.3 ml H20, 1.25 ml 1 M Tris buffer 
pH 6.8, 100 1JI10% SDS, 1.33 ml% (w/v) acrylamide (37.5:1) 0.8% bis-acrylamide 
(National Diagnostics), 50 IJI 10% APS, and 10 IJI TEMED. 
Precast gels: 10%, 12-well Mini-Protean SOX precast gels were acquired from Biorad 
(catalog #456-1035) . 
10X running buffer. For 1 L, 30.3 g Trizma base (Sigma) , 144 g glycine (Sigma) , 10 g 
sodium dodecyl sulfate (SDS) (Sigma), add ultra-pure H20 up to 1 L. Dilute 1 Ox buffer to 
make 1x buffer in ultra-pure H20 . 
25X transfer buffer. For 500 ml, add 18.2 g Trizma base (Sigma) and 90 g glycine 
(Sigma) and add ultra-pure H20 up to 500 mi. Let dissolve overnight. To make 1X 
transfer buffer, 10 ml 25X transfer buffer was diluted in 50 ml methanol (Sigma) with 
ultra-pure H20 up to 250 mi. 
Mason fractionation buffers and reagents 
Tris-acetate buffer. 50 mM tris-acetate pH 8, 100 mM K-acetate , 1 mM OTT (added 
immediately before use), 1 mM ATP (added immediately before use). 
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Triton X-100 buffer. 10 mM tris-acetate pH 8.0, 10 mM K-acetate, 1.5 mM MgCb, and 
0.1% triton X-1 00. 
DOC-Tween 40 buffer. 10 mM tris-acetate pH 8.0, 10 mM K-acetate, 1.5 mM MgCI2 , 
0.1% triton X-100, 0.5% deoxycholate (DOC), and 1% Tween 40. 
Multinuclear activation of a galactosidase indicator (MAGI) assay buffers and 
reagents 
MAGI fixative (500 ml): 1% formaldehyde/0.2% glutaraldehyde (13.5 ml 37% 
formaldehyde/4 ml gluteraldehyde/1 x PBS); stored in a glass bottle wrapped in 
aluminum foil at 4°C. 
5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside (X- gal) (EM Science catalog #9660); 
400 mg of X-gal was reconstituted in DMSO to 40 mg/ml and stored in 1 ml aliquots at -
20°C. 
MAGI staining solution (for every 1 ml), 950 J.!l PBS/20 J.!l 0.2M potassium 
ferrocyanide/20 J.!l 0.2M potassium ferricyanide/1 J.LI 2M MgCb/1 0 J.!l 40mg/ml X-gal. 
Cell lines 
HEp-2 cells (ATCC) were cultured in Opti-MEM with 2% FBS (GIBCO-Invitrogen). WT 
(TIAR +/+)and TIAR knockout (TIAR -/-)mouse embryonic fibroblast lines were a 
generous gift from Dr. Paul Anderson and have been described previously (140) . They 
were cultured in DMEM supplemented with 10% FBS. A549 cells (ATCC) were cultured 
in F-12K media supplemented with 10% FBS. Human embryonic kidney (HEK) 293T 
cells (ATCC #CRL-11268) were grown in complete DMEM High Glucose(+ 4.5 g/L D-
glucose, + L-glutamine) supplemented with 10% FBS, 100 U/ml penicillin (GIBCO-
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Invitrogen), 100 f.lg/ml streptomycin (GIBCO-Invitrogen), and 0.29 mg/ml L-glutamine 
(GIBCO-Invitrogen). The Hela (human cervical cancer) cell clone MAGI-CCR5 
(obtained from the AIDS Research and Reference Reagent Program), which has been 
engineered to express high levels of human CD4, CXCR4, CCR5, and multiple copies of 
integrated HIV-L TR-[3-gal reporter constructs driving the expression of [3-galactosidase 
([3-gal) that has been modified with a nuclear localization signal at its N-terminus (123, 
256) were propagated in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 
j.Jg/ml streptomycin, 500 j.Jg/ml G418, 1 j.Jg/ml puromycin, and 0.1 j.Jg/ml hygromycin B. 
All cells were incubated at 3rC with 5% C02. 
Isolation and culture of primary MOMs 
Human peripheral blood mononuclear cells (PBMCs) were isolated from commercially 
prepared leukopacks (New York Biologies Inc.) by Ficoii-Paque Plus (Amersham 
Biosciences) density gradient centrifugation. Peripheral blood was diluted with an equal 
volume of HBSS and 30 ml was overlayed onto 15 ml of Ficoii-Paque Plus in 50-ml 
conical tubes. The gradients were centrifuged at 400 x g for 30 minutes at room 
temperature (rt) with the centrifuge break turned off. PBMCs, appearing as a dense, 
white band above the red blood cell and granulocyte layer, were collected with a pipette, 
washed three times with 50 ml phosphate buffered saline (PBS) interspersed with 
centrifugation to pellet cells (5 min each at 300 x g) in order to remove residual Ficoii-
Paque Plus, platelets, and red blood cells. PBMCs were used immediately for CD14+ 
monocyte isolation. Primary CD14+ monocytes were isolated from PBMCs using mouse 
anti-human CD14 monoclonal antibody (mAb)-conjugated magnetic beads and LS 
MAGS cell separation columns (Miltenyi Biotec) according to the manufacturer's 
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protocol. C014+ monocytes (6 x 105 cells/well in 12-well plates) were cultured in serum-
free RPM I for 30 min to allow monocytes to adhere to tissue-culture plastic. Serum-free 
medium containing non-adherent cells was removed by aspiration and fresh RPMI 
supplemented with 10% normal human AB serum, 10% FBS, 100 U/ml penicillin, 100 
f.lg/ml streptomycin, and 0.29 mg/ml L-glutamine was added to the cells. Monocytes 
were cultured for a period of eight days, during which they differentiated into MOMs. 
MOM phenotype was confirmed by flow cytometry. 
RSV stocks 
Wild-type (wt) RSV was strain A2, and all mutant viruses were based on this strain. To 
propagate virus, -80% confluent HEp-2 cells in 150 cm2 flasks were infected with RSV 
at a low multiplicity of infection (moi) of 0.01 in 10 ml Opti-MEM + 2% FBS. One to four 
hours post infection (pi), media was replaced with 20 ml fresh media. Media was 
changed every 36-48 hours. Once extensive syncytia formation was observed 
(approximately 3 days post infection for wt, Tr36, and 12 U/A viruses, and approximately 
five to six days post infection for LeC virus}, cells and supernatant were collected in 50-
ml conical tubes. Cell suspension was vortexed for ten seconds, sonicated for 30 
seconds, vortexed again for 10 seconds, and sonicated again for 30 seconds. Cell 
suspension was subjected to centrifugation at 300 x gat 4°C for 5 minutes. Supernatant 
was collected, aliquoted into sterile cryovial tubes, flash frozen in dry ice, and stored at -
80°C. To sucrose purify RSV, the virus suspension was pelleted through 30% sucrose 
onto a 60% sucrose cushion (sucrose w/v in 10 mM Tris, pH 8.1) by centrifugation at 
24,000 x g for 1 h at 4 oc. The white band at the 60/30% sucrose interface was 
collected, diluted approximately 1:10 in OptiMem supplemented with 50 mM HEPES 
and 100 mM MGS04 * 7H20, aliquoted, flash frozen in dry ice, and stored at -80 °C. 
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UV-inactivated virus was generated by exposing virus in 6-well plates to 200 J/m2, 
approximately 15 em from light source. 
Plasm ids 
cDNAs encoding the RSV antigenome were constructed using plasm ids that have been 
described in detail previously; the RSV/6120 eDNA includes a mutation in the SH gene 
that increases plasmid DNA stability without altering the protein coding region (40, 57, 
109, 247). To facilitate manipulation of the RSV Tr region, single nt substitutions were 
made 10, 13 and 14 nts after the last U residue of the L gene end signal to introduce a 
BsiWI site. The Tr region was mutated by introducing PCR products, representing either 
the 5' terminal 57 or 36 nts of Tr, or the 44 nt LeC sequence between the BsiWI site and 
a delta ribozyme. All full-length clones were examined by multiple restriction digests to 
confirm their integrity, and the regions subjected to PCR amplification were sequenced 
to confirm that no spurious mutations had arisen. The plasmid pBru~Envluc2 is a 
single-round replication competent clone of pBru3ori (HIV-1) which contains a deletion in 
the env gene and luciferase in the nef ORF (272). The plasmid pHEF-VSV-G encodes 
for the envelope glycoprotein from vesicular stomatitis virus (VSV) (47). Plasmids 
expressing the minigenomes used in this study were based on the MP28 minigenome, 
described by Fearns et al. previously (82), and were designed to express the 
chloramphenicol acetyltransferase open reading frame (ORF) flanked by the following 3' 
cis-acting sequences: 1) RSV leader (Le) nucleotides 1-36, 2) RSV trailer complement 
(TrC) nucleotides 1-36, 3) RSV TrC nucleotides 1-57, or 4) RSV full-length TrC. All 
minigenomes were flanked with the 36 5'-terminal Tr-region nucleotides on the 5' end of 
the minigenome. pTM1 plasmids encoding RSV N, RSVP, RSV L, and RSV M2-1 
under transcriptional control of the promoter for the T7 RNA polymerase have been 
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described previously (95). We acquired a myc-DDK-tagged open reading frame (ORF) 
DNA clone of homo sapiens dcp1 a (accession number NM_018403) under the control of 
the pCMV6 promoter from Origene (RC201330). 
RSV mutant virus rescue and growth 
The recombinant viruses were rescued as described previously (57). Briefly, HEp-2 
cells in 6-well plates were transfected with a mixture ofT? expression plasm ids 
containing the RSV N, P, L, and M2-1 ORFs and a fifth T?-expression plasmid encoding 
the appropriate RSV antigenome. The cells were co-infected with the MVA strain of 
vaccinia virus expressing T? RNA polymerase (269) and incubated in a C02 incubator at 
32 °C. Three days post-transfection, cells were scraped into the medium, vortexed, 
sonicated, and then pelleted by centrifugation. The supernatant was passaged onto 
fresh HEp-2 cells in 25 cm2 flasks and the flasks were incubated in a C02 incubator at 
37 oc. Virus was passaged in this way every 4-7 days until each virus stock had 
reached a titer equaling or exceeding 2x 106 plaque forming units (pfu)/ml, or for the 
number of passages indicated in the figures and results text. Virus stocks were flash 
frozen in aliquots and stored at -70 oc. Following rescue, each recombinant virus was 
analyzed by reverse-transcription and PCR amplification of the region spanning the end 
of the L gene to the 5' end of the genome to confirm the presence of the mutations. 
RSV multiple-step growth analysis 
HEp-2 cell monolayers in six-well plates were infected with each indicated virus at an 
moi of 0.01 pfu/cell. An aliquot of the inoculum was titrated to confirm that equivalent 
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titers of each virus were used to infect the cells. The virus was allowed to adsorb for two 
hours, after which the cells were washed and the inoculum was replaced with 1 ml of 
Opti-MEM containing 2% FBS and antibiotics and incubated for the indicated periods of 
time. At each indicated time point, the entire medium overlay was removed, clarified by 
low-speed centrifugation, snap-frozen and stored at -70 oc until completion of the 
timecourse. The cell monolayers were washed twice with PBS, and fresh medium was 
added to the culture and incubation continued. The virus titers were determined by 
plaque assay. 
RSV titration and plaque visualization 
Virus was allowed to adsorb to cells for two hours, after which the cells were overlaid 
with Opti-MEM containing 2% FBS and 0.8% methylcellulose and incubated at 37 oc for 
4-5 days. The cell monolayers were fixed with 80% methanol at 4 oc and then incubated 
with monoclonal antibodies specific to the RSV For N protein (Serotec), followed by 
sheep anti-mouse immunoglobulin (lg) G conjugated with horseradish peroxidase 
(HRP). Plaques were visualized by the addition of peroxidase solution substrate 4-CN 
(KPG). 
Mouse studies 
Balb/c female mice in groups of six (or five, where indicated in 
Figure 8) per time point, per virus were inoculated intra nasally under light anesthesia 
with 0.1 ml of Opti-MEM containing 105 5 pfu of Tr155, Tr57, Tr36, or LeC virus. At either 
3, 4, or 5 days pi the mice were sacrificed and the nasal turbinates and lungs were 
harvested. The virus titers in these tissues were determined by plaque assay and the 
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mean log10 pfu/g of tissue was calculated. The limit of detection in the upper and lower 
respiratory tracts was 2.0 and 1.7 log1o pfu/g , respectively. 
Northern blot analysis of viral RNAs 
Cells were scraped into medium and collected by centrifugation. The resulting cell pellet 
was resuspended in Trizol reagent (Invitrogen) and total intracellular RNA was purified 
following the manufacturer's instructions, except that the RNAs were further purified by 
extraction with phenol-chloroform and ethanol precipitation. RNA samples representing 
one-tenth of a well were analyzed by electrophoresis in a 1.5% agarose gel containing 
0.44 M formaldehyde, transferred to nitrocellulose and fixed by UV cross-linking ( 1200 
J/m2). Duplicate blots were hybridized with a positive-sense probe toward CAT 
(minigenome study), or either negative-sense N-specific riboprobe or a positive-sense 
specific riboprobe (RSV Tr-mutant virus study), in a mixture of 6X SSC, 5X Denhardt's 
solution, 0.5% SDS, and 200 IJg of sheared DNA per ml at 65 oc for 20 h. The blots 
were washed in 2X SSC-0.1% SDS at room temperature for 30 min, then at 65 oc for 2 
h and then in 0.1X SSC-0.1% SDS for 15 to 30 min. RNA bands were quantitated by 
either phosphorimage quantitation using a Phosphor-Imager 445 Sl (Molecular 
Dynamics) or by NIH lmageJ analysis of scanned autoradiograms. 
5' RACE analysis of viral RNAs 
HEp-2 cells in six-well dishes were infected with LeC isolates at the passage number 
indicated in the Results section. At 48 h pi, total intracellular RNA was isolated, as 
described above. RNA representing one-tenth of a well of cells was annealed to a 
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positive sense, L-specific primer (5' GAGTGTTGTTAGTGGAGATATACTATC) and used 
as a template for Sensiscript reverse transcriptase (Qiagen) according to the 
manufacturer's instructions. The eDNA was purified and tailed with dATP using terminal 
transferase. The tailed product was amplified by PCR using a nested L-specific primer 
(5' ACTTATAAATCATAAGCATATGAACATC) and a primer that annealed to the dATP 
tail (5' GACCACGCGTTCGA TGTCGAC I I I I I I I I I I I I I I I I). A second round of PCR 
was performed using a nested L-specific primer (5' 
CAGATCAACAGAACTAAACTATAACCAT) to further amplify the product. The resulting 
DNA was sequenced using an L-specific primer. 
Immunofluorescence microscopy 
HEp-2 or TIAR knockout mouse embryonic fibroblasts seeded on coverslips in 12-well 
plates were either mock infected or infected with wt RSV or the Tr36, Lee or LeC 12U/A 
RSV mutant at the indicated moi. As a positive control for SG formation , mock infected 
cells were treated with 0.5 mM sodium arsenite for 30 min immediately prior to fixation . 
At 16.5 h pi , cells were fixed with 5% formaldehyde, 2% sucrose in PBS for 30 min, 
permeabilized with 0.5% lgepal , 10% sucrose in PBS for 20 min, and incubated with the 
indicated antibodies. Following washing in PBS, cells were incubated with isotype-
specific secondary antibodies labeled with Alexa Fluor 488 and Alexa Fluor 633, as well 
as 4' ,6-diamidino-2-phenylindole (DAPI). Cells were analyzed by fluorescence 
microscopy. 
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Transfections 
For plasm ids expressing proteins and/or minigenomes under the control of the T7 
promoter, monolayers of HEp-2 cells were transfected with Lipofectin reagent 
(Invitrogen) according to the manufacturer's instructions. Cells were concomitantly 
infected with the MVA strain of vaccinia virus expressing T7 RNA polymerase, except 
where noted. Six hours after transfection I infection, the media was replaced with Opti-
MEM plus 2% FBS. For plasm ids expressing proteins under the control of mammalian 
promoters, monolayers of HEp-2 cells were transfected using Lipofectamine 2000 
(Invitrogen) according the manufacturer's instructions. Media was replaced 6 hours post 
transfection. 
siRNA experiments 
Mixtures of siRNAs toward dcp1 or p54 (siGENOME Set of 4 MQ-006371-00-0002, 
Human DDX6, NM_004397, 2nmol x 4) were obtained from Dharmacon, Inc. and 
transfected into monolayers of HEp-2 cells using Dharmafect transfection reagents 
according to the manufacturer's directions. 
Antibodies 
The antibodies used in the experiments described are presented in Table 2. 
Table 2. List of antibodies. 
Primary antibodies used with immunofluorescence 
mouse anti-RSV N I Serotec (MCA490) 
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mouse anti-RSV F Serotec (MCA491 G) 
goat anti eiF311 Santa Cruz (sc-16377) 
goat anti-TIA-1 Santa Cruz (sc-1751) 
rabbit anti-dcp1 Abeam (ab47811) 
rabbit anti-p54 MBL (PD009) 
mouse anti-DDX6/p54 Abeam (ab54611) 
rabbit anti-Xrn 1 Santa Cruz (SC-98459) 
goat anti-CPEB Abeam (ab73287) 
Secondary antibodies used with immunofluorescence 
Alexa Fluor® 488 chicken anti-goat lgG 
Invitrogen (A-21467) 
(H+L) *2 mg/ml * 
Alexa Fluor® 488 chicken anti-mouse 
Invitrogen (A-21200) 
lgG (H+L) *2 mg/ml * 
Alexa Fluor® 488 goat anti-rabbit lgG 
Invitrogen (A-11008) 
(H+L) *2 mg/ml * 
donkey anti-goat lgG Alexa Fluor 633 Invitrogen (A-21 082) 
Alexa Fluor® 647 Goat Anti-Rabbit lgG 
Invitrogen (A-21244) 
(H+L) 
donkey anti-goat lgG Alexa Fluor 633 Invitrogen (A-21 082) 
Primary antibodies used with western-blot analysis 
rabbit anti-dcp1 Abeam (ab47811) 
rabbit anti-Xrn1 Santa Cruz (SC-98459) 
goat anti-edc3 Santa Cruz 
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goat anti-edc4 Santa Cruz 
rabbit anti-dcp2 Abeam 
goat anti-RSV Abeam 
rabbit anti-p54 MBL (PD009) 
mouse anti-p54 Abeam (ab54611) 
anti-G3BP BD Transduction (611126) 
goat anti-TIAR Santa Cruz (sc-1749) 
goat anti-TIA-1 Santa Cruz (sc-1751) 
goat anti eiF311 Santa Cruz (sc-16377) 
Phospho-p44/42 MAPK (Erk1/2) 
Cell Signaling Technology 
(Thr202/Tyr204) (D13.14.4E) XP® 
(4370P) 
Rabbit mAb 
p44/42 MAPK (Erk1/2) (137F5) Rabbit Cell Signaling Technology 
mAb (4695P) 
Phospho-p38 MAPK (Thr180/Tyr182) Cell Signaling Technology 
(D3F9) XP® Rabbit mAb (4511 P) 
Cell Signaling Technology 
p38 MAPK (D13E1) XP® Rabbit mAb 
(8690P) 
Phospho-SAPKIJNK (Thr183/Tyr185) Cell Signaling Technology 
(81 E11) Rabbit mAb (4511 P) 
Cell Signaling Technology 
SAPKIJNK (56G8) Rabbit mAb 
(4668P) 
Phospho-Erk5 (Thr218/Tyr220) Cell Signaling Technology 
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Antibody (3371 S) 
Cell Signaling Technology 
Erk5 (D23E9) Rabbit mAb 
(3552S) 
Secondary antibodies used with western-blot analysis 
HRP-conjugated anti-rabbit Santa Cruz (sc-2004) 
HRP-conjugated anti-mouse Santa Cruz (sc-2062) 
HRP-conjugated anti-goat Santa Cruz (sc-2384) 
Cell Signaling Technology 
Anti-mouse lgG (H+L) (Dylight 800) 
(5366S) 
Anti-rabbit lgG (H+L) (Dylight 680 Cell Signaling Technology 
conjugate) (5257S) 
Cell harvesting and western-blot analysis 
HEp-2 cells were lysed in 400 IJI (6-well plates) or 200 IJI (12-well plates) RIPA buffer 
(Boston Bioproducts) with protease inhibitors and HALT phosphatase inhibitors (Roche) 
according the manufacturer's instructions unless otherwise specified. Cells were 
incubated on ice for 10 minutes, after which supernatants were collected in 
microcentrifuge tubes, vortexed, and centrifuged at 16,000 x g for 10 minutes at 4°C. 
Unless otherwise specified, soluble fractions were collected and added to 2X Laemmli 
buffer (BioRad) with 0.1 M dithiothreitol (OTT). 
Samples were separated on 10% SDS polyacrylamide gels at 120 Volts for 
approximately 90 minutes in Tris-glycine-SDS buffer, and transferred to nitrocellulose in 
tris-glycine buffer containing 20% methanol for 3 hours at 30 Volts. Membranes were 
incubated in either TBS plus 5% milk or Odyssey blocking buffer overnight at 4°C. 
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Membranes were incubated with primary antibodies (1: 1000 unless otherwise indicated) 
in either TBS with 0.1% Tween-20 (TBS-T) and 5% bovine serum albumin (BSA) 
(chemiluminescence) or Odyssey blocking buffer with 0.1% Tween-20 (Licor) overnight 
at 4°C on a nutator. Membranes were washed in TBS-T for four times for 5 minutes at 
room temperature and 60 rpm. Membranes were incubated with appropriate secondary 
antibodies (1 : 1 0,000) at room temperature for one hour at 60 rpm and then washed four 
times as above. For chemiluminescence analysis, membranes were blotted with 
Kimwipes and exposed to 3 ml Western Lighting Chemiluminescence Reagent (Perkin 
Elmer) for one minute. Blots were exposed to Blue Basic Autorad Film (ISC Bioexpress) 
for varying times (generally 30- 90 seconds). For Licor analysis, membranes were 
rinsed in TBS and read with the Licor Odyssey reader. Protein bands were quantified by 
measuring fluorescence intensities. 
Mason fractionation technique 
HEp-2 or A549 cells were mock infected or infected with RSV (moi =5). Media was 
changed one hour pi. Eighteen hpi , cells were washed twice with PBS and lysed with 
Tris-acetate buffer. Cells were passed through an 18-guage needle 10 times, and 
incubated on ice for 10 minutes. Samples were centrifuged at 24,000 x gat 4°C for 10 
minutes. Soluble fractions were collected (S 1 ). Insoluble fractions (P1) were 
resuspended in Triton X-1 00 buffer and passed 10 times through an 18-guage needle. 
Samples were incubated on ice for 10 minutes and then centrifuged at 24,000 x gat 4°C 
for 10 minutes. Soluble fractions were collected (S2). Insoluble fractions (P2) were 
resuspended in DOC + Tween 40 buffer and passed 10 times through an 18-guage 
needle. Samples were incubated on ice for 10 minutes and then centrifuged at 24,000 x 
g at 4 oc for 10 minutes. Soluble (S3) and insoluble (P3) fractions were collected. 
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MAGI Assay 
Integration of HIV-1 into P4 or MAGI-CCR5 cells (327) leads to production of the viral 
transactivator, Tat, which binds the HIV-1 L TR and activates expression of the!'-
galactosidase gene in the nucleus. Individual infected cells or syncytia (cells that have 
fused and contain multiple nuclei) are counted in situ with a light microscope by virtue of 
their blue color after incubation with the 13-gal substrate X-gal. The following describes 
the basic protocol performed in order to assay viral infectivity of viral stocks or 
experimental samples. MAGI-CCR5 cells were plated at 1 x 104 cells per well of a 96-
well flat-bottom plate in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 
IJg/ml streptomycin, 500 IJg/ml G418, 1 IJg/ml puromycin, and 0.1 IJg/ml hygromycin B. 
On the next day, cells were infected by removing the medium from each well and 
replacing it with virus containing sample in a total volume of 50 IJI. After 4 h, medium was 
removed by aspiration, wells were washed twice with PBS, and 100 IJI of medium was 
added. Two days later, the medium was removed and the monolayer was fixed at rt with 
a solution of 1% formaldehyde/0.2% glutaraldehyde in PBS for 5 min. The cells were 
then washed three times with 200 IJI of PBS to remove the fixative and incubated for 1 h 
at 3rC in 100 IJI of staining solution (4 mM potassium ferrocyanide,4 mM potassium 
ferricyanide, 2 mM MgCI2, and 0.4 mg X-gal per ml). The reaction was stopped by 
removing the staining solution and washing the cells twice with 100 IJI of PBS. Cells 
were examined under the light microscope and those with dark blue nuclei were counted 
as positive for virus infection. The number of cells that stain positive for !3-gal activity in 
situ is directly proportional to the number of infected cells. 
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Generation of HIV-1 stocks 
Single-round replication competent HIV-1 stocks were generated via transient 
transfection of HEK293T cells with 3 ).!g (per well of a 6 well plate) of pBru~Envluc2 and 
1 J..lg of envelope expression vector using the Lipofectamine 2000 (Invitrogen) method. 
HIV-1 p24939 ELISA 
HIV-1 capsid p24989 in cell-free supernatants and celllysates was measured using a 
laboratory-generated ELISA using the following protocol. A 96-well flat bottom Costar 
EIA plate (cat #3590) was coated with 100 J.!l human polyclonal HIV-1 immunoglobulin 
(HIV-Ig; cat #3957; AIDS Research and Reference Reagent Program, Germantown, MD) 
diluted in PBS (4 J.!l in 10.5 ml PBS per plate). The plate was sealed with microplate 
adhesive film (USA Scientific) and incubated overnight at 3rC (the plate was sealed 
with microplate adhesive film at each subsequent step, prior to returning it to the 
incubator). The coating Ab was removed by rinsing the plate six times with PBS (300 
).!1/well) using an automated plate washer (Thermolab Systems Wellwash 4 MK-2) . The 
plate was blocked with PBS/1 0% NCS (Gibco-lnvitrogen) for 2 h at 3rC (200 J.!llwell). 
The plate was washed six times (300 j..tl/well) with ELISA washing solution (1X PBS with 
0.2% Tween-20) using the plate washer. Plate washing was carried out in this same 
fashion throughout the rest of the protocol. Standards and samples were diluted in 
ELISA diluent (1X PBS containing 10% NCS and 0.5% Triton X-100) and added to the 
plate (100 ).!1/well). Two fold p24989 standard dilutions (2 ng/ml to 0.03125 ng/ml) were 
prepared using commercially-available p24989 recombinant protein (ProSpec, East 
Brunswick, NJ) and were loaded on the plate. Sample dilutions varied from experiment 
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to experiment and were adjusted as necessary to lie within the linear range of detection. 
The plate was incubated 2 hat 3rC and washed six times with ELISA washing solution . 
Primary mouse monoclonal HIV-1 p249a9 Ab (clone 183-H12-5C; AIDS Research and 
Reference Reagent Program, Germantown, MD) was added to each well (1 00 ).!1/well; 
13.125 ).!1 Ab per 10.5 ml ELISA diluent; 1.25 ).!g/ml final concentration) and the plate 
was incubated for 1 h at 3rC. The plate was washed six times with ELISA washing 
solution and 100 ).!1 of secondary Ab (goat anti-mouse horseradish peroxidase [HRP]; 
A2554; Sigma) in ELISA diluent (1 :70,000 dilution) was added to each well. The plate 
was incubated for 1 hat 3r, washed six times with ELISA washing solution using the 
plate washer, and 100 ).!1 of detection solution (equal volumes of TMB Peroxidase 
Substrate and Peroxidase Solution; KPL, Gaithersburg, MD) was added to each well. 
The color reaction was stopped by adding 100 ).!1 of 2M/4N H2S04 just when the lowest 
standard dilutions were beginning to have a hint of blue, typically 20 m after addition of 
detection solution. The plate was read immediately at 450nm in a microplate reader. 
Dcp1 mutagenesis 
We acquired a myc-DDK-tagged open reading frame (ORF) DNA clone of homo sapiens 
dcp1 a under the control of the pCMV6 promoter from Origene (RC201330). This 
construct was subjected to mutagenesis to generate constructs in which S315, S319, 
T321 , or all three residues (Triple A) were replaced with alanine in order to prevent 
phosphorylation of the residues of interest using a Agilent Quickchange II site-directed 
mutagenesis kit according to the manufacturer's directions. The primers used were as 
follows (5' to 3'): 
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S315A forward: ctacacaatcccgttggcccctgttctcagtccc 
S315A reverse: gggactgagaacaggggccaacgggattgtgtag 
S319A forward: ttgagccctgttctcgctcccactctgccagc 
S319A reverse: gctggcagagtgggagcgagaacagggctcaa 
T321 A forward: cctgttctcagtcccgctctgccagctgaag 
T21 A reverse: cttcagctggcagagcgggactgagaacagg 
Triple A: cacaatcccgttggcccctgttctcgctcccgctctgccagctga 
Triple A reverse: tcagctggcagagcgggagcgagaacaggggccaacgggattgtg 
The resultant constructs were subcloned using digestion with Xholl and Hindi and 
ligation into the original backbone using the NEB Quick Ligation Kit according to the 
manufacturer's directions, and sequenced to confirm amino-acid-sequence. 
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Chapter 1: The Relationship between RSV and Stress Granules 
Chapter 1 Introduction 
Stress granules 
As described briefly in the Introduction, stress granules are cytoplasmic aggregates that 
form in response to several types of environmental stress. Canonical stress granules 
contain stable, translationally silent mRNAs, certain translation initiation factors (e1F4E, 
eiF4G, e1F4A, eiF4B, eiF3, eiF2, poly-A binding protein (PABP)), the small ribosome 
subunits (115, 116, 267), and key RNA-binding proteins (T-cell-restricted intracellular 
antigen 1 (TIA-1 ), T-cell-restricted intracellular antigen related protein (TIAR), and 
GTPase activating protein (SH3 domain) binding protein (G3BP1)) (116, 249). Many 
other proteins have been found in stress granules, and the composition of stress 
granules varies widely depending on the stressor, cell type, and environmental factors 
(92, 197). Stress granules are thought to be repositories for mRNAs and initiation 
complexes during times of stress where mRNAs can either be released for active 
translation on free polysomes once the stress is removed, or shuttled to degradation 
machinery (113). 
Known stress-granule pathways 
While the mechanisms of stress-granule assembly are largely unknown, several 
pathways directing stress-granule formation have been described. Typically, stress 
granules are assembled following phosphorylation of eukaryotic translation initiation 
factor 2a (eiF2a) by protein kinase R (PKR), protein kinase RNA-like endoplasmic 
reticulum kinase (PERK), general control nonderepressible 2 (GCN2), or heme-
regulated inhibitor (HRI) kinases (113, 116, 156); however, phosphorylation of eiF2a is 
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not a strict requirement for stress-granule induction. For example, stress-granule 
formation can result from the inhibition of eiF4A RNA helicase independently of eiF2a 
phosphorylation (20, 67, 122, 154, 158, 198). Of note, a number of viruses are known to 
activate PKR (generally by double-stranded RNA intermediates) and/or PERK during 
infection, which could induce stress-granule formation (51). Neither HRI nor GCN2 
activation has been significantly associated with virus infection. 
Stress granule relationships with other viruses 
Stress responses play an important role in regulating mRNA fate during environmental 
stress and generally result in drastically reduced or altered host-gene expression, which 
would likely prove deleterious to viruses that depend on tightly regulated host-cell 
homeostasis and host-cell translation machinery in order to propagate. It therefore is not 
surprising that a large number of viruses have evolved to subvert or block certain 
aspects of the cellular stress response. 
Several viruses (mammalian orthoreovirus, Semliki Forest virus, hepatitis C virus, and 
poliovirus) induce stress-granule formation early during infection, but inhibit stress-
granule formation during intermediate and late phases of infection. Other viruses (Junin 
virus, rotavirus, cardiovirus, West Nile virus, dengue virus, cricket paralysis virus, herpes 
simplex virus 1, HIV-1, HTLV-1, and influenza A virus) inhibit stress-granule formation 
throughout infection. On the other hand, some viruses are reported to tolerate (mouse 
hepatitis coronavirus and vaccinia virus) or even benefit from (transmissible 
gastroenteritis virus) stress-granule formation during infection. Table 3 provides a 
summary of known mechanisms through which these viruses prevent, manipulate, or 
exploit host stress responses (267). 
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Table 3. Phenotypes of virus-stress granule interactions. Adapted from White et 
al., 2012 (267). 
Virus Phenotype Ref. 
Viruses that prevent stress-granule formation 
throughout infection 
Nucleoprotein N and/or 
glycoprotein precursor GPC 
Junin virus inhibit eiF2a phosphorylation (144) 
and arsenite-induced stress 
granules 
Sendai virus Tr region binds 
Sendai virus TIAR and prevents stress- (103) 
granule formation 
RV infection induces 
extended eiF2a 
phosphorylation but not 
Rotavirus stress-granule formation; (172) 
infection can prevent 
arsenite-induced stress 
granules 
Does not induce stress 
Cardiovirus granules; leader protein (32) 
inhibits stress granules by 
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exogenous stress 
TIA-1 !TIAR interaction with 
West Nile and viral 3'-terminal stem-loop 
dengue virus structure inhibits stress-
granule formation (74) 
Prevents canon ical stress 
granules by preventing Rox8 
Cricket 
and Rin (homologues of TIA-
paralysis (119) 
1 and G3BP, respectively) 
virus 
from aggregating in stress 
granules 
Virion host shutoff protein 
Herpes mediates TIA-1 localization to 
(68) 
simplex 1 cytoplasm from nucleus, but 
not to stress granules 
HIV Gag interacts with 
stress-granule protein 
Staufen 1 to form 
encapsidation-destined 
HIV-1 (1) 
ribonucleoprotein complexes 
instead of translationally 
silenced ribonucleoprotein 
complexes 
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Inhibits stress granules 
through Tax protein 
HTLV-1 interaction with histone (136) 
deacetylase 6 protein 
(HDAC6) 
Infection with W mutants 
that lack the dsRNA-binding 
protein E3L form antiviral 
Vaccinia virus stress-granule-like bodies (224) 
associated with PKR 
activation and reduced viral 
replication 
NS1 protein blocks eiF2a 
Influenza A 
phosphorylation and stress- (118) 
virus 
granule formation 
Virus that induce stress granules early during infection, 
and subvert stress granules late in infection 
Stress-granule formation 
induced by cell entry; 
Mammalian inhibited as infection 
(198) 
orthoreovirus progresses; inhibits stress 
granules in response to 
arsenite 
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Induces eiF2a-
phosphorylation-dependent 
stress granules early in 
infection; stress granules 
Semliki 
correlate with host translation (158) 
Forest Virus 
shutoff; SFV infection 
prevents formation of stress 
granules by exogenous 
stressors late in infection 
Induces stress granul.es early 
in infection; inhibits stress 
Hepatitis C granules late in infection by 
(20) 
virus recruiting stress granule 
proteins to viral replication 
factories 
Stress granules induced early 
in el F2a-phosphorylation-
independent manner, 
correlated with translation (154)) 
Poliovirus shutoff; later stress-granule (265) (197) 
prevention due to virus- (266) 
mediated G3BP cleavage 
that unlinks TIA-1 aggregates 
from stalled initiation 
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complexes 
Viruses that tolerate or exploit stress granules 
stress-granule formation 
Mouse 
corresponds with translation 
hepatitis (199) 
inhibition and robust virus 
coronavirus 
replication 
Virus-induced stress granules 
Transmissible recruit nuclear protein PTB; 
gastroenteritis formation of stress granules (231) 
virus correlated with inhibition of 
viral RNA accumulation 
RSVLe and Tr 
As mentioned previously, RSV's genome encodes 11 genes and is flanked by two 
extragenic sequences: 44-nucleotide Le at the 3' end, and 155-nucleotide Tr at the 5' 
end. The Le and TrC sequences display extensive terminal complementarity. In fact, 
the sequences are identical for 10 of the 11 3' terminal nucleotides, corresponding to the 
polymerase-recruitment element, and the sequences are similar between nucleotides 12 
and 36, the region required for efficient encapsidation of replication products. 
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It is unclear why TrC is more than three times longer than Le. A minigenome containing 
the terminal 36 nucleotides of Tr can replicate efficiently (60), indicating that these 
nucleotides contain the minimal replication promoter. Another study demonstrated that 
increasing the length of the TrC sequence increases promoter efficiency (81). It has not 
been determined whether the minimal replication promoter is sufficient to drive 
productive virus propagation in the context of RSV infection. It is possible that the Tr 
region beyond the minimal promoter is important for RSV replication. For example, TrC 
sequence between nucleotides 36 and 155 could augment genome production from 
antigenome, which would help explain the fact that during infection with negative-strand 
viruses, genome is produced in much greater quantities than antigenome. Alternatively, 
Tr region may be involved in other steps of the RSV replication cycle. One study 
demonstrated that the VSV Tr region contains a cis-acting sequence that is necessary 
for packaging of genome-sense nucleocapsids into virions (264). Another possibility is 
that RSV Tr could be involved in subverting host defense mechanisms. The Sendai 
virus (a related paramyxovirus) Tr region reportedly associates with cellular TIAR protein 
and thereby inhibits stress-granule formation and cellular apoptosis (103). 
In these studies, we characterized RSV's Tr region activities in the context of both 
minigenome replicons and recombinant versions of RSV in which the Tr region was 
either truncated with deletion mutagenesis or substituted with inverted LeC sequence. 
Our goals were two-fold: first, to examine the relative strengths of the Le and TrC 
promoter regions, and second, to determine whether the Tr region is involved in 
subverting host defense mechanisms. 
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Note: While I have since used and propagated the viruses described below extensively, 
including rescuing the LeG virus from eDNA, the initial virus mutagenesis and 
experiments described in Sections 1. 2 - 1. 5 were performed several years ago by other 
researchers, as noted in the figure legends. They are discussed here as background 
information for my project. 
Chapter 1 Results 
1. 1 Confirmation that full-length Tr is not necessary for efficient promoter activity 
in a minigenome system 
We first wished to confirm the previously mentioned results demonstrating that full-length 
Tr sequence is not necessary for efficient promoter activity. To compare promoter 
activities of various sequences, we used a minigenome assay. Artificial template RNA 
was created in which the chloramphenicol acetyl tranferase (CAT) ORF was flanked with 
the following RSV cis-acting sequences: 1) full-length Tr region (Tr155), 2) Tr 
nucleotides 1-55 relative to the 5' end (Tr55), 3) Tr nucleotides 1-36. (Tr36), or 4) an 
inverted LeC sequence (LeC). 
HEp-2 cells were co-transfected with constructs encoding the minigenome of interest in 
addition to plasmids expressing RSV polymerase, L; and its associated proteins, N and 
P (see Figure 5). 24 hours after transfection, RNA was harvested and the replication 
product was detected using northern blot with a CAT-specific probe. 
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Figure 5. Schematic diagrams of the RSV minigenomes. Plasmids expressing 
minigenomes encoding CAT (green box) flanked with various RSV promoter 
sequences (indicated , top right) were transfected into cells in addition to plasmids 
encoding RSV L, P, and N proteins under the control of the T7 promoter. Cells were 
concomitantly infected with vaccinia virus expressing the T7 polymerase. The 
replication product was detected using radiolabeled probes against CAT sequence. 
As shown in Figure 6, the 57 -nucleotide trailer showed slightly lower promoter activity for 
unknown reasons; however, the transcripts produced by the TrC-sequence-containing 
constructs were all very similar. Consistent with previous findings, the construct 
containing Le sequence produced less replication product. These data indicate that the 
region beyond 1-36 is not required for efficient replication. 
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Figure 6. Full-length RSV Tr sequence was not necessary for efficient promoter 
activity. HEp-2 cells were transiently transfected with plasmids expressing RSV N, P, 
and L (except where noted) proteins in addition to constructs encoding CAT under the 
control of RSV cis-acting sequences as indicated. Cells were concomitantly infected 
with vaccinia virus expressing the T7 polymerase. Twenty-four hours post transfection , 
RNA was harvested and replication product was detected using northern blot with a 
radio-labeled , CAT -specific probe. 
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1.2 Construction and recovery of mutant viruses 
To investigate the functions of the RSV Tr region in the context of viral infection, severa·i 
RSV mutant viruses were made. Mutations were introduced into a recombinant clone of 
RSV, called RSV/6120 (see Materials and Methods for details) (40). A unique BsiWI 
restriction site was introduced a few nucleotides downstream of the L gene-end signal 
(see Figure 7A and Materials and Methods section for details) and used to create 
deletions in the Tr region, such that the 5' terminal 36 nucleotides of the Tr were joined 
to the BsiWI site (Figure 7A) . The viruses that were generated from these cDNAs are 
referred to as Tr155 and Tr36. It was expected that the Tr36 virus would be able to 
direct synthesis of genome RNA, and that a comparison of Tr155 and Tr36 would 
provide clues as to the role of nucleotides 37 to 155 of the Tr region . 
In order to compare the strengths of the Tre and Le promoters and to determine whether 
the Tr or Tre sequences have additional roles during RSV replication, an RSV eDNA 
was created in which the Tr sequence downstream of the BsiWI site was replaced with 
the 44-nucleotide Lee sequence. This mutation was designed to place the Le promoter 
sequence at the 3' end of the antigenome, which should theoretically have allowed 
genome production; however, several attempts to rescue a virus with the authentic Lee 
sequence substitution were unsuccessful, indicating that placing Lee at this location was 
highly detrimental to virus replication. A Lee sequence was introduced that placed a e 
rather than G residue at position 4 of the Le promoter at the 3' end of the antigenome 
(Figure 78). This nucleotide assignment has arisen spontaneously in the Le regions of 
RSV vaccine candidate viruses (85) and has been shown to direct significant replication 
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promoter activity (59, 82). This virus was successfully rescued and propagated, and is 
referred to as LeC. 
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Figure 7. Mutations made in the RSV Tr region. A) A schematic diagram of the RSV 
genome with the 5' end, where mutations were made (enlarged). The positions of 
nucleotides 1, 36, and 155 relative to the 5' end of the genome, and the position of the 
BsiWI site, are indicated. The regions contained in viruses Tr155 and Tr36 are indicated 
by the lines below, with the deleted regions shown as dashed lines. B) Sequences at the 
5' ends of the Tr36 and LeC virus genomes. The sequences are written as negative-
sense RNA and the L gene-end signal is italicized. The substitutions that were 
introduced to create the BsiWI site are shown in boldface type. The sequences are 
aligned, with spaces introduced to maximize alignment (shown as dashes). Nucleotide 
12 relative to the 5' terminus of the genome, which was found to be a key nucleotide in 
this study, is underlined. Identical nucleotides are shown in red. These viruses were 
made by Rachel Fearns. 
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1.3 LeC virus exhibited impaired growth and a small, faint plaque phenotype 
compared to Tr155 and Tr36 viruses 
The fact that the Lee virus could be rescued and propagated demonstrated that the RSV 
Tr region does not contain a unique, essential, cis-acting packaging signal, contrary to 
what was described for VSV (264). However, during initial propagation of the mutant 
viruses, it was clear the Lee virus replicated with impaired efficiency compared to the 
other viruses. In addition, the Lee virus had a different plaque phenotype than the other 
mutants. As shown in Figure SA, the plaques formed by the Tr155 and Tr36 viruses 
were similar to each other in size and were intensely immunostained, while those formed 
by the Lee virus were smaller and only faintly immunostained. 
To ensure that the inefficient propagation of the Lee virus was due solely to the mutation 
at its genome 5' terminus, the Lee eDNA clone was further manipulated in a single 
cloning step to reintroduce the 155 nt Tr region. The virus produced from this clone, 
LeeR, is theoretically genetically identical to the Tr155 virus. Indeed, the two viruses 
exhibited similar plaque morphology and growth kinetics, confirming that the Lee 
phenotype was specific to the Lee mutation (data not shown). Several independent 
eDNA clones of the Lee virus were rescued and all shared the same growth phenotype. 
Furthermore, isolation of a revertant virus (Lee 12U/A; described below) confirmed that 
the poor growth phenotype of the Lee virus was determined by the genome 5' terminal 
region, and not a spurious mutation elsewhere. 
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To formally compare the growth kinetics of the mutant viruses, cell monolayers were 
infected at a multiplicity of infection (moi) of 0.01, and the levels of infectious virus 
present in the supernatant were measured at 24-hour intervals. All the viruses grew . 
similarly over the first 24 hours, but their growth kinetics diverged thereafter. The Tr36 
virus replicated slightly more slowly than the parental Tr155 virus; however, the 
differences between these viruses were very minor and they reached a similar maximum 
titer by five days post infection (Figure 88). In contrast, the Lee virus grew more slowly 
and reached a maximum titer that was approximately 20-fold lower than the other 
viruses. These results demonstrate that the Tr region beyond the minimal promoter 
does have one or more functions during RSV replication, and that nucleotides 57-155 of 
Tr sequence are required for optimal replication; however, the results clearly show that 
the complete Tr region is not essential for efficient virus growth. The results also 
demonstrate that replacing the Tr promoter with Lee has a deleterious effect on virus 
propagation over a multi-cycle growth period, as well an effect on plaque phenotype. 
To test whether the Tr mutations had a similar effect on virus growth in vivo, mice were 
inoculated with the viruses intranasally, and virus titers in the nasal and lung tissues 
were measured over a five-day period. The virus replication closely mirrored multi-cycle 
growth in cell culture and confirmed that while the Tr36 virus was able to propagate with 
similar kinetics to the Tr155 virus, the LeC virus had impaired growth in comparison 
(1 01 ). These results confirm that the Tr region beyond position 36 does not contain an 
unique sequence that is necessary for efficient RSV replication. The results also confirm 
that replacing the Tr region with the Lee sequence is injurious to virus propagation. 
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c 
Day3 Day4 DayS 
Nasal Lungs Nasal Lungs Nasal Lungs turbinates turbinates turbinates 
LeC 3.1±0.15 2.6±0.21 2.9±0.16 3.0±0.17 2.9±0.19 3.8±0.05 
Tr36 3.9±0.06 4.3±0.04 4.2±0.11 4.5±0.07 4.0±0.08 4.7±0.03 
Tr155 4.4±0.05 4.3±0.09 4.5±0.08 4.6±0.15 4.1±0.12 4.7±0.02 
Figure 8. Multi-cycle growth properties of the mutant viruses. A) Plaque 
phenotypes of the mutant viruses. HEp-2 cells were infected with the indicated viruses 
at an moi of 0.01. Three days post infection, cells were fixed and stained with antibodies 
against the RSV F protein. The upper panel shows plaques within an entire well of a 6-
well dish, and the lower panel shows representative images of plaques taken with 1 Ox 
magnification; the LeC virus plaques are highlighted with arrows. B) HEp-2 cells were 
infected with the indicated viruses at an moi of 0.01 and cell medium supernatant 
fractions were collected at 24 h intervals until the cells were destroyed by infection. The 
mean average virus titers (with standard deviation) are shown for each virus at each 
time point (n=3). C) Mice in groups of six per virus per time point were sacrificed on the 
indicated days postinfection. The numbers show the mean virus titers±standard error 
mean (log 10 pfu/g tissue). Rachel Fearns perfomed the experiments show in Panels A 
and B. Michael Teng performed the experiments shown in Panel C. 
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1.4 The impaired growth and altered plaque phenotype of the LeC virus was not 
due to impaired promoter activity 
To determine whether the impaired growth and altered plaque phenotype of the Lee 
virus were due to differences in the strength of the Le and Tre promoters that lie at the 3' 
ends of RSV mutant virus antigenome, the levels of viral RNA generated by the viruses 
were compared. HEp-2 cells were infected at a high moi (4 pfu I cell) and RNA 
accumulation was analyzed at various points during a single-cycle growth period. 
Northern blot analysis of genome-sense RNA demonstrated that at each time point 
tested, the Lee and Tr36 viruses produced approximately 34% of the RNA produced by 
the Tr155 virus (Figure 9, upper panel; quantification data not shown). These results 
indicate that while nucleotides 1-36 are sufficient for RNA replication to occur, full-length 
Tr region is necessary for maximum RNA production. Importantly, the Lee virus 
produced a similar amount of genome RNA as the Tr36 virus, which indicates that in the 
context of viral infection, the Le replication promoter is equivalent in strength to the 
minimal Tre promoter. Positive-sense RNAs were examined by hybridizing duplicate 
blots with a negative-sense riboprobe against the N gene. This probe detected 
monocistronic N mRNA, polycistronic readthrough mRNAs containing N sequence, and 
antigenome RNA. Importantly, there were no significant differences in the levels of 
mRNA or antigenome accumulation between the Tr36 and Lee viruses (Figure 9, lower 
panel). The fact that the RNA-accumulation profiles of the Lee and Tr36 viruses were 
almost identical suggests that the poor growth and altered plaque phenotype of the Lee 
virus compared to the Tr36 virus(Figure 8) was not due to a difference in their promoter 
strengths. 
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Figure 9. The impaired growth and altered plaque phenotype of the Lee virus was 
not due to impaired promoter activity. HEp-2 cells were infected with the indicated 
virus at an moi of 4 and RNA was isolated at various times post infection (as indicated). 
The RNA was blotted on duplicate blots, which were hybridized with either a positive-
sense F-specific riboprobe (upper panel) or a negative-sense N specific riboprobe (lower 
panel) . These experiments were performed by Rachel Fearns. 
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1.5 A 12U to A substitution relative to the 5' end of the LeC virus genome resulted 
in a rescued plaque phenotype 
Experiments with the LeC virus demonstrated that its plaque phenotype was unstable, 
with occasional reversion to large, intensely stained plaques. To determine whether the 
reversions seen were the result of altered LeC genome sequence, the virus was 
passaged nine times to select for viruses with the revertant phenotype. Plaque analysis 
of the passage nine (p9) viral stock showed that the virus population had evolved such 
that almost all the virus plaques had a phenotype similar to those of the Tr36 virus 
(Figure 1 OA). To characterize the 5' LeC sequence(s) in the revertant virus population, 
RSV genome RNA from cells infected with the p9 stock was amplified by 5' rapid 
amplification of eDNA ends (5' RACE). The resulting PCR products were cloned, and 
nine eDNA clones were sequenced. Several different DNA sequences were obtained, 
indicating that there was variation within the virus population; however, in 9/9 clones, 
position 12 relative to the 5' end of the genome had changed from a U to an A residue. 
Figure 1 OB shows typical sequence traces derived from LeC virus at p6 and p9, with the 
position 12 substitution indicated with an asterisk (note that the sequence is shown as 
positive-sense DNA so the change appears as an A toT substitution). As shown in 
Figure 78, this substitution restored nucleotide 12 to the same assignment as in the wt 
RSV Tr region. 
To determine whether the position-12 change was sufficient to confer the alteration in 
plaque phenotype that was observed in the p9 viruses, the LeC eDNA clone was 
mutated to substitute an A for the U at position 12 relative to the 5' end. This virus (Lee 
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12U/A) was rescued and passaged once (to remove residual vaccinia virus) and its 
plaque phenotype was compared to that of Lee and Tr36 virus stocks. As shown in 
Figure 1 oe, the plaques formed by the Lee virus were weakly stained with N and F 
antibodies, while the plaques formed by the Lee 12U/A virus were intensely stained and 
resembled the plaques formed by the Tr36 virus. These results demonstrate that the 
Lee region was under selective pressure to acquire a mutation that increased its 
similarity to the Tr sequence, and that this single-nucleotide substitution was sufficient to 
restore a strong, intensely stained plaque phenotype for to virus. In addition , we 
observed informally that the 12 U/A virus demonstrated similar growth kinetics and 
reached similar maximum viral titers compared to the Tr36 virus (data not shown). The 
Lee 12U/A virus was an important tool for investigating factors that could be 
responsible for the impaired growth and altered plaque phenotype of the Lee virus. 
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Figure 10. A substitution at position 12 relative to the 5' end of the LeC virus 
genome confered a plaque phenotype similar to that of Tr36 virus. A) 
lmmunostained plaques of LeC virus at passages 6 (p. 6) and 9 (p. 9), as indicated. B) 
Sequence analysis of representative eDNA clones representing the 5' terminal region of 
the p. 6 and p. 9 LeC virus genomes, as determined by 5' RACE analysis of genome 
sense RNA. The sequence is shown as positive-sense DNA and positions 1 and 12 
relative to the genome 5' terminus are indicated by asterisks. The poly A tract adjacent 
to position 1 represents the residues added to the eDNA by terminal transferase during 
the 5' RACE procedure. C) Example plaques from LeC, LeC 12U/A and Tr36 virus 
infections immunostained with anti-F or anti-N antibody, as indicated; the LeC virus 
plaques are highlighted with arrows. The experiments presented in this figure were 
performed by David McGivern and Robin Djang. 
63 
1.61nfection with wt RSV did not result in stress-granule formation 
Previous results revealed that the altered plaque phenotype of Lee virus compared to 
the Tr36 virus was unrelated to promoter activity. In addition, the fact that the virus 
could be rescued and propagated demonstrated that Lee virus did not lack an essential 
cis-acting packaging signal. As described in the Introduction, a previous study 
implicated a role for the Sendai virus Tr transcript in subverting the cellular stress 
granule response (1 03, 208). We hypothesized that the impaired growth of the Lee 
virus may be due to stress responses. Because the relationship with RSV and stress 
granules had not been previously characterized, we first wished to determine whether 
RSV infection resulted in stress granules in infected cells using immunofluorescence. 
HEp-2 cells were mock infected or infected with RSV. After 16 hours, uninfected cells 
were treated with sodium arsenite for 30 minutes as a positive control for stress-granule 
formation. 16.5 hours after infection, cells were fixed and stained with antibodies toward 
RSV N protein to visualize RSV infection, and antibodies toward cellular eiF3 to visualize 
stress granules. The cells were examined by confocal microscopy. As shown in Figure 
11A, e1F3 from mock-infected, untreated cells showed a diffuse cytoplasmic distribution, 
while eiF3 from arsenite-treated cells was condensed into cytoplasmic punctae 
characteristic of stress granules. In cells infected with wt RSV, eiF3 had a similar 
distribution as in mock-infected cells , suggesting that RSV has evolved a mechanism to 
either avoid inducing stress granules or to interfere with their assembly. The experiment 
described above was repeated staining for stress granule-associated protein TIA-1 
instead of eiF3. As shown in Figure 11 B, stress granules containing TIA-1 form in 
response to arsenite treatment, but not in response to infection with RSV, confirming that 
RSV infection does not result in significant stress-granule formation. Of note, stress 
64 
granules formed in approximately 0.5% of RSV-infected cells in both experiments (not 
shown) . 
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Figure 11. Infection with wt RSV did not result in stress-granule formation. HEp-2 
cells were mock infected or infected (moi = 1). At 16 hpi, cells were treated with 0.5 mM 
sodium arsenite for 30 minutes. Cells were fixed and stained with antibodies toward 
RSV N protein (green) and either eiF3 (A) or TIA-1 (B). 
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1. 7 Stress-granule formation was negatively associated with RSV inclusion 
bodies 
As mentioned above, while the majority of RSV-infected cells did not show stress-
granule formation, RSV infection did result in stress-granule formation in 0.5% - 5% of 
RSV-infected cells. We theorized that stress granules formation might limit RSV 
infection, and wished to assess whether there was a correlation between RSV-infected 
cells showing stress granules and RSV inclusion body size. HEp-2 cells were mock 
infected or infected with RSV. 16 hours post infection, cells were treated with sodium 
arsenite for 30 minutes, stress-granule formation was assessed using 
immunofluorescence and confocal microscopy. As demonstrated in Figure 12, we 
observed very few RSV inclusion bodies in areas where there was robust stress-granule 
formation. Inversely, we observed that in areas with large RSV inclusion bodies, stress 
granules were less numerous. These results were not quantified; however, they suggest 
proximity to prominent RSV inclusion bodies is correlated to impaired stress-granule 
formation . 
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arsenite RSV + arsenite 
Figure 12. Areas of cells with prominent RSV inclusion bodies demonstrated 
dispersed stress granules. HEp-2 cells were mock infected (right) or infected with 
RSV (left) . 16 hpi, cells were treated with 0.5 mM sodium arsenite. Cells were fixed and 
stained for RSV N protein (green) and eiF3 (red), and examined by confocal microscopy. 
White arrows indicate areas with prominent RSV inclusion bodies. 
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1.8 RSV infection prevented stress-granule formation by arsenite, but not heat 
shock treatment 
Our studies suggest that RSV infection did not result in significant stress-granule 
formation. There were two possibilities: 1) that RSV infection does not induce stress 
granules, or 2) that RSV infection activates stress pathways, but is able to prevent stress 
granules from forming . To help discern between these possibilities, we wished to 
assess whether RSV could prevent stress-granule formation induced by arsenite. HEp-
2 cells were either mock infected or infected with wt RSV. Thirty-six hours post infection, 
cells were either treated with sodium arsenite for 30 minutes or incubated at 44 oc for 60 
minutes. Stress-granule formation was assessed using immunofluorescence. As 
demonstrated in Figure 13, cells that were mock infected and subsequently treated with 
sodium arsenite or heat shock showed classic stress-granule formation in 100% of the 
cells , as expected. Cells that were infected with RSV and then heat-shocked showed 
stress-granule formation in 100% of cells, similar to mock-infected, heat shocked cells . 
This result demonstrates that RSV infection is not able to prevent stress-granule 
formation induced by heat shock under the conditions tested. In contrast, RSV-infected 
cells that were treated with sodium arsenite showed stress-granule formation in only 
15% of RSV-infected cells, indicating that RSV is able to prevent stress-granule 
formation by certain stressors. 
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Figure 13. RSV infection was able to prevent stress-granule formation by arsenite 
treatment, but not heat-shock treatment. Panel A) HEp-2 cells were mock infected or 
infected with wt RSV (moi =1). 36 hpi, cells were incubated at 44°C for 60 minutes or 
treated with 0.5 mM sodium arsenite for 30 minutes. Cells were fixed and stained with 
antibodies toward RSV N protein (first column) or cellular eiF3rJ (second column). 
Samples were analyzed using fluorescent microscopy. Panel B shows the quantification 
of the results shown in Panel A. Stress granules were assessed in at least 100 cells 
from each group. 
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1.9 RSVinfection at 16 hpi did not prevent arsenite-induced stress-granule 
formation 
RSV infection was able to prevent stress-granule formation by arsenite at 36 hpi. 
Because our previous results indicated that RSV infection did not result in stress-granule 
formation at 16.5 hpi, we wished to determine whether the virus was able to prevent 
arsenite-mediated stress-granule assembly at this time point. HEp-2 cells were mock 
infected, infected with RSV, and treated with sodium arsenite. 16.5 hours post infection, 
cells were fixed and assessed for stress-granule formation using immunofluorescence 
and confocal microscopy. As shown in Figure 14, cells that were mock infected or 
infected with RSV did not demonstrate significant stress-granule formation, while cells 
treated with sodium arsenite form stress granules as expected. Cells that were infected 
with RSV for 16 hours and then treated with sodium arsenite showed stress-granule 
formation similarly to arsenite-treated cells, indicating that RSV infection was not able to 
subvert arsenite-induced stress granules under the conditions tested . It is likely that the 
stoichiometry of stress-granule preventors vs. stress-granule inducers play a role in the 
outcome of stress granules, and it is possible that if we had used a larger moi of virus 
and/or a lower concentration of arsenite, RSV infection may have been able to prevent 
arsenite-induced stress granules at 16.5 hpi. 
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Figure 14. RSV did not prevent arsenite-induced stress granules at 16 hpi. HEp-2 
cells were mock infected or infected with RSV (moi = 1). 16 hours post infection, the 
indicated samples were treated with 0.2 mM sodium arsenite as for 30 minutes. 16.5 
hours post infection, cells were fixed and stained with DAPI (blue), or stained with 
antibodies toward RSV N protein (green} and eiF3 (red). Cells were examined by 
confocal microscopy. 
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1.10 Infection with LeC mutant resulted in significant stress-granule formation 
Our results demonstrated that infection with wt RSV did not result in significant stress-
granule formation (Figure 11) and that RSV is able to prevent arsenite-induced stress-
granule formation under certain conditions (Figure 13). These data suggested that RSV 
may have a mechanism to block stress-granule formation . We theorized that putative 
RSV-mediated, stress-granule subversion was due to Tr-region activity, as with the case 
of Sendai virus, and that the impaired growth of the LeC virus may be due to stress-
granule induction. To determine whether LeC infection differed from other RSV viruses 
with regard to stress-granule formation, cells were mock infected, treated with sodium 
arsenite, or infected with wt RSV, Tr35, LeC or LeC 12U/A mutant viruses as above. 
16.5 hours after infection, cells were fixed and stained with antibodies toward RSV N 
protein to visualize RSV infection, and cellular eiF3 to visualize stress granules. The 
cells were examined by confocal microscopy. Cells infected with the Tr36 or LeC 12U/A 
viruses showed very little stress-granule formation (Figure 15, panels D and F, 
respectively). In contrast, cells infected with LeC virus showed significantly more stress-
granule formation (Figure 15E). These stress granules were not as discrete or as 
numerous as in the cells treated with arsenite; however, they were clearly discernible 
(Figure 16). Occasionally the stress granules were located directly adjacent to RSV 
inclusion bodies, suggesting the possibility of transient interaction, as has been shown 
previously (208). The percentages of infected cells showing stress granules were 
quantified and it was found that 53.1-64.7% of LeC virus infected cells showed stress-
granule formation, compared to 0.4-1.8% of cells infected with LeC 12U/A virus (Figure 
15). These results demonstrate that there is a relationship between the sequence at the 
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5' end of the RSV genome and stress-granule formation, and that the impaired growth 
and weak plaque phenotype of the LeC virus is correlated with stress-granule formation. 
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Figure 15. The LeC virus induced stress-granule formation in infected cells. 
Panels A-F) Replicate cultures of HEp-2 cells were infected with indicated viruses at an 
moi of -1 . Cells were immunostained for RSV N (column i) and cellular eiF3 (columns ii 
and iii) at 16.5 h pi and examined by confocal fluorescence microscopy. The panels in 
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column iii are enlarged images of the top left quadrants of the images in column ii. At 
least 1 00 N expressing cells from each culture in two independent experiments were 
examined and the percentages of infected cells containing stress granules are indicated 
alongside the panels. Controls of mock infected cells and cells that were mock infected 
and then treated with 0.5 mM arsenite for 30 min immediately prior to fixation are shown 
in panels A and B, as indicated. 
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Figure 16. Localization of stress granules relative to RSV inclusion bodies in LeC 
virus infected cells. Cells were infected with LeC virus at an moi of 2. At 16.5 h pi the 
cells were immunostained for RSV N (column i) and cellular eiF3 (column ii) and 
examined by confocal microscopy. Column iii shows a merged image of N, eiF3 and 
DAPI stained cells. 
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1.9 Co-infection studies demonstrated that wt RSV could inhibit LeG-mediated 
stress-granule formation 
There were two possible explanations for the differences among infections with wt, Tr36, 
LeC, and 12 U/A viruses with regard to stress-granule formation . The first was that the 
WT, Tr36, and LeC12 U/A viruses were able to actively subvert the stress-granule 
response, while the LeC virus was not. The second possibility was that a property of the 
LeC virus induced stress-granule formation, while the WT Tr155, Tr36 and LeC 12 U/A 
viruses did not. To help distinguish between these possibilities, a mixed-infection 
experiment was performed. HEp-2 cells were infected with wt RSV, LeC virus, or both 
LeC and wt RSV at an moi of 2 and 6, respectively. 16.5 hours post-infection , cells were 
fixed and stained for RSV N protein and eiF3, and stress-granule formation was 
assessed using confocal microscopy. As shown in Figure 17, stress-granule formation 
was present in 3.9- 5.4% of wt RSV-infected cells, while stress-granule formation was 
observed in 44.1 - 51 .1 %of LeG-infected cells , consistent with previous results. 
Surprisingly, cells that had been infected with both wt RSV and LeC virus showed stress 
granules in 4.1 - 4.2 % of cells, similar to cells infected with only WT virus. These results 
suggest that wt RSV is able to actively disrupt or prevent LeG-mediated stress-granule 
formation. 
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Figure 17. wt RSV blocked stress-granule formation induced by the LeC virus. A) 
Replicate cultures of HEp-2 cells were infected with indicated viruses at an moi of 2 in 
the case of the LeC virus, and 6 in the case of wt RSV. Cells were immunostained for 
RSV N and cellular eiF3 at 16.5 h pi and examined by confocal microscopy. B) Bar 
graph illustrating proportions of cells that showed stress-granule formation . At least 100 
cells from each culture were examined and the percentages of infected cells containing 
stress granules calculated. The data from two independent experiments are shown 
(represented by the black and grey bars). 
83 
1. 12 The weak-plaque phenotype of LeC was not restored in TIAR knockout cells. 
As mentioned earlier, lseni et al. reported that the Tr transcript of Sendai virus binds 
stress granule-associated protein TIAR, and proposed that this enables Sendai virus to 
subvert stress-granule assembly (1 03). We hypothesized that RSV utilizes a similar 
mechanism to prevent stress granules, and that the LeC virus displays impaired growth 
characteristics because it is unable to sequester TIAR and thereby prevent stress-
granule assembly. If this model were correct, it would be expected that the LeC virus 
would have a plaque phenotype similar to wt RSV in cells lacking TIAR. To test this 
possibility, mouse embryo fibroblasts derived from TIAR-knockout mice were infected 
with wt RSV, or the Tr36, LeC, or LeC 12U/A viruses and assessed for plaque 
phenotype. The absence of TIAR expression was confirmed by western blot analysis 
(Figure 18A). Contrary to what we expected, compared to the other viruses, LeC virus 
displayed a small/faint plaque phenotype in TIAR knockout cells similar in size and 
intensity to LeC plaques in HEp-2 cells (Figure 188). These data show that RSV 
subversion of stress-granule formation is independent of TIAR, and suggest that, unlike 
the situation with Sendai virus, the difference between LeC and wt RSV growth is not 
related to the ability of the Tr or TrC sequence to sequester TIAR. 
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Figure 18. The LeC virus phenotype was small and faint in TIAR knockout cells. 
A) Western blot analysis of total intracellular proteins from mouse embryonic stem cells 
derived from a WT (+/+)(lane 1), or TIAR knockout(-/-) mouse (lane 2). The 40 kDa 
TIAR protein was detected with a polyclonal antibody. B) Monolayers of TIAR-/-cells 
were infected with wt RSV, Tr36, Lee and Lee 12U/A viruses. Four days post-infection, 
virus plaques were immunostained with anti-F antibody. The pictures on the left are 
photographs of the infected wells. The pictures on the right are close-ups of the 
plaques, as visualized with microscopy. 
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1.13 Arsenite treatment and LeC infection induced stress-granule formation in 
TIAR KO cells 
Because we had hypothesized that stress responses were responsible for Lee's 
impaired growth and weak plaque phenotype, we had expected that Lee virus would 
have a restored plaque morphology in TIAR KO cells , which we had assumed were 
deficient in stress-granule formation . To determine whether stress granules were able to 
form in these cells, we treated them with sodium arsenite or infected them with the Lee 
virus; two conditions that induced stress granules in other cells. As demonstrated in 
Figure 19, both arsenite treatment and Lee infection induced stress granules in TIAR 
knockout cells. These data indicate that TIAR is not necessary for Lee infection- or 
arsenite-induced stress granule-like formations. They are also consistent with previous 
results showing that the weak-plaque phenotype of the Lee virus correlates with stress-
granule formation. 
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Figure 19. Arsenite treatment and LeC infection induced stress granules in TIAR 
KO cells. Monolayers of TIAR-/- cells were mock infected, mock infected and treated 
with arsenite for 30 min immediately prior to fixation , or infected with LeC virus at an moi 
of -1 . The cells were immunostained for eiF3 at 16.5 h pi and examined by fluorescence 
microscopy. 
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1.14 Transfected RSV proteins and minigenome prevented stress-granule 
formation. 
Because the results shown in Figure 18 and Figure 19 indicated that RSV-mediated 
stress-granule subversion was not due to TIAR sequestration , we wished to further 
explore the conditions during which RSV infection is able to block stress-granule 
formation. Our results did not rule out the possibility of the RSV Tr region having a role 
in stress-granule prevention, however, we wished to examine whether expression of 
certain RSV proteins was sufficient to prevent stress-granule assembly. To investigate 
whether RSV proteins associated with RSV polymerase are able to prevent stress 
granules, we transiently expressed either N, P, M2-1, and LorN, P, L, M2-1 , and the 
Tr155 minigenome in cells. The minigenome was added in case active replication was 
needed for stress-granule subversion. Twenty-four hours post infection, cells were 
treated with 0.5 mM sodium arsenite for 30 minutes, and stress-granule formation was 
assessed using immunofluorescence and confocal microscopy. As shown in Figure 20, 
cells that were mock transfected, arsenite-treated demonstrated robust stress-granule 
formation , as expected. Cells that were transfected with N, P, M2-1 , and L formed 
stress granules in response to arsenite; however, there were very few cells that stained 
for N protein, indicating that the transfection efficiency was low. This was also the case 
for cells transfected with N,P, M2-1 , L, and the minigenome; however, the cells that were 
transfected (as indicated by positive staining for N protein (green)) showed reduced 
stress granules compared to other cells. Because the transfection efficiency was so 
poor, no firm conclusions can be drawn from these results ; however, it is possible that 
expressing N, P, M2-1 , and Lin setting in which the polymerase is active is sufficient to 
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prevent stress granules. These findings suggest that a minigenome system may be a 
useful tool for investigating RSV-mediated stress-granule subversion, and warrant 
further investigation. 
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Figure 20. Transfected proteins and minigenome may have been sufficient to 
prevent arsenite-induced stress-granule formation. HEp-2 cells were transiently 
transfected with plasmids expressing RSV N, P, L, and M2-1 proteins and /or the Tr155 
minigenome in addition to a plasmid expressing the T7 polymerase. 24 hours post 
transfection, cells were treated with 0.5 mM sodium arsenite for 30 minutes. Cells were 
fixed and immunostained with antibodies toward RSV N protein (green) and eiF3 (red) . 
Slides were examined using confocal microscopy. 
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1.15 RSV infection did not alter the electrophoretic profile of stress granule-
associated proteins. 
We next wished to determine whether RSV infection altered key proteins associated with 
canonical stress granules. To address this question, HEp-2 cells were mock infected or 
infected with increasing levels of RSV. 18 hours post infection, cells were treated with 
sodium arsenite for 30 minutes as a positive control for stress. Cells were lysed, and 
stress-granule-associated proteins were detected using western-blot analysis. As 
shown in Figure 21, none of the proteins tested was altered in response to RSV 
infection; however, we did not test all proteins that have been associated with cellular 
stress responses, so it is possible that other stress granule-associated proteins are 
altered during RSV infection. 
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Figure 21. RSV infection did not alter the electrophoretic mobility of key stress 
granule-associated proteins. HEp-2 cells were mock infected or infected with 
increasing levels of RSV (the moi used is indicated). 18 hours post infection, cells were 
lysed with RIPA buffer containing protease inhibitors (but not phosphatase inhibitors). 
Proteins were assessed using SDS-PAGE and western blot analysis with antibodies 
toward the indicated proteins. 
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Chapter 1 Discussion 
Summary of results 
The goals of this study were to investigate possible roles of the RSV Tr region . In 
summary, our results demonstrated that replacing the RSV Tr region with the LeC 
sequence resulted in slower growth and lower maximum virus titer in both cell-culture 
systems and mice (Figure 8 and data not shown), as well as a small, weakly stained 
plaque phenotype. The impaired growth and weak plaque phenotype of RSV was not 
due to differences in promoter activity, since mRNA accumulation during LeC infection 
was similar to that of the Tr36 virus (1 01 ). However, infection with the LeC virus resulted 
in significant stress-granule formation in infected cells, while infection with wt RSV or 
other mutant viruses did not. Coinfection with wt RSV and the LeC virus demonstrated 
that wt RSV is able to block LeG-mediated stress-granule induction, and studies using 
TIAR knockout cells showed that unlike Sendai virus, RSV prevention of stress granules 
is independent of TIAR. These studies suggest that stress-granule formation is 
deleterious for RSV infection, and that RSV has evolved mechanisms for subverting 
host-cell stress responses. 
Conflicting study 
It should be noted that shortly after our results described above were published (1 01 ), a 
similar study was published that contradicted our results (143). In the paper, Lindquist et 
al. reported that RSV induces and benefits from significant stress-granule formation. In 
their hands, infection with RSV resulted in stress-granule formation in approximately 
25% of infected cells at 16 hpi, and that cells with stress-granule formation contained 
larger RSV inclusion bodies than those without stress-granule formation. They further 
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reported that cells deficient in G3BP resulted in a 1 0-fold decrease in replication and 
concluded that stress-granule formation was beneficial for RSV replication. 
It is unclear why they observe more stress granules in infected cells than we did. It is 
notable that their results demonstrated that only 25% of infected cells showed stress-
granule formation. Thus, in both our study and theirs, the majority of wt RSV-infected 
cells do not form stress granules, which is consistent with the hypothesis that RSV has a 
mechanism to subvert the stress response. The authors concluded that because cells 
containing stress granules showed larger RSV inclusion bodies, it could be inferred that 
stress granules were beneficial to RSV biology; however, there is no formal data to 
suggest that RSV inclusion bodies are sites of RSV replication. Finally, the authors 
concluded that because RSV replicated less efficiently in cells lacking G3BP, an ATP-
dependent RNA helicase, it could be inferred that stress granules are beneficial to RSV. 
It is possible, however, that G3BP is directly or indirectly important for RSV replication in 
a capacity separate from stress-granule formation. An exciting possibility is that 
interfering with stress granule assembly increases the availability of G3BP for 
participation in RSV replication. 
In support of our conclusions regarding RSV's subversion of stress-granule formation, 
Fricke et al. recently published a study demonstrating that RSV is able to subvert stress-
granule formation by sequestering phosphorylated p38 mitogen-activated protein kinase 
(MAPK) and 0-linked N-acetylglucosamine transferase (OGT) into RSV inclusion 
bodies, thereby preventing the activation of MAPK-activated protein kinase 2 (MK2) (88). 
In addition, the group performed a well-controlled experiment in which they 
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demonstrated that in the small percentage of RSV-infected cells that showed stress-
granule formation , the presence of small inclusion bodies was associated with the 
presence of stress granules. In addition, there was a significant negative association 
between cells showing large, prominent inclusion bodies and stress-granule presence. 
Taken together, their and our results demonstrate that infection with RSV does not result 
in significant stress-granule formation, and that the virus is able to actively subvert stress 
responses. 
Possible explanations for LeG-mediated stress-granule induction: gain of function 
or loss of function? 
There are at least three possible explanations for why the LeC virus induced stress 
granules in a significant proportion of infected cells whereas the LeC 12A/U, Tr36, and 
WT viruses did not. One possibility is that the Le promoter generated an RNA species 
that induced stress-granule formation (possibly because of the unnatural context of the 
Le promoter in the LeC virus). Another possibility is that the Tr36, LeC 12U/A, and WT 
viruses can actively inhibit stress-granule formation, while the LeC virus has lost its 
ability to subvert the stress response. The third possibility is a combination of these 
proposed mechanisms: it is possible that LeC is inherently more disposed to induce 
stress-granule formation, that all the viruses are able to prevent stress granules within 
certain limits, and that in the approximately 50% of LeG-infected cells demonstrating 
stress-granule formation , the virus was defeated in its anti-stress granule activities. 
Regardless of whether Lee has a gain-of-function ability to induce stress granules, the 
data shown in Figure 17 provide evidence that wt RSV is able to actively prevent stress-
granule formation. In this experiment, co-infection of cells with both LeC and WT viruses 
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resulted in a very low level of stress granule-containing cells, indicating that wt RSV was 
able to inhibit stress-granule formation by the Lee virus. The Tr36 virus infection did not 
induce stress granules, suggesting that the sequence required for stress-granule 
subversion may be located within the terminal 36 nucleotides of Tr, in a region that 
shares significant sequence similarity to Lee sequence (Fig. 1 B). This is supported by 
the fact that a single point mutation in the Lee sequence (12 U/A) that increased the 
similarity of the Lee sequence to that of Tr was sufficient to enable the Lee virus to 
avoid stress-granule formation. This single nucleotide change might have restored a key 
sequence element or secondary structure to the Lee viral RNA. It is unclear if the 
sequence in question functions in the context of the encapsidated genome or 
antigenome RNA, or if it is present in an unencapsidated transcript generated from the 
Tre promoter. However, in a recent study we showed that the terminal 36 nts of the Tre 
promoter region could signal synthesis of an RNA transcript initiated at position 3 and 
extended approximately 25 nucleotides (185), and it is possible that this transcript is 
involved in subverting stress-granule formation . 
Alternatively, it is possible that the Lee virus induces stress-granule formation because 
of its altered Tr sequence, but that RSV's ability to actively interfere with stress-granule 
formation is not directly related to Tr sequence. For example, Lee may form increased 
levels of dsRNA intermediates during replication that activate PKR signaling and thereby 
induce stress-granule formation that hampers its replication cycle. wt RSV is able to 
prevent Lee-mediated stress-granule formation, but it could be mediating this effect by 
sequestering p38 and OGT, as described by Fricke et al. An exciting possibility is that 
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the RSV Tr region binds and sequesters p38 or OGT in order to subvert stress 
responses. 
Possible mechanisms for RSV-mediated stress-granule subversion 
In light of the recent study by Fricke et al., we conclude that it is probable that RSV-
mediated stress-granule subversion is due to sequestration of p38 and OGT in viral 
inclusion bodies; however, the details of this mechanism have not been worked out, and 
it is possible that RSV has more than one mechanism for blocking the stress response. 
Our studies demonstrate that RSV is able to prevent LeG-induced stress granules. 
Similarly to the results shown here, a mutant version of Sendai virus containing LeC in 
place of Tr induced stress granules to a greater extent than the WT virus (1 03). Sendai 
virus Tr-specific sequence was found to bind to TIAR, suggesting that it sequesters this 
protein to subvert stress-granule formation. However, RSV subversion of stress 
granules was independent of TIAR (Figure 18). It is possible that the RSV Tr sequence 
binds to an alternative stress-granule protein, such as TIA-1, a stress granule-associated 
scaffold protein that is closely related to TIAR (92, 114). Unfortunately, mouse embryo 
fibroblasts in which TIA-1 is knocked out did not support RSV infection, preventing us 
from performing an experiment similar to that shown in Figure 18 to test the importance 
of TIA-1. The deficiency in RSV growth was unrelated to the absence of TIA-1, as a 
"sister" control cell line also failed to support RSV cell-to-cell spread (data not shown). It 
is possible that RSV Tr might modulate the cellular stress-granule response due to a 
direct interaction with stress-granule proteins other than TIAR; however, a study by 
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Santangelo et al. showed no evidence of stress-granule protein sequestration by RSV 
RNAs (208). 
Another possibility is that RSV inhibits stress-granule formation at a step upstream of 
stress-granule assembly. Santangelo et al. reported that wt RSV cannot inhibit the 
stress-granule response if infected cells are treated with arsenite prior to infection (208). 
This could either be because arsenite treatment overwhelms the stress granule-
subverting activity of RSV, or because arsenite induces stress granules via an 
alternative pathway than RSV infection, and the virus is not able to inhibit the arsenite-
mediated pathway at the concentration used in the study. Another possibility is that 
RSV-mediated stress subversion requires the accumulation of a specific factor (for 
example, Tr RNA) before it is able to mediate stress-granule prevention, and that 
pretreatment with arsenite does not allow this to occur. Our results shown in Figure 13 
demonstrating that a well established RSV infection can interfere with stress-granule 
formation induced by other stressors in certain cases indicate that the stochiometry of 
the factors involved (stress-granule inducers vs. stress-granule preventers) may 
determine the stress-granule formation outcome. Our results as well as others' suggest 
that stress-granule induction is not a Boolean phenomenon; rather, the degree of stress-
granule formation by chemical stressors is commensurate with the concentration of 
stressor (data not shown). Given the study by Lindquist et al., in which conditions very 
similar to those used by our lab were used that yielded differing outcomes, it seems 
probable that RSV infection lingers near the interface of stress induction versus stress 
subversion, and that many factors can tip the balance in either direction. More studies 
will be needed to work out the mechanisms of RSV-mediated stress-granule subversion. 
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Evidence that stress granules are deleterious for RSV propagation 
There is a growing body of evidence that stress granules are inherently antiviral. Our 
data suggest that stress granules may be responsible for the impaired growth and 
plaque phenotype of the Lee virus. Although the Tr36 and Lee viruses generated 
similar levels of RNA, they differed significantly with regard to virus growth and plaque 
phenotype (Figure 8), and their differences in plaque phenotype correlated with their 
propensity to elicit a cellular stress-granule response (Figure 15). Emerging evidence 
suggests that a number of viruses are restricted by the cellular stress-granule response 
(140, 199) and unsurprisingly, several viruses are known to either prevent or manipulate 
stress-granule formation (74, 75, 103, 158, 172, 198, 229, 265) . 
The correlation between stress-granule formation and RSV plaque phenotype suggests 
that stress granules were likely responsible for hindering Lee virus growth, but a 
mechanism for this inhibition has not been determined. Stress granules are involved in 
RNA translation and degradation control (16, 17), suggesting that they might inhibit Lee 
virus growth by limiting its protein expression. However, metabolic labeling analysis 
indicated that there was little, if any, difference in Lee viral protein synthesis compared 
to that of other viruses at a time (16 hours post infection) when stress granules were 
clearly detectable (data not shown). 
One exciting possibility is that stress granules may limit growth of the Lee virus by 
manipulating cytokine production. This is supported by reports that stress granules can 
post-transcriptionally regulate cytokine expression (15). Preliminary studies have 
indicated that the Lee virus did not differ significantly from the Tr36 and Lee 12 U/A 
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viruses in the amount of interferon that was produced during infection (M. Galliano, R.E. 
Randall, and R. Fearns, unpublished data,); however, interferon is not a major player in 
RSV immune responses. Other cytokines and chemokines important during RSV 
infection, such as IL-8, IL-6, and RANTES, have not been examined in the context of 
LeC infection. 
Future studies 
An increasing number of scientists are reporting mechanisms by which viruses are able 
to overcome cellular stress responses, and an emerging theme is that viruses and 
cellular stress responses have co-evolved in such a way that there is a delicate 
equilibrium established between stress induction and stress subversion. We have 
demonstrated that RSV is able to prevent stress-granule formation in the majority of 
infected cells, but that occasionally fails in its stress-prevention activities. Furthermore, 
the virus can be modified in such a way (i.e. the LeC virus) that the balance is tipped in 
favor of stress-granule induction. Future studies are needed to determine the 
mechanism by which RSV is able to subvert stress-granule formation , the factors 
involved in determining the extent to which RSV can battle stress responses, and 
whether stress granules are definitively deleterious for RSV propagation. 
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Chapter 2: RSV Interactions with P-bodies and P-bodv-associated Proteins 
Chapter 2 Introduction 
Processing bodies (p-bodies) 
As described briefly in the Introduction, p-bodies are constitutively present in the 
cytoplasm of most cells, and are believed to be sites of mRNA decapping and 
degradation. They increase in size and number during environmental stress when 
cellular translation is stalled. P-bodies contain decapping proteins 1 and 2 (dcp1 and 
dcp2), exonucleases such as Xrn1, deadenylases, and RNA-binding proteins with roles 
in nonsense-mediated mRNA decay pathways and micro-RNA gene silencing processes 
such as DDX3, Ago2, p54/DDX6, Lsm1 , PatL 1, and G3BP. While mRNA decay occurs 
inside p-body structures, p-bodies are not required for nonsense-mediated decay. The 
proportions of mRNA decay that take place inside vs. outside p-bodies has not been 
resolved (21 ). 
P-body assembly 
As with stress granules, the mechanisms of p-body formation are largely 
uncharacterized. Some studies suggest that p-body formation involves mRNA and 
RNA-binding protein aggregation since cells treated with RNase show dispersed p-
bodies (78). There is some evidence that the DEAD-box helicase p54 (also called DDX6 
and rck), which is discussed extensively in Chapter 3, is required to coat and relax 
mRNPs before their entry into p-bodies (77). 
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Nonsense-mediated decay pathway 
Nonsense-mediated decay is a major mRNA degradation pathways that takes place in 
p-bodies. This process is initiated when the poly-A tail on capped and polyadenylated 
mRNAs is shortened by deadenylase enzymes. The mRNA is then decapped by the 
dcp1/dcp2 decapping complex. Cap removal renders the transcript susceptible to 
exonucleases such as Xrn1, which degrade RNA in a 5' to 3' direction (Figure 22). 
3' 
5' AAAAAAAAAAA 
1 Shortening of poly-A tail 
5' AA 3' 
1 Dcp1-dcp2 cleavage of cap 
5' AA 3' 
1 5' to 3' exonuclease degradation 
Figure 22. Nonsense-mediated decay pathway. Nonsense-mediated decay is 
initiated when the poly-A tail (A's) on capped (red clouds) and polyadenylated mRNAs 
(blue wavy lines) is shortened by deadenylase enzymes. The mRNA is then decapped 
by the dcp1/dcp2 complex, which is stabilized by enhancers edc3, edc4, p54, and Xrn1. 
Cap removal renders the transcript susceptible to exonucleases such as Xrn1 , which 
degrade RNA in a 5' to 3' direction. 
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Decapping proteins 
As mentioned above, during nonsense-mediated decay, the 7-methylguanosine cap is 
cleaved from mRNAs by the dcp1/dcp2 complex. Studies in yeast have shown that dcp2 
contains the catalytic activity necessary for the reaction, and that dcp1 is an essential 
cofactor that is believed to stabilize dcp2 in a closed , catalytically-active conformation 
necessary for decapping (220). The crystal structure of dcp1 in yeast has recently been 
characterized, and it revealed two important domains - one for binding dcp2, and 
another for binding decapping enhancers (219). In humans, dcp1 and dcp2 exist in a 
complex with enhancer proteins Edc3, Edc4 (also called Hedls), p54, and exonuclease 
Xrn1 ((35, 83). Edc4 is important for enhancing the catalytic activity of dcp2 and 
stabilizing the association between dcp1 and dcp2 (83). Our results have identified dcp1 
as important during RSV infection, as discussed in this chapter. 
Virus interactions with p-bodies 
P-body-associated activities help regulate mRNA stability, metabolism, and expression. 
It therefore stands to reason that viruses could evolve to manipulate p-body formation 
and/or co-opt p-body proteins for use in viral replication cycles. Several viruses are 
reported to disperse p-bodies, degrade p-body proteins, and/or hijack p-body 
constituents to enhance replication . The following table summarizes such virus-p-body 
interactions: 
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Table 4: Virus interactions with cellular p-bodies 
Virus Interactions with Cellular P-bodies 
Virus Mechanism of P-body Interaction Ref. 
Vi.ruses that disperse or redistribute p-bodies during infection 
Disrupt p-bodies; mediate 
Poliovirus and coxsackievirus degradation of Pan3, Xrn1, and (72) 
Dcp1 
Adenovirus 
Influenza virus 
Viral E4 11 K protein disrupts p-
bodies by redistributing p-body 
components Lsm-1, Gee-1, Ago2, 
and Xrn1 to aggresomes for 
presumed proteolytic destruction 
Viral protein NS1 associates with p-
body protein Rap55; NS1-Rap55 
complex prevents viral RNPs from 
entering p-bodies 
(94) 
(168) 
Viruses that co-opt p-body components to augment replication 
West Nile virus 
Infection results in progressive 
dispersion of p-bodies; virus directs 
relocalization of p-body components 
Lsm1, DDX3, DDX6, and Srn1 to 
virus replication factories for 
enhanced replication 
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(46, 
74) 
Yellow fever virus, dengue Xrn1 is necessary for production of (173, 
virus, Kunjin virus, West Nile sfRNA, which may be important for 215, 
virus virus replication 223) 
Conflicting reports: One study 
indicates viral RNAs are localized to 
(182, 
p-bodies; another study contends 
HIV1 196, 
they are not; Gag forms complexes 
201) 
with p54/DDX6 and Ago2 to 
promote virion assembly 
HCV core proteins colocalize with 
DDX6 in p-body-like punctate 
complexes; DDX3 enhances HCV 
Hepatitis C virus replication; re-distributes p-body (20) 
components p54/DDX6, Lsm1, 
Wrn 1, PA TL 1 , and Ago2 into viral 
replication factories 
Viral nucleoprotein N binds to 5' cap 
of cellular mRNAs in p-bodies to 
prevent decapping and subsequent 
Hantavirus degradation; these complexes are (167) 
released back into cytoplasm where 
the virus uses protected/"snatched" 
caps to prime virus mRNA synthesis 
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Requires p-body components 
Lsm1 p-7p complexes, Pat1 p, and 
Dhh1 p required for efficient 
Brome mosaic virus (186) 
translation of viral transcripts and 
for viral RNA entry into replication 
complexes 
Promote degradation of cellular 
RNAs to promote translation of viral 
Gamma herpes virus mRNAs; viral protein SOX induces (61) 
endonucleolytic cleavage of cellular 
RNAs for degradation by Xrn1 
Hypothesis 
In the previous chapter, we discussed our studies exploring the relationship that RSV 
has with cellular stress granules. We next wished to characterize the relationship the 
virus has with cellular p-bodies. We hypothesized that RSV infection altered either p-
body-associated proteins or p-body structures. 
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Chapter 2 Results 
2.1 RSV infection altered the electrophoretic mobility of dcp1, but not of other p-
body-associated proteins. 
Our studies discussed in Chapter 1 focused on the relationship between RSV infection 
and host-cell stress granules. We next wished to investigate RSV's relationship with p-
body proteins and structures. To determine whether RSV infection results in altered p-
body-associated proteins, HEp-2 cells in 6-well plates were mock infected or infected 
with increasing levels of RSV. After 17.5 hours, one well was treated with 0.5 mM 
sodium arsenite for 30 minutes. Eighteen hours after infection, samples were harvested 
and analyzed using SDS-PAGE and western blot analysis with antibodies toward a 
panel of p-body-associated proteins. As seen in Figure 23, neither the levels nor 
migration patterns of dcp2, edc3, edc4, eiF3, or Xrn1 were changed eighteen hours after 
infection. On the other hand, the electophoretic mobility of dcp1 was altered in RSV-
infected cells. In mock-infected cells, dcp1 migrated as a doublet (Figure 23, lane 1 ); 
however, in arsenite-treated cells (lane 2) or cells infected with RSV at an moi of 1 or 5 
(lanes 5 and 6), dcp1 migrated as only the upper band. These results indicate that dcp1 
is altered in response to RSV infection, and that the effect is dose dependant. 
To determine whether RSV infection results in an altered dcp1 migration pattern in a 
more authentic cell type, we repeated the experiment described above in A549 cells and 
obtained similar results, confirming that altered dcp1 migration profile seen during RSV 
infection was not cell specific (Figure 24). Figure 25 shows the RSV-mediated 
electrophoretic shift from a doublet to a single upper band in greater resolution than the 
previous figures . 
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eiF3 
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Figure 23. RSV altered the elecrophoretic mobility of dcp1, but not other p-body-
associated proteins. HEp-2 cells were mock infected, treated with 0.5 mM sodium 
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arsenite for 30 minutes, or infected with increasing levels of RSV at the indicated moi. 18 
hour post infection, cells were lysed with RIP A buffer. Soluble fractions of samples were 
assessed using western blot analysis and antibodies toward the indicated proteins. 
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Figure 24. RSV infection resulted in altered dcp1 migration in A549 cells. A549 
cells were mock infected, treated with 0.5 mM sodium arsenite for 30 minutes, or 
infected with increasing levels of RSV at the indicated moi. 18 hours post infection, cells 
were lysed and soluble fractions were assessed using western blot analysis and 
antibodies toward the indicated proteins. 
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Figure 25. RSV infection mediated electrophoretic shift from doublet to a single 
upper band. Hep-2 cells were mock infected, treated with 0.5 mM sodium arsenite for 
30 minutes, or infected with RSV (moi = 5). 18 hours post infection, cells were lysed with 
RIPA buffer. Soluble fractions of samples were assessed using western blot analysis 
and an antibody toward dcp1. 
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2.2 The shift in dcp1 electrophoretic mobility observed during RSV infection was 
due to dcp1 phosphorylation. 
Post-translational modifications of dcp1 
Several studies have demonstrated that dcp1 can be post-translationally modified by 
phosphorylation. Blumenthal et al. found that dcp1 is phosphorylated during certain 
stages of neuronal development and in response to arsenite treatement (31 ). Xu et al. 
reported that dcp1 is phosphorylated in Arabidopsis plants during dehydration stress 
(271 ), and Rzeczkowski et al. discovered that dcp1 is phosphorylated in mammalian 
cells in response to treatment with IL-1 a, anisomycin, or sorbitol (206). Ma et al. recently 
reported that dcp1 is phosphorylated during murine oocyte development (28) , and Aizer 
et al. demonstrated that dcp1 is phosphorylated during mitosis (4) . These studies 
suggest that dcp1 phosphorylation is important during development, stress, immune 
responses, and cell division. Most of these studies describing dcp1 phosphorylation had 
not been published at the time of our studies. Because Blumenthal et al. had reported 
dcp1 phosphorylation during arsenite stress and neuronal development, we 
hypothesized that the RSV-mediated shift in dcp1 migration was due to phosphorylation 
of dcp1. Cells were mock infected, treated with sodium arsenite (as a positive control for 
dcp1 phosphorylation), or infected with RSV. Eighteen hours after infection, cells were 
lysed and either mock treated or treated with A-phosphatase, which dephosphorylates 
serine, threonine, and tyrosine residues. As shown in Figure 26, dcp1 from mock-
infected cells migrated as a doublet (lane1) , while dcp1 from arsenite-treated or RSV-
infected cells migrated as only the upper band (lanes 3 and 5). In contrast, the samples 
from each group that were treated with phosphatase migrated as only the lower band 
(lanes 2, 4, and 6}, indicating that the upper band results from dcp1 phosphorylation . 
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Figure 26. RSV-mediated change in dcp1 migration was due to phosphorylation. 
HEp-2 cells were mock infected, treated with sodium arsenite, or infected with RSV (moi 
= 5), and lysed as described, except that phosphatase inhibitors were not incuded in the 
RIP A buffer. Soluble fractions were either mock treated or treated with 'A phosphatase 
(Santa Cruz, 100 U in a 50 j.JI reaction according to manufacturer's instructions) for 30 
minutes. Samples were examined using western blot analysis with an antibody toward 
dcp1a. 
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2.3 RSV infection mediated dcp1 migration shift in all cell-lysate fractions. 
To further explore RSV-mediated dcp1 phosphorylation, we wished to determine 
whether the phenomenon was unique to specific cellular fractions. Mason et. al. 
developed a protocol for fractionating RSV-infected celllysates using increasingly 
stringent buffers alternated with centrifugation as depicted below: 
Total cell extract 
Tris acetate buffer 
2400 xg spin 
51 Pl ~ Triton X-100 
2400 xg spin 
52 P2 ~ DOC+ Tween 40 
2400 xg spin 
53 
Figure 27. RSV fractionation technique schematic. 
P3 
Mason et al. used in vitro transcription assays to determine that the 83 fraction most 
active with regard to RSV transcription (149). We wished to determine whether 
phosphorylated versus unphosphorylated dcp1 accumulated in a specific RSV fraction. 
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HEp-2 cells were mock infected or infected with RSV (moi =5). Eighteen hours after 
infection, cells were lysed and fractionated using Mason's technique. Dcp1 
phosphorylation was assessed using SDS-PAGE and western blot analysis. As shown 
in Figure 28, dcp1 was most concentrated in the S1 fraction , but was present in all 
fractions. In addition, dcp1 migrated as the upper band in all fractions from RSV-
infected cells (lanes 2, 4, 6, and 8) . These results indicate that accumulation of 
phosphorylated dcp1 was not specific to any RSV fraction . Dcp1 showed a slight 
increase in level in the P1 fraction , consistent with other data indicating that RSV 
infection may sometimes result in increased levels of dcp1 . Future studies are needed 
to investigate this phenomenon. 
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Figure 28. DCP1 was phosphorylated in all fractions of RSV-infected cells. Mock-
infected or RSV-infected HEp-2 cells were fractionated using a technique developed by 
Mason et al., as described in the Materials and Methods section. Samples were 
assessed for dcp1 phosphorylation using SDS-PAGE and western blot with an antibody 
toward dcp1 . S 1, S2, and S3 refer to soluble fractions, and P3 is the insoluble fraction. 
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2.4 Purified RSV was sufficient to mediate dcp1 phosphorylation. 
As discussed in detail in the Materials and Methods section, the RSV stocks used in the 
majority of our experiments are derived from the clarified supernatant of RSV-infected 
cells. In brief, cells are infected with RSV at a very low moi. Three to five days after 
infection, the supernatants are collected and centrifuged to remove cells. Because the 
virus stocks contain cellular debris and proteins secreted by the infected cells including 
soluble RSV envelope glycoproteins and cytokines such as IL-1 (which has been 
reported to induce dcp1 phosphorylation), we wished to determine whether RSV itself 
and/or another factor in the supernatant-derived RSV stocks was responsible for 
inducing dcp1 phosphorylation. 
To determine whether something in the supernatant other than RSV was able to induce 
dcp1 phosphorylation, the supernatant from RSV-infected cells was centrifuged at an 
ultra-high velocity in order to pellet the virus. Supernatant from above the pellet (which 
presumably contained little to no virus) was collected and a plaque assay was 
performed. The supernatant (sup) was found to have a negligible amount of virus. To 
address whether RSV was sufficient to mediate dcp1 phosphorylation , we purified RSV 
using a sucrose-cushion method (sue.) in which ultra-centrifuged RSV formed a band at 
the interface between 30% and 60% sucrose solutions. Because banded virus was 
diluted 1:10 in sterile media, the maximum percentage of sucrose in purified virus 
preparations was 6%. HEp-2 cells were mock infected, treated with supernatant from 
RSV-infected cells , treated with 6% sucrose (to determine whether sucrose in purified 
RSV preparations influenced dcp1 phosphorylation), or infected with sucrose-purified 
RSV. One hour after infection, cells were lysed and dcp1 phosphorylation was assessed 
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using SDS-PAGE and western blot analysis. As shown in Figure 29A, dcp1 from mock-
infected cells (lane 1) or sucrose-treated cells (lane 2) migrated as a doublet. Dcp1 from 
cells treated with supernatant (lane 3) or infected with sucrose-purified RSV (lane 4) 
migrated as primarily the upper band. These results indicate that one or more factors in 
preparations of RSV that have not been purified is able to mediate dcp1 
phosphorylation. Importantly, these results also demonstrate that purified RSV is 
sufficient to mediate dcp1 phosphorylation. 
To determine whether infection with purified virus was able to mediate dcp1 
phosphorylation over a longer period, HEp-2 cells were mock infected, infected with the 
supernatant of ultracentrifuged virus, treated with 6% sucrose, or infected with sucrose-
purified virus. One hour post infection, the media was changed. Eighteen hours after 
infection, cells were lysed and dcp1 phosphorylation was assessed using SDS-PAGE 
and western blot analysis. As shown in Figure 298, dcp1 from mock infected cells (lane 
1 ), supernatant-treated cells (lane 2), or sucrose-treated cells (lane 3) migrated as a 
doublet, while dcp1 from sucrose-purified RSV (lane 4~ migrated as only the upper band. 
These results indicate that treatment of cells with neither the supernatant from RSV-
infected cells nor 6% sucrose are able to mediate dcp1 phosphorylation 18 hours after 
treatment (17 hours after removal of treatments) . In addition , these results confirm that 
purified RSV is sufficient to mediate dcp1 phosphorylation late in RSV infection. Taken 
together, our results indicate that although one or more factors in unpurified virions is 
able to mediate a transient increase in dcp1 phosphorylation , purified RSV is sufficient to 
induce dcp1 phosphorylation. 
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Figure 29. Purified RSV was sufficient to mediate dcp1 phosphorylation. A) HEp-2 
cells were mock infected, treated with supernatant from RSV-infected cells that was 
centrifuged at 24,000 x gat 4 oc for 1 hour, or infected with sucrose-purified RSV (moi 
=5). One (Panel A) or eighteen (Panel B) hours post treatment/infection, cells were 
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lysed and examined using western blot analysis with an antibodies toward dcp1 or RSV 
proteins. 
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2.5. TN F-a and /L-1, but not IFN-a, mediated dcp1 phosphorylation 
Several cytokines are induced during RSV infection. Kurt-Jones et al. showed that RSV 
F protein interacts with TLR-4 to induce proinflammatory cytokine production (128) , and 
many cytokines are reportedly induced during RSV infection in vitro, including IL-6, TN F-
a, IL-1[3, IFN-y, IL-2, IL-12, IL-4, IL-5, IL-10, IL-13, G-CSF, and GM-CSF (218), as well 
as IFN-a and IFN[3 (187). Because our results suggested that a component in the 
supernatant of RSV preparations was able to transiently induce dcp1 phosphorylation, 
we wished to determine whether cytokines associated with RSV infection could mediate 
the effect. HEp-2 cells were treated with increasing concentrations of TN F-a, IL-1 [3 , or 
IFN-a for one hour. Cells were lysed and assessed for dcp1 phosphorylation using 
SDS-PAGE and western blot analysis. As shown in Figure 30, dcp1 was 
phosphorylated in response to all levels of TN F-a and IL-1 [3 . In contrast, treatment with 
IFN-a did not result in dcp1 phosphorylation at any of the concentrations tested . These 
results indicate that cytokines that are potentially present in RSV virion preparations that 
have not been purified may contribute to dcp1 phosphorylation. 
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Figure 30. TNF-a and IL-1 induced dcp1 phosphorylation, whereas IFN-a did not. 
HEp-2 cells were mock treated (lane 1) or treated with the indicated concentrations of IL-
1 (lanes 2-4), TN F-a (lanes 5-7), or IFNa (lanes 8-1 0). One hour post treatment, cells 
were lysed with RIPA buffer and samples were analyzed using SDS-PAGE and western 
blots using an antibody toward dcp1. 
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2.6 Dcp1 was phosphorylated early during RSV infection, and remained 
phosphorylated throughout infection. 
Our results from previous experiments indicated that dcp1 is phosphorylated both early 
during infection (1 hpi) and well after infection is established (16-18 hpi). To more 
extensively examine the kinetics of dcp1 phosphorylation during RSV infection, we 
performed a time course. HEp-2 cells were either mock infected, infected with regular 
RSV, infected with sucrose-purified RSV, or treated with sodium arsenite. At the 
indicated times post infection, cells were lysed and dcp1 phosphorylation was assessed 
using SDS-PAGE and western-blot analysis. As demonstrated in Figure 31 , panels A 
and C, dcp1 was phosphorylated within 15 minutes of RSV infection, and remained 
phosphorylated throughout infection with either regular RSV (clarified supernatants from 
RSV-infected cells) or sucrose-purified RSV. These results suggest that dcp1 
phosphorylation is triggered by an early event in RSV infection such as RSV-cell binding 
or fusion. In addition, these results indicate that one or more aspects of RSV infection 
mediates sustained dcp1 phosphorylation throughout infection. 
2.6 UV-inactivated RSV mediated transient dcp1 phosphorylation. 
To determine whether RSV replication is necessary in order for the virus to mediate 
dcp1 phosphorylation, the time course described above was also performed with both 
UV-inactivated regular RSV or UV-inactivated sucrose-purified RSV. RSV was 
irradiated at 200 J/m2. A plaque assay was performed to confirm that these conditions 
were sufficient to abrogate RSV replication (Figure 31, panel E). As shown in Figure 31 
panels 8 and D, dcp1 from cells infected with UV-inactivated RSV showed a transient 
increase in dcp1 phosphorylation while virus was in contact with cells (lanes 2-4); 
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however, once the media was replaced, the increase in dcp1 phosphorylation began to 
reverse (lanes 5-7) . By twenty-four hours post infection, dcp1 from cells infected with 
UV-inactivated RSV had a similar migration pattern to dcp1 from mock-infected cells 
(compare lanes 1 and 7). These results indicate that replication-competent RSV is not 
necessary for mediating dcp1 phosphorylation; however, replication-competent RSV is 
necessary for maintaining dcp1 phosphorylation throughout infection. Of note, the dcp1 
phosphorylation profiles from samples infected with regular RSV preparations looked 
remarkably similar to those infected with sucrose-purified RSV (compare panels A and 
C, and panels B and D). 
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Figure 31. DCP1 was phosphorylated throughout RSV infection. HEp-2 cells were 
mock infected, infected with RSV (A), UV-inactivated RSV (8), sucrose-purified RSV (C) , 
or UV-inactivated, sucrose-purified RSV (D) , or treated with 0.5 mM sodium arsenite. 
For samples treated with UV-inactivated virus, RSV was subject to 200 J/m2 irradiation . 
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Samples were lysed in RIP A buffer at the indicated times post infection and soluble 
fractions were analyzed using SDS-PAGE and western blot analysis with an antibody 
toward dcp1 a. 
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2.7 RSV-mediated dcp1 phosphorylation correlated with ERK112 activation during 
infection. 
Mitogen-activated protein kinases (MAPKs) 
MAPKs are a family of serine/threonine-specific enzymes that regulate cellular 
responses to a number of stimuli , including environmental stress, DNA damage, 
proinflammatory cytokines, mitogens, and infections. MAPKs take part in phospho-relay 
signaling cascades, in which kinases are sequentially phosphorylated and are thereby 
rendered enzymatically active and able to phosphorylate the next substrate in the 
cascade: 
stimulus , ... , activator , ... , MKKK , ... , MKK , ... , MAPK , ... , Substrate 
Figure 32. Classical MAPK signaling pathway. 
MAPKs are catalytically inactive under normal cellular conditions and require 
phosphorylation in order to become active. In a typical cascade, a stimulus induces 
phosphorylation of an activator protein, which in turn activates a MAP-kinase-kinase 
kinase (MKKK). MKKKs activate MAP-kinase kinases (MKKs) , which activate MAPKs. 
MAPKs phosphorylate protein substrates on serine and/or threonine residues. 
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Figure 33: Mitogen-activated protein kinase cascades. Schematic showing the four 
major subfamilies of MAPK proteins, their cognate MAPKKs (MKKS), and MAPKKKs 
(MKKKs) , as well as general activators and outcomes of respective pathways. 
Four important subfamilies of MAPKs have been identified: extracellular signal-regulated 
kinases (ERK1/2), c-Jun amino-terminal kinases (JNK), p38, and ERK5. It is important 
to note that a large number of stimuli can lead to activation of MAPKs; however, the 
MKKs that phosphorylate their cognate MAPKs are very specific for each subfamily (25, 
139). For example, MEK 1 and MEK 2 (MKKs) phosphorylate ERK1/2 but do not 
phosphorylate JNK, p38, or ERK5. MAPKs are activated and deactivated by 
phosphorylation and de-phosphorylation, respectively . This process allows cells to 
regulate diverse cellular processes such as gene expression , movement, cell division, 
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proliferation, survival, metabolism, apoptosis, and host-defense mechanisms, including 
responses to infections (1 06). 
Because dpc1 was phosphorylated so early during RSV infection, we speculated that 
RSV-mediated dcp1 phosphorylation was part of a MAPK signaling pathway. Of note, 
the studies above linking dcp1 phosphorylation to MAPK activation had not been 
published at the time of our investigation. To test the possibility of MAPK involvement in 
RSV-mediated dcp1 phosphorylation, we first sought to determine whether MAPK 
activation correlates temporally with dcp1 phosphorylation during RSV infection. HEp-2 
cells were mock infected or infected with sucrose-purified RSV. At the indicated times 
post infection, cells were lysed. Dcp1 phosphorylation, ERK1/2 activation, JNK 
activation, and p38 activation were assessed using SDS-PAGE and western blot 
analysis. As shown in Figure 34, ERK1/2 activation occurred within 15 minutes of RSV 
infection and correlated with dcp1 phosphorylation throughout infection. JNK did not 
show increased levels of phosphorylation at any point during infection. P38 showed low 
levels of phosphorylation at 15 minutes and 24 hours post infection, but not at any other 
time points. Because dcp1 is phosphorylated throughout RSV infection, these results 
identified ERK1/2 as the most likely MAPK of those tested to be involved in RSV-
mediated dcp1 phosphorylation. 
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Figure 34. ERK1/2 activation correlated with dcp1 phosphorylation during RSV 
infection. HEp-2 cells were mock infected or infected with sucrose-purified RSV (moi = 
5). Samples were collected at indicated times post infection. Media was changed after 
60 minutes. Cells were harvested in RIPA buffer containing phosphatase and protease 
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inhibitors and analyzed using western blots and indicated antibodies. 24 hours post 
infection, one well was treated with sodium arsenite for 30 minutes. Dcp1 , phospho-
ERK1/2, phospho-JNK, phospho-p38, and RSV proteins were detected using SDS-
PAGE and western blot analysis. 
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2.8. Inhibitors to ERK112 decreased RSV-mediated dcp1 phosphorylation 
To further explore the possibility of MAPK involvement in RSV-mediated dcp1 
phosphorylation, we used pharmacological MAPK inhibitors during RSV infection. The 
targets of the inhibitors used are shown in Table 5. While some inhibitors are highly 
specific, others inhibit more than one kinase. 52-7-oxozeanol is a chemical that has 
been demonstrated to strongly inhibit MKKK TAK1 , and thereby repress ERK1/2, JNK, 
and p38 activation (73, 135, 211). U0126 and PD98059 inhibit MEK1 and thereby 
ERK1/2 activation (69), but also have been reported to inhibit MEK5 and thereby ERK5 
activation . 88203580 specifically inhibits p38 activation (69). SP600125 strongly 
inhibits JNK activation; however its usefulness is limited as it can also inhibit activation of 
at least 20 other kinases, including PI3K and AKT (243), as well as p38, ERK1/2, and 
A TF2 (28). HEp-2 cells were mock treated with DMSO or treated with inhibitors that 
block ERK1/2, JNK, and/or p38 activation (table 2). One hour after treatment, cells were 
mock infected or infected with sucrose-purified RSV. One hour post infection, cells were 
lysed and dcp1 phosphorylation was assessed using SDS-PAGE and western blot 
analysis. In addition, total and phosphorylated ERK 1/2, ERK 5, JNK, and p38 were 
detected. 
Table 5. Pharmacological MAP kinase inhibitors 
ERK1/2 JNK p38 
Compound Mechanism ERK 5 inhibition 
inhibition inhibition inhibition 
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ATP-competitive 
5Z-7- irreversible 
strong strong strong unknown 
oxozeanol inhibitor of ERK2, 
MEK1 , and TAK1 
suppressor of 
U0126 strong - - strong 
MKK1 activation 
prevents 
PD98059 activation of strong - - strong 
MEK1 and MEK5 
prevents MEK1 none (2 IJM) 
PD184352 strong - -
activation moderate (20 IJM) 
reversible 
SP600125 weak strong weak unknown 
inhibitor of JNK 
prevents 
SB203580 phosphorylation - - strong unknown 
of p38 
As shown in Figure 35A, ERK 1/2, ERK 5, p38, and JNK were each phosphorylated in 
response to arsenite treatment (lane 2); however, only ERK 1/2 was phosphorylated in 
response to RSV infection (lane 3). This activation was blocked by inhibitors to ERK 1/2 
(lanes 4-8). Dcp1 from cells that were mock infected migrated as a doublet (lane 1 ), 
while cells that were arsenite-treated or infected with RSV migrated as primarily the 
upper band (lanes 2 and 3) . Treatment with 7-oxozaneal abrogated the RSV-mediated 
increase in phosphorylation , and resulted in even less dcp1 phosphorylation than is 
present in mock-infected cells (lane 4), indicating that MAPK signaling is likely involved 
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in RSV-mediated dcp1 phosphorylation. Dcp1 from RSV-infected cells pretreated with 
U0126 (lane 4), PD98059 (lane 5) , 1 IJM PD184352 (lane 6) , or 10 IJM PD184352 (lane 
7) migrated as a doublet that appeared similar to dcp1 from mock-treated, mock-infected 
cells (lane 1 ). The ratio of phosphorylated to unphosphorylated dcp1 in these samples 
was similar to that of mock-infected cells (Figure 358), suggesting that RSV-mediated -
dcp1 phosphorylation is part of the ERK1/2 signaling pathway. Dcp1 from RSV-infected 
cells pretreated with SP600125 (lane 8) or 88203580 (lane 7) migrated as primarily the 
upper band, indicating that neither JNK nor p38 is involved in RSV-mediated dcp1 
phosphorylation . Consistently, pretreatment with the p38 inhibitor resulted in increased 
levels of phosphorylated dcp1 , indicating that the p38 pathway might be involved in 
negatively regulating dcp1 phosphorylation. Because ERK 1/2 showed consistent 
activation that correlated with dcp1 phosphorylation during RSV infection, and because 
inhibitors to ERK 1/2 abrogated RSV-mediated dcp1 phosphorylation, we conclude that 
RSV-mediated dcp1 phosphorylation is part of the ERK 1/2 pathway; however, further 
studies are needed to determine whether dcp1 is a direct substrate for ERK 1/2 and 
whether other kinases are involved in the effect. 
Of note, two groups have since reported MAPK involvement in dcp1 phosphorylation. 
Xu et al. reported that arabidopsis dcp1 is phosphorylated through the MPK6 pathway 
(271 ). In addition, Rzeczkowski et al. demonstrated that the MAPK JNK is able to 
directly phosphorylate dcp1. Their studies focused on JNK; however, the authors 
speculated that more than one MAPK could phosphorylate dcp1 based on the results of 
their experiments using non-specific MAPK inhibitors (206). 
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Figure 35. RSV-mediated dcp1 phosphorylation was ERK1/2 dependent. A) HEp-
2 cells were mock treated with DMSO or treated with indicated inhibitors for one hour. 
Samples were then mock infected or infected with RSV (moi = 5) for one hour, and 
harvested as above. Samples were examined using western blot analysis with the 
indicated antibodies. B) The fluorescent intensity of the dcp1 bands were calculated 
using Licor Odyssey software, and the proportions of upper band intensity (black, upper) 
and lower band intensity (gray, lower) were calculated. Representative of three 
independent experiments. 
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2.9 Investigation to determine whether RSV envelope proteins are necessary 
and/or sufficient to mediate dcp1 phosphorylation. 
2.9.1 Dcp1 was phosphorylated by neither arsenite nor RSV at 4°C. 
Our results demonstrated that dcp1 was phosphorylated very early during RSV infection, 
and our and others' experiments implicated MAPKs in dcp1 phosphorylation. We 
hypothesized that dcp1 phosphorylation occurred during a very early step of the RSV 
replication cycle such as virus attachment to and/or fusion with host cells. To determine 
whether RSV internalization is necessary for RSV-mediated dcp1 phosphorylation, we 
infected cells with RSV at 4°C in parallel with cells infected at 3rc. We used arsenite 
treatment as a positive control for dcp1 phosphorylation. One hour post infection, cells 
were lysed and dcp1 phosphorylation was assessed using SDS-PAGE and western blot 
analysis. As shown in Figure 36, dcp1 migrated as a doublet in mock infected cells 
incubated at 3rC and as only the upper band in arsenite-treated or RSV-infected cells 
incubated at 3rC. In contrast, dcp1 from all groups incubated at 4°C migrated as a 
doublet. Since dcp1 from cells treated with arsenite (which is internalized by passive-
transport aquaglyceroporins (145, 258)) was not phosphorylated at 4°C, we cannot draw 
any conclusions regarding whether RSV internalization is necessary for dcp1 
phosphorylation. It is possible that the kinases responsible for dcp1 phosphorylation are 
not enzymatically active at 4 oc. 
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Figure 36. Dcp1 was phosphorylated by neither arsenite nor RSV at 4°C. HEp-2 
cells on duplicate plates were mock infected, treated with 0.5 mM sodium arsenite, or 
infected with sucrose-purified RSV (moi = 5). One plate was incubated at 3rC, and the 
other was incubated at 4°C. One hour post infection, cells were lysed in RIP A buffer and 
incubated on ice for ten minutes. Lysates were centrifuged at 16,000 xg for ten minutes 
at 4°C. Soluble fractions were assessed for dcp1 phosphorylation using SDS-PAGE and 
western blot analysis with an antibody toward dcp1 a. 
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2.9.2 Transient overexpression of RSV F and G proteins was not sufficient to 
mediate dcp1 phosphorylation. 
To further explore the possibility that RSV-mediated dcp1 phosphorylation is facilitated 
by attachment to and/or fusion with host cells, we transiently overexpressed RSV F, 
RSV G, or VSV G proteins in HEp-2 cells. 48 hours post transfection , cells were lysed 
and dcp1 phosphorylation was assessed using SDS-PAGE and western blot analysis. 
As shown in Figure 37, dcp1 from mock infected cells (lane 1) migrated as a doublet and 
dcp1 from RSV-infected cells (lane 2) migrated as only the upper band, consistent with 
previous results. Dcp1 from all transfected cells (lanes 3 through 11) migrated as a 
doublet. These results indicate that transient overexpression of RSV envelope proteins 
is not sufficient to mediate dcp1 phosphorylation. It is possible that expression of both 
RSV F and G are necessary for dcp1 phosphorylation or that a form of RSV For G that 
is not present in transfected cells is necessary for dcp1 phosphorylation. 
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Figure 37. Transient overexpression of RSV envelope proteins was not sufficient 
to induce dcp1 phosphorylation. HEp-2 cells were mock transfected (lanes 1 and 2) , 
mock infected (lane 1 ), infected with RSV (moi = 5, lane 2) or transfected with 
mammalian expression vectors encoding RSV F (lanes 3-5) , RSV G (lanes 6-8) , or VSV 
G (lanes 9-11). proteins (IJg DNA are indicated). 48 hours post infection or transfection, 
cells were lysed with RIP A buffer and samples were centrifuged at 16,000 xg for ten 
minutes. Soluble fractions were assessed for dcp1 phosphorylation using SDS-PAGE 
and western blot analysis with an antibody toward dcp1 a. 
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2.9.3 Unsuccessful incorporation of RSV envelope proteins into virus-like-
particles 
Our results suggested that merely overexpressing RSV envelope proteins was not 
sufficient to mediate dcp1 phosphorylation, so we attempted to incorporate the proteins 
into lentivirus virus-like particles (VLPs) in order to isolate the RSV proteins without the 
context of an RSV infection, but in a manner that better simulates the mechanism by 
which the proteins encounter host cells during RSV infection. In brief, 293T cells were 
transfected with a plasmid encoding HIV-Gag proteins in addition to plasmids encoding 
RSV F, RSV G, or VSV G protein. 48 hours post transfection, supernatants were 
collected and an ELISA was performed to determine the p24 content of the VLP 
preparations. In a parallel experiment, pseudotyped defective virus particles (DVPs) 
capable of a single-round of infection were made. 293T cells were transfected with an 
HIV construct lacking envelope proteins (HIV~env-luc) in addition to plasmids encoding 
RSV F, RSV G, or VSV G protein. 48 hours post transfection , supernatants were 
collected and an ELISA was performed to determine p24 concentration in particles. For 
DVPs, a multinuclear activation of a galactosidase indicator (MAGI) assay was 
performed to determine infectious titer. This experiment was performed to confirm that 
RSV envelope proteins had been incorporated into the DVPs since only particles with 
intact envelope proteins would be able to enter the cells. Next, HEp-2 cells were mock 
infected, infected with RSV, or infected with either VLPs (10 ng p24) or DVPs (10 ng 
p24). 24 hours post infection, cells were lysed and dcp1 phosphorylation was assessed 
using SDS-PAGE and western blot analysis. As shown in Figure 38, dcp1 from mock-
infected cells migrated as a doublet (Panels A and B, lane 1), and dcp1 from RSV-
infected cells migrated as only the upper band (Panels A and B, lane 2), as expected. 
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Dcp1 from cells infected with VLPs or DVPs migrated as a doublet (Panels A and B, 
lanes 2-8). The results of the MAGI assay (panel C) indicated that the DVPs in which 
we attempted to incorporate RSV envelope proteins F and/or G were not internalized. 
This likely suggests that the VLPs and DVPs did not properly incorporate the RSV 
envelope proteins. Because we were unable to confirm that the VLPs and DVPs used in 
the experiment incorporated the RSV envelope proteins, we cannot draw any 
conclusions from this experiment. We have since learned that the VLPs and DVPs 
would have a much greater chance of incorporating the RSV envelope proteins if the 
cytoplasmic tails were deleted from the envelope proteins using mutagenesis (Suryaram 
Gummuluru, personal communication) . Future studies are needed to further investigate 
this. 
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Figure 38. Unsuccessful attempt to make virus-like particles. 293T cells were 
transfected with a plasmid encoding HIV Gag proteins (to make VLPs) or HIV~Env-luc 
(to make DVPs) and constructs encoding RSV F, RSV G, and/or VSV G protein. 48 
hours post transfection, clarified supernatants were collected and p24 concentration was 
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determined using ELISA (data not shown) . HEp-2 cells were mock infected, infected 
with RSV (moi =5), or infected with 10 ng p24/ml of indicated VLPs or DVPs. Twenty-
four hours post infection, cells were lysed in RIPA buffer. Samples were centrifuged at 
16,000 x gat 4°C for 10 minutes. Soluble fractions were assessed for dcp1 
phosphorylation using SDS-PAGE and western blot analysis. C) Internalization of 
defective-virus particles was tested using a MAGI assay. In brief, MAGI-R5 cells were 
infected with indicated particles. One hour post infection, media was changed. Forty-
eight hours post infection, cells were fixed and stained with X-gal to identify cells with 
successful virus internalization. Nora Ramirez did the p24 ELISAs for this experiment. 
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2.9.4 RSV G protein was not necessary for RSV-mediated dcp1 phosphorylation. 
To further investigate the question of whether RSF envelope proteins are sufficient to 
mediate dcp1 phosphorylation , we tested recombinant viruses that lacked the RSV G 
protein in our dcp1 phosphorylation assay. As mentioned previously, RSV G is 
necessary for attachment to cells and has two forms: soluble and insoluble. The 
insoluble form is present on the surface of RSV virions, while the soluble form is 
secreted from RSV-infected cells and abundant in the supernatant of cells in late stages 
of infection. The soluble form is known to have immunomodulatory activities (251 ). Our 
previous results indicated that both RSV itself, as well as a factor in the supernatant of 
RSV-infected cells (Figure 29), were able to mediate dcp1 phosphorylation. Since RSV 
G protein is present both on virus particles (insoluble form) and as a secreted factor in 
RSV supernatants (soluble form) , we wished to determine whether the protein is 
sufficient for RSV-mediated dcp1 phosphorylation . To test this possibility, HEp-2 cells 
were mock infected, infected with wt RSV grown in HEp-2 cells (as a positive control for 
dcp1 phosphorylation) , infected with wt RSV grown in Vero cells, infected with UV-
inactivated wt RSV grown in Vero cells, infected with !::.G virus grown in Vero cells , or 
infected with UV-inactivated !::.G virus grown in Vero cells. Ninety minutes post infection, 
cells were lysed and assessed for dcp1 phosphorylation using SDS-PAGE and western 
blot analysis. As shown in Figure 39, dcp1 from mock-infected cells (lane 1) migrated as 
a doublet, while dcp1 from all infected cells (lanes 2 - 6) migrated as only the upper 
band. These results indicate that recombinant RSV grown in Vero cells was able to 
mediate phosphorylation, and that RSV G protein was not necessary for RSV-mediated 
dcp1 phosphorylation . Because it is possible that cytokines or another factor in the 
146 
virion preparations were able to mediate dcp1 phosphorylation, we cannot rule out the 
possibility that RSV G is able to mediate the effect. 
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Figure 39. Recombinant RSV was able to mediate dcp1 phosphorylation, but RSV 
G protein was not necessary for RSV-mediated dcp1 phosphorylation. HEp-2 cells 
were mock infected, infected with wt RSV grown in HEp-2 cells, wt RSV grown in Vero 
cells, UV-inactivated RSV grown in Vero cells, l:lG virus grown in Vero cells, or UV-
inactivated l:lG virus grown in Vero cells. Ninety minutes post infection, cells were lysed 
in RIPA buffer and analyzed for dcp1 phosphorylation using SDS-PAGE and western 
blot with antibodies toward dcp1 and 13-tubulin (loading control). Lysates from virus-
infected cells were kindly provided to us by Michael Teng . 
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2.9.5 Experiments in which RSV was incubated with antibodies toward RSV F 
protein confirmed that the antibody was able to prevent RSV infection; however, 
conclusions could not be drawn regarding the role of the RSV F protein in 
mediating dcp1 phosphorylation. 
To further investigate whether RSV F protein is the factor responsible for RSV-mediated 
dcp1 phosphorylation, we attempted to block the theoretical interaction between RSV F 
and its cognate MAPK-activator protein. HEp-2 cells were mock infected or infected in 
duplicate with RSV pre-incubated in 1.5-ml polypropylene tubes with increasing 
concentrations of a neutralizing antibody toward RSV F protein. Sixty minutes post 
infection, cells were lysed and dcp1 phosphorylation was assessed using SDS-PAGE 
and western blot analysis. A duplicate set of samples was incubated for 24 hours before 
cells were lysed and RSV infection was confirmed using SDS-PAGE and western blot 
using a polyclonal antibody toward RSV proteins. As shown in Figure 40A, incubating 
RSV with anti-F antibodies at either 10 IJg/ml or 100 IJg/ml prevented productive RSV 
infection (lower panel). Unfortunately, the conditions under which this experiment was 
performed prevented RSV from inducing robust dcp1 phosphorylation (lane 2), so 
conclusions could not be drawn regarding the antibody's effect on RSV-mediated dcp1 
phosphorylation. 
Another experiment was performed in which RSV was incubated with the antibody 
toward RSV F, antibodies toward various cytokines, or heparin at 3rC (as opposed to 
room temperature) for two hours before treatment of cells for one hour. As seen in 
Figure 408, dcp1 from RSV-treated cells was phosphorylated (lane 2), indicating that 
these experimental conditions were more conducive to RSV-mediated dcp1 
phosphorylation than those of the previous experiments. However, none of the pre-
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treatments tested decreased RSV-mediated dcp1 phosphorylation (lanes 3-7), so no 
conclusions can be drawn from these experiments regarding the role of the RSV F 
protein in RSV-mediated dcp1 phosphorylation. 
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Figure 40. Experiments in which RSV was incubated with antibodies toward RSV 
F protein confirmed that the antibody was able to prevent RSV infection; 
however, conclusions could not be drawn regarding the role of the RSV F protein 
in mediating dcp1 phosphorylation. A) HEp-2 cells were mock infected with media 
(lane 1) or infected with RSV (lanes 2-6) that was pre-incubated on a nutator with 
increasing concentrations (IJg/ml) of an antibody toward RSV F protein for one hour at 
room temperature in Opti-MEM + 2% FBS in polystyrene tubes. One set of cells was 
lysed one hour post infection to assess dcp1 phosphorylation (top panel). The other set 
of cells was lysed 24 hours post infection to assess RSV infection (bottom panel). Cells 
were lysed and soluble fractions were analyzed using SDS-PAGE and western blot with 
antibodies toward dcp1 or RSV proteins. B) RSV preparations (1 00 )ll of virus diluted in 
900 )ll of Opti-MEM with 2% FBS) were treated with 20 )lg/ml of mouse lg (Southern 
Biotech), 20 )lg/ml of anti-F antibody, 20 )lg/ml of anti-IL-113 (clone 2805, R&D Systems 
catalog #MAB601), 20 )lg/ml of anti-IL-6 (clone 6708, R&D Systems catalog #MAB206), 
20 )lg/ml of anti-TNF-a (clone NF-7, Abeam catalog #ab9809), or 100)lg of heparin 
(EMD Millipore catalog #375093) for 2 hours at 3rC with intermittent gentle vortexing. 
Treated virus preparations were added to HEp-2 cells and cells were incubated for 1 
hour at 3rC. The cells were lysed and analyzed for dcp1 phosphorylation by western 
blot. 
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2.10 Dcp1 did not immunoprecipitate with RSV F protein during RSVinfection. 
Jining Lu's research group used bioinformatics to determine that RSV F protein shares a 
similar motif to p-body-associated, dcp1-binding-partner protein GW182 (unpublished 
data). We speculated that perhaps RSV F protein mimics GW182 in order to bind dcp1 
and thereby interfere with dcp1 activities. To test this possibility, we used 
immunoprecipitation to determine whether RSV F protein binds to dcp1 during RSV 
infection. HEp-2 cells were either mock infected or infected with RSV (moi = 5). 
Eighteen hours post infection, cells were lysed with RIPA buffer. Samples were 
incubated with an antibody toward RSV F protein, and SDS-PAGE and western blot 
analysis were used to detect the presence of GW182, dcp1, and RSV proteins. As 
shown in Figure 41, RSV proteins were detected only in samples infected with RSV, as 
expected. Both GW182 and dcp1 were immunoprecipitated at very low levels. There 
were similar levels of GW182 and dcp1 proteins in samples from mock infected cells and 
RSV-infected cells, suggesting that the proteins were nonspecifically 
immunoprecipitated. These results indicate that under the conditions tested, RSV F 
protein does not bind to dcp1. 
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Figure 41. Dcp1 did not immunoprecipitate with RSV F protein. HEp-2 cells were 
mock infected or infected with RSV (moi = 5). Eighteen hours post infection, cells were 
lysed in RIPA buffer and centrifuged at 16,000 xg at 4°C. Samples were pre-cleared by 
incubation with sepharose beads at 4°C for one hour and then centrifugation at 2,400 xg 
at 4 oc for 3 minutes. Samples were next incubated with an antibody toward RSV F 
protein at 4°C for one hour and then centrifuged at 2,400 xg at 4°C for 3 minutes. 
Samples were analyzed using SDS-PAGE and western blot with antibodies toward the 
indicated proteins. 
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2.11 Dcp1 phosphorylation occurred in response to some, but not all, 
environmental stresses. 
As mentioned previously, dcp1 is phopshorylated in response to several types of stress, 
including arsenite treatment (31 ), dehydration stress (271 ), and treatment with IL-1 a, 
anisomycin, or sorbitol (206). Because our lab is interested in cellular stress responses 
and pathways governing stress-granule formation, we wished to determine whether dcp1 
was indeed phosphorylated by all forms of stress. We exposed cells to several forms of 
environmental stress known to induce stress-granule formation , including arsenite 
treatment (Panels A and B), thapsigargin treatment (Panels A and C), heat shock (Panel 
A) , and UV-irradiation (Panel D). Dcp1 phosphorylation was assessed using 80S-
PAGE and western blot analysis. As shown in Figure 42, dcp1 from untreated cells 
migrated as a doublet (lane 1 of Panels A-D). Dcp1 from cells treated with 0.25 mM or 
higher sodium arsenite migrated as primarily the upper band (Panel A, lane 4 and Panel 
B, lanes 4-6), confirming previous results indicating that sodium arsenite treatment 
induces dcp1 phosphorylation. There results also indicated that arsenite-mediated dcp1 
phosphorylation is dose dependent. Dcp1 from thapsigargin-treated cells migrated as a 
doublet that favored the bottom band compared to mock-treated cells (Panel A, lanes 5-
6 and Panel B, lanes 2-6). These results suggest that thapsigargin treatment not only 
does not result in increased dcp1 phosphorylation, but may even decrease levels of 
dcp1 phosphorylation. Dcp1 from heat-shocked proteins migrated as a doublet similar to 
dcp1 from mock-treated cells , indicating that heat shock does not result in increased 
dcp1 phosphorylation (Panel A, lane 7). Finally, dcp1 from cells exposed to all levels of 
UV-irradiation tested migrated as only the upper band. These results indicate that dcp1 
is phosphorylated as a result of UV-irradiation (Panel D, lanes 2-6). 
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As discussed at length in Chapter 1, we created a mutant of RSV whose trailer region 
was replaced with the inverted complement of the Leader sequence (LeC). Infection 
with this virus resulted in significantly increased stress-granule formation compared to wt 
RSV. We speculated that perhaps dcp1 phosphorylation was part of a process 
employed by RSV to prevent stress-granule formation . To determine if there was a 
correlation between inhibition of stress-granule formation and dcp1 phosphorylation, we 
examined whether LeC infection resulted in dcp1 phosphorylation. HEp-2 cells were 
mock infected, treated with sodium arsenite, treated with thapsigargin, infected with wt 
RSV, or infected with LeC virus. Eighteen hours post infection, cells were lysed and 
dcp1 phosphorylation was assessed using SDS-PAGE and western blot analysis. As 
shown in Figure 43, dcp1 from cells that were mock infected, mock treated (lane 1) 
migrated as a doublet as expected. Dcp1 from cells treated with arsenite was 
phosphorylated, and dcp1 from cells treated with thapsigargin migrated as primarily the 
lower band, consistent with previous results. Dcp1 from cells infected with either wt RSV 
or LeC virus migrated as primarily the upper band, indicating that LeC infection mediates 
dcp1 phosphorylation. 
Taken together, our results demonstrate that dcp1 is phosphorylated as a result of 
arsenite, UV-irradiation, and infection with LeC virus (all known to induce stress-granule 
formation) , but not in response to thapsigargin or heat shock. 
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Figure 42. Dcp1 was phosphorylated in response to some, but not all, 
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environmental stress. Panel A: HEp-2 cells were untreated (lane 1 ), treated with 0.05 
mM (lane 2), 0.1 mM (lane 3), or 0.5 mM (lane 4) sodium arsenite, treated with 1 tJM 
(lane 5) or 10 1-1M (lane 6) thapsigargin, or incubated at 44°C for sixty minutes. Panel 8: 
HEp-2 cells were treated with indicated concentrations of sodium arsenite. Panel C: 
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HEp-2 cells were incubated with indicated concentrations of thapsigargin . Panel D: 
HEp-2 cells were exposed to indicated levels of UV-irradiation and then incubated at 
3rC for four hours. All cells were lysed in RIP A buffer and samples were centrifuged at 
16,000 xg at 4°C for ten minutes. Soluble fractions were assessed for dcp1 
phosphorylation using SDS-PAGE and western blot analysis. 
158 
mock ars. thaps. WTRSV Lee 
dcpl 
Lane: 1 2 3 4 5 
Figure 43. Infection with LeC mediated dcp1 phosphorylation. HEp-2 cells were 
mock infected (lanes 1-3), treated with 0.5 mM sodium arsenite for 30 minutes (lane 2), 
treated with 10 1JM thapsigargin for 30 minutes (lane 3), infected with RSV (moi = 5, lane 
4) , or infected with LeC (moi =3, lane 5). Eighteen hours post infection, cells were lysed 
and assessed for dcp1 phosphorylation using SDS-PAGE and western-blot analysis with 
an antibody toward dcp1 a. 
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2.12 Dcp1 phosphorylation did not occur in response to infections with all viruses. 
Dcp1 phosphorylation as a result of infection has not been reported for any other virus. 
To determine whether other viruses are able to mediate dcp1 phosphorylation, we 
collaborated with other laboratories in our department with access to various viruses. 
The first virus we tested for ability to mediate dcp1 phosphorylation was HIV-1, a 
retrovirus . Primary human monocyte-derived macrophages were mock infected (lanes 1 
and 2) or infected with HIV-1 (lanes 3 and 4). 72 hours post infection, samples from 
each group were treated with 1.0 mM sodium arsenite for 30 minutes (lanes 2 and 4). 
Cells were lysed and dcp1 phosphorylation was assessed using western blot analysis. 
As shown in Figure 44, Panel A , dcp1 from mock infected cells (lane 1) migrated as a 
doublet , while dcp1 from arsenite-treated cells (lane 2) migrated as the upper band, 
confirming that dcp1 is likely able to be phosphorylated in primary monocyte-derived 
macrophages. Dcp1 from HIV-1-infected cells (lane 3) migrated as a doublet, while 
dcp1 from cells that were treated with arsenite (lane 2) or infected with HIV-1 and then 
treated with arsenite (lane 4) migrated as the upper, phosphorylated form. These results 
indicate that HIV-1 infection does not result in dcp1 phosphorylation. 
We next wanted to assess dcp1 phosphorylation during infection with viruses that are 
more similar to RSV. We focused on measles virus (MV), mumps virus, and canine 
distemper virus (CDV). These viruses are negative-strand, enveloped RNA viruses that, 
like RSV, are in the family Paramyxoviridae. HEp-2 cells were mock infected, infected 
with MV, mumps virus, or CDV. Cells were treated with sodium arsenite or infected with 
RSV as positive controls for dcp1 phosphorylation. Twenty four hours post infection , 
cells were lysed and dcp1 phosphorylation was assessed using western blot analysis. 
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As seen in Figure 44 panel 8, dcp1 from cells infected with MV (lanes 2 and 3), mumps 
virus (lanes 4 and 5) or CDV (lane 6) migrated as a doublet, while dcp1 in cells treated 
with arsenite (lane 7) or infected with RSV (lane 8) migrated as the upper band. These 
results suggest that MV, mumps virus, and CDV do not mediate dcp1 phosphorylation in 
HEp-2 cells. 
Because HEp-2 cells are not as permissive to MV infection as other cell types, we 
wished to assess dcp1 phosphorylation during MV infection of a more authentic cell 
type. Immortalized 8-cells were mock infected or infected with MV. Twenty-four hours 
post infection, cells were lysed and dcp1 phosphorylation was assessed. The results in 
Figure 44 panel C demonstrate that dcp1 in 8-cells does not migrate as a doublet. It is 
possible that dcp1 is constitutively phosphorylated in immortalized 8 cells; however, 
because dcp1 does not migrate as a doublet in these cells, we cannot draw any 
conclusions from this experiment as to whether MV mediates dcp1 phosphorylation in 8-
cells. We observed an additional band between 175 and 250 kDa that appeared in 
samples infected with MV but not mock-infected cells. It is possible that our dcp1 
antibody cross reacts with a viral protein. The only MV protein in this molecular-weight 
range is the L protein; however, we do not believe that it is the MV L protein, because 
this is expressed at a low level in infected cells. Alternatively, it is possible that dcp1 is 
modified with different post-translational modifications in 8-cells infected with MV. 
Future experiments are needed to explore this possibility. 
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Figure 44. DCP1 was not phosphorylated during infection with HIV-1, measles 
virus, mumps virus, or canine-distemper virus. Panel A: Primary macrophages 
were mock infected (lanes 1 and 2) or infected with HIV-1AoA (lanes 3 and 4). 72 hours 
post infection, samples from each group were treated with 1.0 mM sodium arsenite for 
30 minutes (lanes 2 and 4). Cells were lysed with RIPA buffer, and samples were 
centrifuged at 16,000 xg at 4°C. Soluble fractions were analyzed using SDS-PAGE. 
Blots were probed using an antibody toward human dcp1 a. Panel 8 : HEp-2 cells were 
mock infected (lane 1 ), infected with measles virus with an moi of 0.1 (lane 2) or 3 (lane 
3), infected with mumps virus at an moi of 0.1 (lane 4) or 3 (lane 5), infected with canine 
distemper virus at an moi of 0.1 (lane 6), treated with 0.5 mM sodium arsenite for 30 
minutes (lane 7) or infected with RSV at an moi of 5 (lane 8). Twenty-four hours post 
infection, cells were lysed with RIPA buffer, and samples were centrifuged at 16,000 xg 
at 4°C. Soluble fractions were analyzed using SDS-PAGE. Blots were probed using an 
antibody toward human dcp1. Panel C: Epstein-Barr virus-transformed human B-
lymphoblastic cell s (B-LCL) were mock infected (lane 1) or infected with MV clone 3 
(lane 2) or MV clone 6 (lane 3). Twenty-four (confirm) hours post infection, cells were 
lysed and soluble fractions were analyzed using SDS-PAGE and western blots with an 
antibody toward dcp1 a. 
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2.13 Dcp1 knockdown did not alter RSV protein expression during RSVinfection. 
Because our data suggested that RSV infection induced a change in the phosphorylation 
state of dcp1, we wished to determine whether dcp1 has a role in RSV's replication 
cycle. We first addressed this question by examining the effects of knocking down dcp1 
on RSV protein expression . HEp-2 cells were mock transfected or transfected with an 
siRNA directed toward dcp1. Twenty-four hours later, cells were mock infected or 
infected with RSV. RSV protein levels were assessed by western blot analysis 24 and 
48 hours post infection. As shown in Figure 45, siRNA treatment of cells caused a 
significant decrease in dcp1 levels; however, RSV protein expression was similar in 
control siRNA-transfected and dcp1 siRNA-transfected cells , indicating that dcp1 is 
likely not necessary for RSV protein production. 
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Figure 45. Dcp1 knockdown did not alter RSV protein expression. HEp-2 cells 
were mock transfected (lanes 1 and 3) or transfected with siRNA toward human dcp-1 a 
(lanes 2 and 4). 24 hours post transfection, cells were mock infected (lanes 1 and 2) or 
infected with RSV (moi =1) (lanes 3 and 4) . Cells were lysed 24 (data not shown) , 48, 
and 72 (data not shown) hours post infection and examined using western blot analysis. 
Blots were probed with antibody toward human dcp1 a. 
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2.14 Transient overexpression of dcp1 resulted in decreased RSV-mediated 
cytopathic effects. 
To examine the impact of dcp1 overexpression on RSV infection, HEp-2 cells were 
either mock transfected or transfected with a plasmid encoding human dcp1a. 24 hours 
post transfection, cells were mock infected or infected with RSV. Cells were examined 
by microscopy 48 hours post infection (Panel A) , and then lysed and examined using 
western blot analysis with antibodies toward dcp1a, RSV proteins, or ~-tubulin. As 
shown in Figure 46, cells that were either mock transfected, mock infected, or dcp1-
transfected, mock infected looked healthy and confluent. Cells that were mock 
transfected and infected with RSV showed extensive syncytia formation and cell death -
in vitro hallmarks of productive RSV infection. In contrast, cells overexpressing dcp1 
that were infected with RSV showed a drastic decrease in syncytia formation and cell 
death. These results indicate that dcp1 may play a role in host defenses against RSV 
infection. Figure 468 shows that oxerexpression of dcp1 did not affect significantly 
affect RSV protein production. These data suggest that dcp1 may have antiviral 
activities. 
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Figure 46. Dcp1 overexpression resulted in attenuated RSV-mediated cytopathic 
effects. HEp-2 cells were either mock transfected (only transfection reagents, no 
plasm ids) or transfected with a plasmid encoding human dcp1 a. 24 hours post 
transfection, cells were mock infected or infected with RSV (moi =0.5). Cells were 
examined by microscopy 48 hours post infection (Panel A) , and then lysed and 
examined using western blot analysis with antibodies toward dcp1 a, RSV proteins, and 
13-tubulin (Panel B). 
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2.15 A dcp1 mutant in which serine 315, serine 319, and threonine 321 were 
replaced with alanines abrogated RSV-mediated dcp1 phosphorylation. 
In order to examine the role of dcp1 phosphorylation in RSV infection, we wished to 
create a dcp1 construct that was deficient in phosphorylation. Rzeczkowski (206) and 
Aizer (4) showed that dcp1 is phosphorylated at serine 315 and Blumenthal et al. 
showed that dcp1 was phosphorylated at serines 315 and 319, as well as thereonine 
321 (31). We created mutant dcp1 constructs in which serine 315, serine 319, threonine 
321, or all three residues were replaced with alanines in order to abrogate 
phosphorylation at those sites. Of note, these constructs are tagged with FLAG 
sequences and therefore migrate slightly more slowly than endogenous dcp1. To test 
whether these residues were phosphorylated during RSV infection, we transiently 
overexpressed WT or mutant dcp1 in cells. Twenty-four hours later, we infected cells 
with RSV. Dcp1 phosphorylation was assessed using SDS-PAGE and western blot 
analysis with antibodies toward dcp1 . As shown in Figure 47, dcp1 migrated as a 
doublet (lane 1) in mock infected cells and as primarily the upper band in RSV-infected 
cells (lane 2), consistent with previous results. These bands are much fainter than 
bands from samples in which exogenous dcp1 was expressed, indicating that dcp1 was 
indeed overexpressed in transfected cells. Dcp1 from cells overexpressing the WT dcp1 
construct migrated as a triplet in mock-infected cells. Recall that the transfected dcp1 is 
FLAG-tagged. Unphosphorylated dcp1 expressed from these constructs migrates at 
approximately the same rate as phoshorylated endogenous dcp1, so these bands are 
not distinguishable. The bottom-most band is unphosphorylated, exogenous dcp1 . The 
center band is a combination of both phosphorylated, endogenous dcp1 and 
unphosphorylated, exogenous dcp1. The upper band is phosphorylated exogenous 
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dcp1. Dcp1 from wt-dcp1 transfected, R8V-infected cells migrated as a doublet, since 
both endogenous and exogenous dcp1 were phosphorylated. Dcp1 from mock-infected, 
8315A-transfected cells migrated as a doublet, while dcp1 from R8V-infected, 8315-A 
transfected cells migrated as a triplet. The margin between the two upper bands was 
significantly narrower than the margin between the two upper bands in R8V-infected 
cells that were transfected with WT dcp1. This indicates that there is likely more than 
one phosphorylation event required for full dcp1 phosphorylation, and that 8315 is one 
of the residues phosphorylated during R8V infection. Dcp1 from cells transfected with 
8319A or T321 migrated as a triplet, with significantly more exogenous dcp1 
phosphorylated in response to R8V infection. Of particular interest, dcp1 from cells 
transfected with the triple-A mutant in which 8315, 8319, and T321 were all mutated to 
A residues migrated as a doublet in both mock-infected and R8V-infected cells. This 
indicates that dcp1 in which these residues are mutated cannot be phosphorylated in 
response to R8V infection. Taken together, these results suggest while there is likely 
more than one phosphorylation event that occurs during R8V infection, the events are 
limited to phosphorylation(s) of 8315, 8319, and T321. It is clear that 8315 is one of the 
residues phosphorylated during R8V infection; however, it is unclear whether 8319 or 
T321 is the other residue phosphorylated during infection since dcp1 from 8319A and 
T321A have similar migration profiles. While we cannot make firm conclusions 
regarding the number and nature of R8V-mediated dcp1 phosphorylation events, the 
triple A mutant is an important tool for investigating the significance of R8V-mediated 
dcp1 phosphorylation since it is not phosphorylated during R8V infection. 
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Figure 47. 8315 was phosphorylated during R8V infection, and dcp1 
phosphorylation was limited to 8315, 8319, and T321 during R8V infection. HEp-2 
cells were mock infected or transiently transfected with constructs expressing wt dcp1, 
or dcp1 in which 8315, 8319, and/or T321 were mutated to alanine residues. Twenty-
four hours post transfection, cells were infected with R8V (moi = 5). Twenty-four hpi, 
cells were lysed in RIPA buffer and dcp1 phosphorylation was assessed using 808-
PAGE and western blots with antibodies toward dcp1 a. 
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Chapter 2 Discussion 
Our investigation into the relationships that RSV has with cellular p-bodies and their 
associated proteins revealed that p-body-associated, decapping factor dcp1 is altered 
during RSV infection. This protein is important for decapping and mRNA regulatory 
activities in cells, and it is possible that these activities are important during viral 
infections as well. Doughterty et al. recently reported that dcp1 is rapidly phosphorylated 
during poliovirus infection (44, 72), a finding that lends evidence to the hypothesis that 
cellular mRNA decapping and degradation processes can interact with RNA viruses 
during replication . 
Decapping and degradation processes have several implications during viral infection. 
Host-cell responses to viruses could rely heavily on these processes to regulate cellular 
mRNAs encoding antiviral mediators such as cytokines and chemokines. They could 
also potentially represent control points for host cells to regulated viral mRNAs. On the 
other hand, it stands to reason that viruses may have evolved to manipulate host-cell 
degradation processes in order to either facilitate an intracellular protein-expression 
milieu that is optimal for virus replication, or to prevent prospective host-cell-mediated 
virus-mRNA degradation. 
Elusive mechanism of RSV-mediated dcp1 phosphorylation 
Our results showed that dcp1 is phosphorylated within 15 minutes of RSV infection. The 
results shown in Figure 31 demonstrate that infection with sucrose-purified RSV resulted 
in sustained dcp1 phosphorylation over a twenty-four hour period. In contrast, infection 
with UV-inactivated RSV resulted in transient dcp1 phosphorylation only while the virus 
was in contact with the cells, as the effect began to reverse after the virus was removed 
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at one hour post infection. These results provide evidence that dcp1 phosphorylation is 
mediated by early events in the RSV replication cycle such as attachment, fusion, or cell 
entry, and maintained subsequently upon infection and de novo RSV- protein synthesis. 
Our data indicated that one or more factors in the supernatants of RSV-infected cells 
was able to mediate dcp1 phosphorylation (Figure 29}, and that the cytokines TNF-a 
and/or IL-1 ~could have been responsible for this effect. In addition, our data showed 
that purified RSV was able to mediate dcp1 phosphorylation (Figure 29); however, we 
were not able to determine the mechanism by which this occured. Our initial hypothesis 
was that binding of the RSV attachment protein G to cell surface molecules was 
responsible for inducing dcp1 phosphorylation since G is known to interact with ERK 1/2; 
however, experiments using a mutant virus in which the G protein was deleted showed 
that G is dispensable for RSV-mediated dcp1 phosphorylation, as shown in Figure 39. It 
is possible, however, that dcp1 was phosphorylated by cytokines in the RSV ~G virion 
preparations, so our data did not rule out the possibility that RSV G can mediate dcp1 
phosphorylation. 
We next shifted our focus to determine whether RSV F protein could mediate the effect, 
since F protein is involved in cell binding and has been shown to activate TLR4 
signaling , which is involved in inflammatory cytokine production. Unfortunately, attempts 
to determine the role ofF protein in dcp1 phosphorylation by overexpressing F (Figure 
37} , incorporating RSV F into VLPs (Figure 38), or using neutralizing antibodies against 
F (Figure 40) were not successful. As mentioned previously, personal communication 
with Rahm Gumuluru and colleagues revealed that deleting the cytoplasmic tail of the F 
protein would likely improve its incorporation into lentivirus-based VLPs. 
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Further studies are needed to discern the roles of RSV G and F proteins in dcp1 
phosphorylation. For example VLPs incorporating cytoplasmic-tail-deficient G and/or F 
proteins could be used to assess their abilities to mediate dcp1 phosphorylation. In 
addition, sucrose-purified viruses in which F or G have been deleted could be used to 
assess their role(s) in this effect. 
MAPK involvement in RSV-mediated dcp1 phosphorylation 
Our data showed that ERK1/2 was activated shortly after exposure of the cells to RSV, 
and that this correlated with dcp1 phosphorylation (Figure 34). In addition , we found that 
inhibiting ERK1/2 with four separate inhibitors known to prevent ERK1/2 activation 
abrogated RSV-mediated dcp1 phosphorylation (Figure 35), suggesting dcp1 
phosphorylation is a downstream effect of RSV-induced ERK1/2 activation. While RSV 
infection has been reported to activate the MAPKs p38 (193, 225, 252) and JNK (252) , 
these kinases were not activated in our experiments (possibly because of differences in 
types of cells used in experiments) , and inhibiting these enzymes did not decrease RSV-
mediated dcp1 phosphorylation (Figure 35). 
Several studies have shown that ERK1/2 activation is important during RSV infection. 
Kong et al. showed that RSV attachment to cells activated ERK1/2 pathways within 5 
minutes, and that inhibition of ERK1/2 activation impaired RSV replication (125). 
Pazdrak and colleagues showed that ERK1/2 activation is required for maximum 
induction of RANTES production during RSV infection in alveolar epithelial cells using a 
posttranscriptional mechanism (193), and ERK1/2, p38, and JNK activation have been 
correlated with RSV-mediated cytopathic effects related to inflammation (112). Monick 
et al. reported that RSV-mediated ERK1/2 activation is required for both RSV-induced 
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inflammation and extended survival of cells (171) . Importantly, Chen et al. confirmed 
that ERK1/2 activation occurred within 5 minutes of RSV infection and found that 
ERK1/2 was required for RSV-induced IL-8 production (50). In addition, they showed 
that inhibitors of ERK1/2 decreased IL-8 protein levels by 50% but had little effect on IL-
8 mRNA levels, suggesting that the effect was post-transcriptional. These findings are 
consistent with a model in which dcp1 phosphorylation is involved in post-
transcriptionally regulating IL-8 production. 
Dcp1 residues phosphorylated during RSV infection 
Our results indicated that mutating serine 315, serine 319, and threonine 321 completely 
abrogated RSV-mediated dcp1 phosphorylation (Figure 47); however, teasing out the 
individual contributions has proven to be more complicated. Serine 315 is clearly 
involved in dcp1 phosphorylation, as phosphorylation in response to RSV infection was 
significantly reduced in cells overexpressing S315A. This is consistent with studies by 
Blumenthal, Rzeczkowski , and Ma, which have shown that 8315 is the most important 
residue involved in dcp1 phosphorylation. Of note, RSV infection of cells overexpressing 
S315A resulted in a dcp1 phosphorylation intermediate that migrated more quickly than 
dcp1 in cells overexpressing WT dcp1 , but more slowly than unphosphorylated dcp1 
(Figure 47). This indicates that there is more than one phosphorylation event. Data 
using the triple mutant indicate that the phosphorylation events are limited to 8315, 
8319, and T321; however, because the dcp1 profiles from cells overexpressing S319A 
or T321A look similar, it is difficult to discern the contributions of these residues to dcp1 
phosphorylation. It is possible that they are both phosphorylated during RSV infection. 
Alternatively , it is possible that only one of them is normally phosphorylated during 
infection, but that phosphorylation of other residues can occur in the event that 
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phosphorylation at one site is blocked. Future studies could involve using double 
mutants to tease out the contributions of individual amino acids to dcp1 phosphorylation 
during RSV infection. 
Significance of dcp1 phosphorylation during RSV infection 
Our findings indicated that decapping protein dcp1 is rapidly phosphorylated during RSV 
infection. Many studies have shown putative roles for dcp1 phosphorylation. 
Blumenthal and colleagues reported a correlation between dcp1 phosphorylation and 
neuronal development (31) and Aizer et al. demonstrated that dcp1 was phosphorylated 
at S315 and during mitosis (4). Ma et al. showed that phosphorylated dcp1 important for 
decapping-mediated degradation of maternal mRNAs during oocyte maturation (147), 
and Rzeczkowski and coworkers showed that dcp1 phosphorylation was important in 
mediating p-body distribution (206). Importantly, this group also demonstrated that 
phosphorylated dcp1 regulated IL-8 production. Studies in yeast have shown that dcp1 
phosphorylation is associated with decreased decapping activity (129), however the 
biological effect of dcp1 phosphorylation in mammalian cells has yet to be fully 
elucidated. 
Phosphorylation is a post-translational modification that can alter protein function in 
many ways. As discussed previously, phosphorylation can act as a molecular switch to 
turn proteins "on" or "off' by mediating conformational changes. It is possible that dcp1 
phosphorylation is important in the protein's ability to interact with dcp2 or other proteins 
important during mRNA decapping, and that dcp1 is phosphorylated as part of a host-
cell response to orchestrate optimal expression of proteins involved in antiviral pathways 
such as cytokines and chemokines. Another possibility is that RSV-mediated dcp1 
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phosphorylation aids RSV propagation, for example by down-regulating certain 
cytokines. Another possibility is that dcp1 phosphorylation during RSV infection is 
significant for another, hitherto undefined function of the protein. Future studies are 
needed to determine the significance of dcp1 phosphorylation during RSV infection. 
Conclusions 
In conclusion, we have demonstrated that sucrose-purified RSV infection results in dcp1 
phosphorylation within 15 minutes of infection and that this effect is mediated, at least in 
part, by ERK1/2 activation. We have preliminary data suggesting that overexpression of 
a dcp1 mutant (Triple A) in which RSV-mediated dcp1 phosphorylated was abrogated 
nearly doubled RSV-indL:Jced IL-8 production (data not shown), indicating that 
phosphorylated dcp1 is important for regulating IL-8 production during RSV infection. 
We propose a model in which RSV attachment to and/or fusion with moieties in the host-
cell plasma membrane activates ERK1/2-mediated dcp1 phosphorylation, and that 
phosphorylated dcp1 regulates one or more effector molecules important in host antiviral 
defense processes such as cytokine production . 
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Chapter 3: Investigation into a case of possible structural mimicry of cellular p54 
by RSV nucleoprotein 
Chapter 3 Introduction 
RSV inclusion bodies 
When RSV infects cells, RSV N, P, L, and M2-1 proteins (43, 90) localize in cytoplasmic 
aggregates known as inclusion bodies as early as four hours after infection (unpublished 
data). Garcia et. al. used transient transfections to demonstrate that RSV N and P 
proteins are the minimal requirements for inclusion body formation (90) . The role of 
inclusion bodies during infection has not been characterized . They have long been 
thought to be sites of RSV replication; however, this has not been proven and recent 
studies suggest that they may be sites where host-cell proteins are sequestered to avoid 
stress responses (88). 
The following picture (Figure 48) shows cells that have been infected with RSV for 16 
hours at an moi of 0.5 in order to visualize both infected and uninfected cells . The cells 
have been stained with DAPI (blue) to visualize the nucleus, and for RSV N protein 
(green) to visualize RSV infection (they are also stained for cellular protein dcp1 (red)). 
The cell just left of center is undergoing productive infection, and the green structures 
are RSV inclusion bodies. RSV N protein is most concentrated around the periphery of 
the inclusion bodies in an 0-ring configuration, but is also present inside the inclusion 
bodies and diffusely throughout the cytoplasm. In addition, RSV N protein is seen at the 
plasma membrane of adjacent cells, which are possibly being infected. 
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Figure 48. RSV inclusion bodies. Cells are stained with DAPI (blue) to visual ize the 
nucleus, with antibodies toward RSV N protein (green) to visualize inclusion bodies, and 
with antibodies toward dcp1 (red). 
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Brown et al. showed that host factors heat shock protein 70 (HSP 70) and actin localize 
to RSV inclusion bodies during infection (37) , although a role for these proteins in the 
RSV replication cycle has yet to be elucidated. Recently, Fricke et al. demonstrated that 
cellular p38 and OGT proteins are sequestered in RSV inclusion bodies, thereby 
inhibiting MK2 activities and stress-granule formation (88) . It is possible that identifying 
additional cellular factors that are recruited to RSV inclusion bodies will provide 
important clues to elucidating aspects of the RSV replication cycle and/or RSV 
interactions with host defense mechanisms. 
Cellular DEAD-box protein p54 
Human p54 (also referred to as rck and DDX6) is a cellular, DEAD-box RNA helicase 
that is generally associated with negatively regulating translation. p54 homologues are 
found in Saccharomyces cerevisiae (DHH1), Caenorhabditis elegans (CGH-1) , Xenopus 
(Xp54), and Drosophila (Me31 B). Although its activities have not been extensively 
characterized , several putative functions have been reported, including translational 
repression (52, 54, 164-166, 181), decapping enhancement (55), mRNA shuttling (226), 
RNA unwinding (5), pre-mRNP assembly (232, 236), and ribonucleoprotein (RNP) 
remodeling (80, 105, 217). Not surprisingly, p54 has been shown to be important in the 
development of mammals (153) ; however, its role in development has not been fully 
elucidated. p54 is included in some stress granules, though it is not a requirement for 
canonical stress-granule composition. It is found in all p-bodies, and the protein has 
recently been reported to be required for p-body formation (18, 84, 163). However, its 
specific activities in these structures are unknown. Minshall et al. proposed a model in 
which one domain (D2) of p54 acts as a protein binding platform, while the ATP/helicase 
domain mediates ribonucleoprotein (RNP) remodeling and thereby regulates the balance 
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between translational repression and activation (163). Of particular interest, Chu and 
Rana demonstrated that p54 interacts with argonaute proteins Ago1 and Ago2 in active 
RNA-induced silencing complexes (RISCs) in the context of both siRNA and miRNA, 
and showed that p54 is the effector molecule in miRISC that represses translation. They 
proposed that the specificity of the repression may be determined by the sequence of 
miRNA binding to complementary sites in the 3' UTR of target mRNA (52). 
p54 implicated in viral replication cycles 
Given its role in translational regulation, it is not surprising that p54 has been 
increasingly recognized as important for virus biology. Jangra et al. found that p54 
helicase activity is essential for efficient Hepatitis C virus (HCV) replication (1 04). The 
group later showed that Patl 1, LSm1, and p54 localization top-bodies was not required 
for p54's role in HCV infection (195). Ariumi et al. showed that the virus sequesters p54 
and other p-body components to HCV replication factories (20). p54 also has roles in 
HIV infection. Chable-Bessia et al. reported that p54, GW182, LSm-1, and Xrn1 (all p-
body components) repressed HIV-1 gene expression by preventing viral transcripts from 
associating with polysomes. In addition, they found that knocking down p54 resulted in 
HIV-1 reactivation in PBMCs isolated from HAART-treated HIV-infected persons (45). In 
seeming contrast, another group showed that p54 aids in HIV capsid assembly (201 ), 
thereby facilitating viral replication. Several other viruses have reported relationships 
with p54. Yu et al. demonstrated that p54 is required for efficient genome packaging of 
prototype foamy virus (PFV) (274), and p54 has been shown to bind the 3' UTR of 
Dengue virus and to facilitate Dengue virus replication (260). The adenovirus 11 k 
protein binds and escorts p54 to aggresomes to be degraded (94), and p54 has been 
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demonstrated to play an important role in the replication cycle of Brome mosaic virus 
(BMV) (12). 
Hypothesis 
The studies discussed in Chapters 1 and 2 of this dissertation focused on RSV's 
relationship with stress granules, p-bodies, and p-body-associated protein dcp1. During 
the course of these studies, we identified p54 as a protein that might be important during 
RSV replication because it appeared to localize to RSV inclusion bodies during infection. 
We hypothesized that p54 was important either for the RSV replication cycle or for host 
antiviral activities toward RSV. 
Results 
3.1 A polyclonal antibody toward cellular p54 recognized a component within RSV 
inclusion bodies. 
While investigating RSV's relationship with cellular stress granules, we sought to 
determine whether RSV proteins colocalize with stress granule- and p-body-associated 
protein p54. To determine whether this was the case, cells were mock infected or 
infected with RSV. 16 hours post infection, cells were fixed and immunostained with 
antibodies toward RSV N and cellular p54. 
In mock infected cells, p54 had a punctate distribution consistent with p-bodies that are 
constitutively present under steady-state conditions (Figure 49). In RSV-infected cells , 
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the p54 antibody stained both punctate dots characteristic of p-bodies, as well as 
regions inside RSV inclusion bodies. p54 did not appear to be part of stress granules, 
which are larger than p-bodies, under either condition. Interestingly, the molecule 
recognized by the p54 antibody didn't colocalize perfectly with RSV N. As shown in 
Figure 498, the bulk of RSV N protein formed 0-rings around the inclusion bodies, while 
the component recognized by the p54 antibody localized to the inside core of inclusion 
bodies. These results indicate that the RSV N protein partially colocalizes to RSV 
inclusion bodies with a molecule recognized by the p54 polyclonal antibody. 
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Figure 49. Cellular p54 protein appeared to localize to RSV inclusion bodies. 
HEp-2 cells were either mock infected or infected with RSV (moi = 1 ). After 16 hours, 
cells were fixed and immunostained with DAPI (blue), RSV N protein (green), and 
human p54/rck (red). Slides were examined by confocal microscopy. Panel B shows an 
enlargement of the merged image of RSV-infected cells. 
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3.2 Monoclonal antibody toward p54 did not stain components inside RSV 
inclusion bodies. 
We next wished to determine whether a different antibody toward p54 yielded the same 
result. HEp-2 cells were mock infected or infected with RSV. 16 hours post infection, 
cells were fixed and immunostained using the same antibody toward RSV N that was 
used in the previous experiment to visualize RSV inclusion bodies; however, a 
monoclonal antibody toward p54 was used to stain for p54 instead of the polyclonal 
antibody used previously. As demonstrated in Figure 50, p54 appeared in puncate dots 
in mock infected cells as before. However, in RSV-infected cells, the monoclonal 
antibody toward p54 did not stain components inside RSV inclusion bodies as the 
polyclonal antibody had. Instead, the p54 distribution was altered in cells demonstrating 
prominent RSV inclusion bodies. In these cells, p54 appeared in large, amorphous 
aggregations that were not characteristic of either stress granules or p-bodies. 
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Figure 50. Monoclonal antibody toward p54 did not recognize p54 in RSV 
inclusion bodies. HEp-2 cells were either mock infected (a and b) or infected with RSV 
(moi = 1) (c) . After 14 hours, some cells (b) were treated with 0.5 mM sodium arsenite 
for 30 minutes as a positive control for cellular stress, and all cells were fixed and 
stained with RSV N protein (green) and human p54 (red). Slides were examined by 
fluorescent microscopy. 
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3.3 RSV infection resulted in a second, faster-migrating band recognized by 
po/yclonal p54 antibody. 
Because our immunofluorescence results indicated that p54 might colocalize with RSV 
proteins, we theorized that perhaps p54 had a role in the RSV replication cycle. We next 
wished to assess whether RSV infection altered the elecrophoretic mobility of cellular 
p54. HEp-2 cells were mock infected, infected with RSV, or treated with sodium 
arsenite. 16 hours post infection, cells were lysed and p54 in soluble and insoluble 
(pellet) fractions was assessed using SDS-PAGE and western blot analysis with either 
our polyclonal or monoclonal antibodies toward p54. As shown in Figure 51, both the 
polyclonal and monoclonal antibodies recognized a protein that migrated as a -54 kDa 
band, as expected. In RSV infected cells, the polyclonal p54 antibody recognized an 
additional, faster-migrating protein (Figure 51, hereafter referred to as "protein X"); 
however, this protein was not detected by the monoclonal p54 antibody. Taken 
together, our results indicated that the polyclonal p54 antibody recognized a protein in 
RSV inclusion bodies that migrated as a -40-45 kDa band. 
The polyclonal antibody was raised against a 5' terminal peptide of p54. The 
monoclonal antibody was raised against recombinant, full-length protein corresponding 
to amino acids 1-484 of human p54. We theorized that RSV infection resulted in an 
alternate, possibly truncated, form of p54. 
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Figure 51. RSV infection resulted in second, faster-migrating band recognized by 
the polyclonal p54 antibody. HEp-2 cells were mock infected or infected with RSV 
(moi = 5). After 18 hours, cells were lysed with RIPA buffer and centrifuged at 16,000 xg 
for 10 minutes. Total , soluble, and pellet fractions were analyzed by western blot with 
polyclonal (left) or monoclonal (right) antibodies toward cellular p54. 
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3.4. Protein X was present in cell fractions corresponding to high RSV 
transcription activity. 
As mentioned in Chapter 2, Mason et al. developed a technique for concentrating viral 
RNPs using serial fractionation (see Chapter 2,Figure 27) . To assess whether protein X 
was present in the fraction corresponding to high RSV transcriptional activity, HEp-2 
cells were mock infected or infected with RSV. 16 hours post infection, cells were lysed 
and analyzed using SDS-PAGE and western-blot analysis with the polyclonal antibody 
toward p54. As shown in Figure 52A, the faster-migrating protein recognized by the 
polyclonal p54 antibody migrated in the S3 fraction of RSV-infected cells, which 
correlates with the highest RSV in vitro transcription activity. To determine whether 
protein X was recognized by the polyclonal p54 antibody in a more authentic cell line, 
the experiment was repeated in A549 cells. As seen in Figure 528, the faster-migrating 
protein was present in the S3 fraction of A549 cells. 
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Figure 52. Protein X was found in R5V cell fraction corresponding to highest R5V 
in vitro transcription activity. HEp-2 (A) or A549 (B) cells were mock infected or 
infected with RSV (moi =5). 18 hours post infection, cells were fractionated according to 
the method described by Mason et al. Samples were analyzed using SDS-PAGE and 
western blot with a polyclonal antibody toward cellular p54. 
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3.5 Protein X was not present in RSV virions 
Because the results above indicated that Protein X was only recognized in samples from 
RSV-infected cells, we theorized that perhaps the protein was a viral component of RSV. 
Protein X was approximately 43 kDa, which corresponded to the size of RSV N protein; 
however, Figure 52 demonstrated that while N was found in all RSV fractions, protein X 
was found primarily in the S3 fraction. To test the possibility that protein X was a viral 
protein, we used SDS-PAGE and western blot analysis to determine whether p54 
recognized a factor in either wt RSV or Lee virions. We included samples from RSV-
infected cells as positive controls. As demonstrated in Figure 53, the polyclonal antibody 
toward p54 recognized p54 in the S1 and S3 fractions of RSV-infected cells , as well as 
in Lee virus preparations. The antibody recognized Protein X in both the S1 and S3 
fractions of RSV-infected cells , but it did not recognize Protein X in virions. These data 
suggested that Protein X was not a viral structural protein. 
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Figure 53. Protein X was not recognized in RSV virions. HEp-2 cells were infected 
with RSV and fractionated according to the method described by Mason et al. Samples 
from the S 1 and S3 fractions, as well as virions from wt RSV and LeC virus preparations, 
were analyzed using SDS-PAGE and western blot with a polyclonal antibody toward 
p54. 
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3.6 siRNA toward p54 did not affect RSV protein production 
Because our results suggested that RSV infection may result in a truncated form of p54, 
we wished to determine whether p54 is important in the RSV replication cycle. HEp-2 
cells were transfected with siRNA against p54. Twenty-four hours post transfection, 
cells were infected with RSV. Twenty-four hpi, cells were lysed and analyzed using 
SDS-PAGE and western blot analysis with antibodies toward p54 and RSV proteins. As 
shown in Figure 54, p54 was reduced in cells transfected with siRNA toward p54 (lanes 
4 and 5 (duplicate), top panel). RSV protein production was similar in siRNA-treated 
cells (lanes 4 and 5, bottom panel) to that of mock-transfected cells (lanes 2 and 3 
(duplicate), bottom panel) . These data suggest that p54 may not be necessary for 
efficient RSV protein production, but it is difficult to draw firm conclusions since the 
siRNA knockdown was not efficient. 
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Figure 54. siRNA toward p54 did not affect RSV protein production. HEp-2 cells 
were mock transfected (lanes 1-3) or transfected with siRNA toward p54. 24 hours post 
transfection, cells were mock infected (lane 1) or infected with RSV (lanes 2-5). 24 hpi , 
cells were lysed and assessed using SDS-PAGE and western blot analysis with 
polyclonal antibodies toward p54 (top) or RSV proteins (bottom) . 
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3. 7 Protein X was identified as RSV nucleoprotein. 
We next sought to determine whether the faster-migrating protein X recognized by the 
polyclonal p54 antibody was indeed a truncated or alternatively spliced version of p54, or 
whether it was another protein entirely using mass spectometry analysis. HEp-2 cells 
were mock infected or infected with RSV. 16 hours post infection, cell were lysed and 
protein was immunoprecipitated with the polyclonal p54 antibody. Samples were 
separated on SDS-PAGE gels and stained with Coomassie Blue. The band 
corresponding to protein X was excised and analyzed by mass spectometry. As shown 
in Figure 55, protein X was present in only RSV infected cells, as was the case in earlier 
experiments. The mass-spectometry results indicated that protein X showed substantial 
similarity with RSV N protein. These surprising results demonstrated that the polyclonal 
antibody toward p54 likely recognized RSV N in addition to cellular p54. 
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Figure 55. Protein X was identified as RSV N protein. HEp-2 cells were mock 
infected or infected with RSV (moi =5). 18 hours post infection, cells were fractionated 
according to the method described by Mason et al. Samples from the S3 fractions were 
immunoprecipitated with the polyclonal p54 antibody, and samples analyzed using SDS-
PAGE and Coomassie Blue staining . The band indicated by the arrow was excised and 
subject to mass-spectometry analysis. 
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3.8 The polyclonal p54 antibody recognized purified N protein. 
To confirm that the polyclonal p54 antibody was able to recognize RSV N protein, an 
experiment was performed in which lysates from RSV-infected cells, RSV N protein 
purified from baculovirus, or RSV P protein purified from baculovirus were analyzed 
using SDS-PAGE and western blot with the polyclonal p54 antibody. 
As shown in Figure 56A, the purified preparations of P and N were very clean, with no 
other prominent bands. Figure 568 demonstrates that the polyclonal antibody toward 
p54 recognizes baculovirus-purified N protein (lane 3), which runs slightly more slowly 
than N protein from RSV-infected cells (lane 4) due to the addition of a histidine tag and 
tobacco etch virus protease cleavage site. The antibody did not recognize P protein. 
Taken together, these results indicate that the polyclonal antibody toward p54 is cross-
reactive with RSV N protein. 
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Figure 56. The polyclonal p54 antibody recognized purified N protein. A) RSV 
proteins P and N were purified from baculovirus as described in the Materials and 
Methods section. Samples were run on 10% SDS gels and stained with Coomassie 
Blue. B) HEp-2 cells were either mock infected (lane 1) or infected with RSV (lane 4). 
18 hours post infection, cells were lysed. Samples from these cells and samples from 
the baculovirus-purified Nand P shown in panel A were analyzed using SDS-PAGE and 
western blot with the polyclonal antibody toward p54. The experiment in this figure was 
performed by Robin Djang. 
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3.9 The polyclonal p54 antibody recognized RSV N in inclusion bodies after 
approximately 12 hours of infection. 
Although the results of previous experiments indicated that the polyclonal p54 antibody 
recognized RSV N, we believe that the antibody toward p54 and the antibody toward 
RSV N recognize two antigenically different populations of the viral protein. Recall that 
in immunofluorescence experiments shown in Figure 57, the antibody toward RSV N 
bound to N in 0-rings around inclusion bodies, while the antibody toward p54 recognized 
N protein in the "core" of inclusion bodies. The results suggest that there are two 
conformationally distinct populations of RSV N. It is possible that N protein on the 
periphery of or inside inclusion bodies incorporates one or more post-translational 
modifications, such as phosphorylation, methylation, and/or acetylation that creates an 
antigenically distinct subpopulation of the protein. 
To determine whether there was a temporal relationship between the two forms of RSV 
N we performed a time course to assess at what point during RSV infection the p54 
antibody would recognize viral protein. HEp-2 cells were mock infected or infected with 
RSV. At various points post infection, cells were fixed and analyzed using 
immunofluorescence. As shown in Figure 48, RSV N protein was not present in mock 
infected cells, but steadily increased as RSV infection progressed. From 8 hpi onward, 
RSV N was present in small, yet distinct, inclusion bodies in addition to being diffusely 
present in the cytoplasm. The p54 antibody stained punctate dots characteristic of p-
bodies in mock infected cells and at 4 and 8 hpi; however, from 12 hpi onward, the 
antibody primarily stained RSV N protein inside RSV inclusion bodies. Of particular 
interest is the fact that the p54 antibody did not recognize RSV N at 8 hpi, when 
inclusion bodies were apparent, but did recognize N at 12 hpi. Studies have shown that 
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after RSV entry into a cell, the virus genome primarily undergoes transcription until 12-
15 hpi, at which point the balance of polymerase activity shifts from transcription to 
genome replication (29). Alternatively, it is possible that the p54 antibody didn't 
recognize N protein until a certain accumulation threshold had been reached. These 
results indicate that that the p54 antibody recognizes an alternative population of RSV N 
protein that might be concomitant with a shift from RSV transcription to replication. _ 
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Figure 57. The p54 antibody recognized N 12 hours post RSV infection. HEp-2 
cells were mock infected or infected with RSV. At the indicated times post infection, 
cells were fixed and stained with DAPI (blue) and antibodies toward RSV N (green) or 
p54 (red). Cells were examined using confocal microscopy. 
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3.10 The po/yclonal p54 antibody recognized transfected RSV N protein 
To gain more information about the population of RSV N recognized by the p54 
antibody, we wished to determine whether the p54 antibody recognized RSV N that was 
transiently expressed in HEp-2 cells by a plasmid. HEp-2 cells transiently transfected 
with an empty vector or plasmids expressing RSV N, RSV Nand P, or RSV N, P, and L. 
Twenty-four hours post transfection, cells were either lysed or fixed , and anti-p54-
antibody recognition of RSV N was examined using western blot analysis or 
immunofluorescence, respectively. 
As shown in Figure 58A, the polyclonal p54 antibody recognized N in lysates from RSV 
infected cells , as well as N in cells transfected with Nor Nand P. It is unclear why N 
was not recognized in cells transfected with N, P, and L, although p54 in that lane 
appears very weak, indicating that there may have been less protein loaded. In cells 
transfected with empty vector, p54 appears in enlarged p-bodies or stress granules. It is 
possible that the transfection process or vaccinia virus in the sample elicited a stress 
response and that transfected N protein blocked this response; however, this has not 
been confirmed. 
As shown in Figure 588, the p54 antibody recognized RSV N in the context of RSV 
inclusion bodies in cells transfected with Nand P, which have been shown to be the 
minimum RSV protein requirements for inclusion body formation (90). These results 
suggest that the form of RSV N recognized by the polyclonal p54 antibody is present in 
cells transfected with the protein. 
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Figure 58. The polyclonal p54 antibody recognized transfected N. HEp-2 cells 
were mock infected or infected with RSV, or transfected with empty vector, or RSV N, 
RSV Nand P. Twenty four hours later, cells were lysed and analyzed using SDS-PAGE 
and western blot analysis with a polyclonal antibody toward p54 (A) or fixed and 
analyzed using immunofluorescence with antibodies toward RSV N (green) or cellular 
p54 (red)(B) . Samples were examined using confocal microscopy. Michael Allen 
helped with the experiments presented in this figure. 
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3.11 RSV N protein showed similarity to cellular p54 
The fact that the polyclonal p54 antibody recognizes RSV nucleoprotein, but does not 
recognize other proteins present in the samples tested suggests that p54 and RSV N 
might have an antigenically similar motif. We used BLAST bioinformatics to examine 
whether RSV N protein shared amino-acid similarity with with the p54 peptide sequence 
used to raise the polyclonal p54 antibody. As demonstrated in Figure 59, RSV N and 
the p54 peptide share sequence similarity at a motif corresponding to the area adjacent 
to the RNA-binding residues of RSV N. This result indicates p54 and RSV N share 
similar primary structure that may translate to structural similarities between the two 
proteins. 
207 
RSVN 
p54 peptide 
(RNA-binding residues) 
/ Sl? ~ 
Figure 59. RSV N protein motif shows similarity to cellular p54. The amino-acid 
sequence of RSV N protein was compared to the cellular p54 sequence using 
bioinformatic BLAST analysis. Black arrows indicate sequence identity, grey arrows 
indicate similarity, and the blue arrow indicates a difference in the peptide to which the 
p54 antibody was raised and the human p54 sequence. In human p54, this amino acid 
is K, which is more similar to the RSV sequence. 
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3.12 Dcp1 antibody recognized a component inside RSV inclusion bodies: a 
cautionary tale. 
Because our immunofluorescence and western blot experiments demonstrated that p54 
and RSV N shared an antigenically similar motif, and our BLAST analysis showed that 
the two proteins share sequence similarity, we hypothesized that RSV N protein may 
mimic p54 during infection. It seemed possible that given their amino-acid similarity, 
RSV N might be able to bind p54 interacting partners and thereby manipulate cellular 
responses to viral infection such as stress-granule or p-body formation. To explore this 
possibility, we screened a number of known p54 interacting partners to determine 
whether they were altered during RSV infection. As discussed at length in Chapter 2, 
we identified dcp1 as a protein whose migration on SDS gels was altered as a result of 
RSV infection. We next used immunofluorescence to determine whether the 
cytoplasmic distribution of dcp1 was changed during RSV infection. HEp-2 cells were 
mock infected or infected with RSV. 18 hours post infection, cells were fixed and 
immunostained to visualize RSV infection and dcp1 distribution. 
As shown in Figure 60A, samples from mock-infected cells showed dcp1 in p-bodies, as 
expected. In RSV-infected cells, the antibody used stained protein inside RSV inclusion 
bodies, similar to the staining seen with the polyclonal p54 antibody. As presented in 
Chapter 2, there is no strong evidence for dcp1 colocalizing with RSV inclusions; 
however, the specificity of this antibody was lot dependent, as shown in Figure 60A. 
Because of our experience with the cross-reactive p54 antibody, we wished to confirm 
the apparent dcp1 I RSV N colocalization was real using a method not reliant upon 
potentially cross-reactive antibodies. U20S cells stably expressing red fluorescent 
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protein (RFP)-tagged dcp1 were mock infected or infected with RSV. 18 hours post 
infection, cells were fixed and stained with antibodies toward RSV N. 
Figure 608 demonstrates that in mock infected cells, dcp1 was present in p-bodies as 
expected. In RSV-infected cells, dcp1 was in p-bodies, but was excluded from RSV 
inclusion bodies. Taken together, these results indicate that the antibody used in the 
experiment shown in Figure 60A likely recognized a component other than dcp1, and 
that dcp1 does not localize to RSV inclusion bodies. 
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Figure 60. Dcp1 distribution during RSV infection. HEp-2 cells (A) or U20S cells 
stably expressing RFP-tagged dcp1 (B) were mock infected or infected with RSV (moi = 
1, Panel A, or moi = 0.5, Panel B). 18 hours post infection, cells were fixed and stained 
for DAPI (blue) (A and B), RSV nucleoprotein (green), (A and B) and p54 (red)(A). Cells 
were examined using fluorescent microscopy. 
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3.13 Dcp1 antibody recognized RSVP protein. 
Because the antibody toward dcp1 recognized a component inside RSV inclusion 
bodies, we thought it likely that the antibody was recognizing an RSV protein, similarly to 
the p54 antibody. To determine whether this was the case, we performed an experiment 
in which HEp-2 cells were transiently transfected with vectors expressing His-tagged 
RSV N or P proteins. They were then immunoprecipitated using antibodies toward the 
His tag , and analyzed using western blot and the antibody toward dcp1 that recognized 
protein inside RSV inclusion bodies. Samples were also probed with the cross-reactive 
polyclonal antibody to p54. As shown in Figure 61 , both dcp1 and p54 were 
immunoprecipitated nonspecifically for unknown reasons. However, consistent with 
previous results, the p54 antibody recognized RSV N protein, and the antibody toward 
dcp1 recognized a protein that migrated at the same size as RSV P protein in the 
sample from cells overexpressing RSVP. These results indicate that the dcp1 antibody 
is able to recognize RSV P. 
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Figure 61. An antibody toward dcp1 recognized RSV P protein. HEp-2 cells were 
transfected with empty vector or plasm ids expressing his-tagged RSV N or his-tagged 
RSVP proteins. Twenty-four hours post transfection, cells were lysed and His-tagged 
proteins were immunoprecipitated with an antibody toward His. Sample were analyzed 
using SDS-PAGE and western blot with antibodies toward dcp1 or p54. This experiment 
was performed by Julie K. Duncan. 
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Chapter 3 Discussion 
In summary, our results demonstrated that a polyclonal antibody toward cellular p54 
cross-reacted with RSV N protein, that the two proteins share amino-acid similarity, and 
that there are two antigenically-distinct populations of RSV N protein. In addition, an 
antibody toward dcp1 recognized RSV P protein. 
A cautionary tale 
Because of our experience with two cross-reacting antibodies, we recommend that great 
care be taken when interpreting co-localization data with RSV proteins. While the 
polyclonal antibody that recognized RSV N was very specific in that it seemed to 
recognized only p54 and RSV N, the dcp1 antibody was not as clean and at times 
recognized RSVP, N, and G proteins (data not shown). It seems likely that because 
certain RSV proteins are highly expressed compared to host proteins, they have a high 
propensity for nonspecifically interacting with antibodies. This indicates that several 
methods should be employed when determining the authenticity of colocalization 
observations regarding the viral proteins. 
p54 and N similarity 
Our results demonstrating that an antibody toward p54 can recognize RSV N in a 
number of contexts suggests that they share a similar epitope. Bioinformatic analysis 
confirmed that the proteins share a sequence with similar primary amino-acid structure. 
This lends credence to the possibility that they may be structurally similar and might 
share or interfere with each others' activities. 
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Viral mimicry? 
It is possible that our results with the cross-reactive antibody toward p54 (which also 
recognizes RSV N) reveal an unfortunate artifact; however, it is possible that this 
phenomenon has significant implications for the RSV replication cycle and is not merely 
a coincidence. One possibility, mentioned earlier, is that RSV N protein mimics p54. 
The idea that a viral protein may mimic a cellular factor is not without precedent, as 
myriad examples of structural, molecular, and epitope mimicry by viruses have been 
previously described. Molecular mimicry is a phenomenon in which pathogens have 
"captured" host genes during evolution to encode proteins with primary amino-acid 
sequences and structures that are similar to cellular proteins (7, 179). Structural mimicry 
occurs when pathogens encode proteins that display no obvious amino-acid sequence 
similarity to host factors, but are structurally similar enough to their homologs that they 
can be recognized by host immune effectors, as described by Stebbins et al. (238) 
Several viruses are known to mimic host proteins. Poxviruses and herpesviruses, which 
are very large DNA viruses with between 100-200 genes, encode numerous 
homologues to cytokines, chemokines, and cytokine receptors. Herpesviruses are 
especially notorious for producing cytokine homologues (7, 19, 34, 108, 126, 160, 212, 
235, 237, 248, 268, 273) and chemokine homologues (33, 65, 66, 76, 86, 124, 127, 146, 
190, 194, 207,233,239,261, 277), most likely to either suppress the host immune 
response to viral infection or to recruit potential target cells to the site of infection. For 
example, Kaposi's sarcoma herpes virus (KSHV/HHV-8) encodes the viral protein vMIP-
3, a homologue of human CCL4, which recruits CCR4+ Th2 cells to the site of infection 
(239). Th2 cells are believed to counteract Th1-mediated control of KSHV infection. 
Poxviruses, on the other hand, specialize in producing cytokine-receptor homologues (8, 
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9, 11, 53, 71, 102, 150, 175, 189,200,209,210,227,230,240, 270), chemokine-
receptor homologues (2, 131-134, 161, 180, 192,253, 257), and cytokine- and 
chemokine-binding proteins (1 0, 36, 93, 130, 17 4, 184, 191, 228, 230) in order to 
suppress the antiviral immune response. For example, vaccinia virus encodes a protein, 
B 18R, which acts as a soluble interferon receptor capable of binding interferon-a and -[3, 
thereby disrupting antiviral immune responses (53). Specific roles for theses 
immunomodulatory proteins vary widely; however, a unifying theme is manipulating host 
immune responses to facilitate viral propagation. Smaller viruses have also been 
reported to encode cytokine homologues. HIV tat protein mimics chemokines to 
competitively displace beta-chemokine receptors CCR2 and CCR3 from binding their 
cognate chemokines (6). Of particular interest, RSV G protein mimics the chemokine 
CS3C to bind the CS3C-recptor CX3CR1 in order to induce leukocyte chemotaxis and 
facilitate infection (251 ). Several viruses have evolved mimicry mechanisms for 
manipulating other aspects of the immune system. Poxviruses, herpesviruses, 
retroviruses, paramyxoviruses and picornaviruses are reported to express homologues 
of proteins that regulate the complement system and/or homologues of proteins that bind 
complement receptors and aid in host-cell entry (reviewed by Bernet et al. (30) and 
Mastellos et al. (151 ). Some viral expression of proteins with epitopes that are similar to 
host molecules contributes to autoimmune disease. For example, dengue virus proteins 
NS1, p4M, and E are antigenically similar to epitopes on platelets, endothelial cells, and 
coagulatory molecules, and cross-reactive antibodies to the viral proteins facilitate 
autoimmune disease that contributes to the dengue virus pathogenesis (137, 141, 142). 
In addition, some studies suggest that human coronoavirus 229 may mimic myelin basic 
protein and interact with autoreactive T cells, thereby contributing to multiple sclerosis 
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(242). It is undetermined whether this mimicry benefits the virus. Other viruses mimic 
host proteins in order to manipulate cell-cycle progression and proliferation. Human 
cytomegalovirus (CMV)-encoded protein kinase UL97 has been shown to mimic 
cdc2/Cyclin-dependent kinase 1 in order to promote nuclear egress coincident with viral 
arrest of the cell cycle, as described by Hamirally et al. (1 00). Herpes simplex virus 
(HSV) VP16 has been shown to mimic the human basic leucine-zipper protein (LZIP) in 
order to associate with host cell factor (HCF) in order to control cell-cycle progression 
(87). HSV-1-encoded viral protein ICPO is a functional mimic of host E3 ubiquitin ligases 
capable of degrading the cellular DNA damage response E3 ligase RNF8, thereby 
promoting viral propagation (49). Finally, there is evidence that Hepatitis B virus (HBV) 
surface antigen (HBsAg) mimics components of the apoptotic cell clearance pathway in 
order to subvert the adaptive immune response (255). 
These examples demonstrate that viruses have evolved elegant mechanisms to coexist, 
subvert, and manipulate host defense processes. It is possible that RSV N mimics p54 
in order to interfere with one or more of its activities, including translational repression, p-
body formation , or RNP remodeling . Alternatively, perhaps RSV N mimics p54 inside 
inclusion bodies in order to recruit RNP-remodeling proteins and facilitate replication. It 
is, of course, possible that p54 is important during RSV replication in a manner that is 
independent from viral mimicry. Further studies are needed to elucidate the relationship 
between RSV biology and host protein p54. 
Two populations of N 
Our results suggest that there are two antigenically distinct populations of RSV N protein 
(Figure 49): one population that is concentrated at the periphery of inclusion bodies, and 
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another that comprises the core of inclusion bodies. In addition, while antibodies toward 
RSV proteins recognize N in all cell fractions, remarkably, the antibody toward p54 
recognized only N in the S3 fraction of the same lysates (Figure 52). 
It is possible that the two forms of N could have different post-translational modifications. 
The possibility of an alternative population of RSV N protein that may be concomitant 
with a shift from RSV transcription to replication lends credence to an exciting 
hypothesis that post-translationally-modified RSV N protein might have an epigenetic 
role in the RSV replication cycle. In eukaryotes, DNA is wound tightly around proteins 
called histones, which act to compact nucleic acid. Histone modifications can include 
lysine methylation, arginine methylation, lysine acetylation, and serine/threonine/tyrosine 
phosphorylation (96, 241, 254). The cellular machinery responsible for regulating gene 
transcription is extremely sensitive to these changes, For example, acetylation of lysine 
serves to neutralize the positive charge of the amino acid , thereby reducing the 
attraction between the histone and negatively charged DNA. This results in a loosened 
chromatin structure, which gives polymerases access to the nucleic acid. In general, 
histone acetylation is associated with active transcription , although the two are not 
obligatorily linked (120). 
Examples of post-translational modifications to viral nucleoproteins have previously been 
described. Mass-spectometry analysis showed that Ser-2 of Menangle virus (a porcine 
paramyxovirus) is acetylated during infection, although no functional role for the 
modification has been reported (221 ). Hepatitis delta virus (HDV) encodes two proteins, 
small and large delta antigens, which are involved in viral replication and assembly, 
respectively. Both viral proteins are acetylated in vivo. The small delta antigen of HDV is 
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acetylated at lysine 72 and mutation of this residue causes a cellular redistribution of the 
protein from the nucleus to the cytoplasm. This suggests that acetylation of the small 
delta antigen may be required for efficient viral RNA replication (177). 
Post-translationally modified RSV N could serve a role similar to that of histones, and 
modified N protein could be either more or less tightly associated with RSV genomic and 
antigenomic RNA during transcription and replication. Perhaps RSV replication takes 
place in the core of inclusion bodies, and packaging takes place at the periphery. Future 
studies are needed to characterize the nature and significance of the two populations of 
RSV N protein. 
Conclusions 
Our data provide evidence that RSV N protein may mimic cellular p54. It is possible that 
RSV N interferes with one or more p54 activities, such as recruiting binding factors, 
remodeling mRNP complexes, or repressing translation. In addition, our data support 
the hypothesis that there are two antigenically distinct populations of N. Future studies 
are needed to elucidate any mechanisms by which N may mimic p54, as well as to 
reveal the differences in the two N populations. 
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Overview Discussion 
Our studies indicate that RSV interacts with many aspects of host stress responses. We 
have shown that RSV blocks stress-granules from forming in the majority of infected 
cells, that RSV infection results in the alteration of a protein associated with mRNA 
degradation, and that RSV N protein shares antigenic simialrity to a protein involved in 
regulating mRNA homeostasis. These studies not only advance our understanding of 
RSV-host interactions, but also provide a launching pad to more thoroughly investigate 
how RSV and hosts intermingle to promote propagation and survival , respectively. 
Future Directions: stress-granule project 
The studies presented in Chapter 1 revealed two important findings. First, RSV has a 
mechanism for subverting stress responses. This is confirmed by a recent report by 
Fricke et al. that RSV blocks stress-granule formation by sequestering p38 and OGT in 
viral inclusion bodies (88). Second, a mutant RSV virus that induces stress granules 
during infection was correlated with impaired growth and a weak plaque phenotype. 
This lends support to a growing body of evidence that cellular stress responses may be 
linked to primordial immune responses, and that stress granules may have antiviral 
activity. 
Additional studies are needed to determine the mechanism of RSV-mediated stress-
granule subversion. Preliminary evidence suggested that an RSV minigenome 
expressing full-length RSV Tr in addition to RSV polymerase-associated proteins might 
have been sufficient to block stress granules (Figure 20). These minigenomes could be 
used to determine whether RSV Tr is involved in subverting stress responses, and 
whether RSV Tr interacts with host-cell proteins involved in stress-granule formation. 
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While stress granules are associated with stalled translation and are thought to direct 
select transcripts to p-bodies for degradation, studies are needed to determine the 
mechanisms by which stress granules may combat RSV infection. This could be 
accomplished by inducing stress-granules in cells (using heat, chemicals, or 
overexpression of G38P), and examining the effects these treatments have on RSV 
replication , mRNA and protein production, plaque phenotype, and I or cytotoxicity. 
Future Directions: dcp1 project 
The studies in chapter two focused on the relationship between RSV and p-body-
associated decapping factor dcp1, and revealed that dcp1 is phosphorylated throughout 
RSV infection via the ERK 1/2 pathway, These results are significant for several 
reasons. First, dcp1 phosphorylation has not been described for any other virus. 
Second, preliminary data (not shown) indicated that dcp1 phosphorylation is important in 
regulating cytokine responses to viral infection, revealing dcp1 as an important molecule 
in innate immune response. Third, these findings add to the increasing evidence that 
cellular RNA-processing structures and proteins are important for cellular antiviral 
responses. 
Future studies are needed to elucidate the mechanism of RSV-mediated dcp1 
phosphorylation and to determine how dcp1 phosphorylation might communicate with 
innate immune pathways. Our results suggest that dcp1 is phosphorylated very early 
during RSV infection, likely before the virus is internalized. We believe that it is probable 
that RSV mediates dcp1 phosphorylation during initial interactions between receptors on 
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the host cell membrane and the RSV F and/or G protein(s). Studies using purified F 
and/or G could help determine whether these proteins are sufficient to mediate dcp1 
phosphorylation. Alternatively, mutant RSV viruses lacking RSV For G could provide 
valuable insights into whether these proteins are necessary for the effect. 
Rzeckowski et al. demonstrated that the phosphorylation status of dcp1 could influence 
IL-1-induced IL-8 production (206), and our preliminary data suggested that cells 
overexpressing a phospho-deficient dcp1 mutant resulted in higher levels of IL-8 
production in response to RSV infection at 24 hpi than cells overexpressing wt dcp1. 
Additional studies are needed to confirm this effect and to determine whether dcp1 
phosphorylation is important for regulating other proinflammatory cytokines such as IL-6 
and/or TN F-a or other aspects of host antiviral responses such as surfactant production . 
Our results indicated that RSV-mediated dcp1 phosphorylation was part of the ERK 1/2 
pathway, however, further experiments are needed to determine whether dcp1 is a direct 
substrate for ERK 1/2. Kinase assays could be used to explore this possibility. In 
addition, studies could be conducted to determine whether dcp1 is phosphorylated 
obligatorily during ERK 1/2 activation. 
Finally, future studies are needed to determine whether dcp1 phosphorylation is 
important for decapping activities and/or binding interacting partners. As mentioned 
previously, dcp1 is an essential cofactor for the catalytically active decapping protein 
dcp2. The mutants we generated for this study are tagged with FLAG. Cells 
overexpressing wt or phospho-deficient dcp1 could be used to immunoprecipitate dcp1 
(with an antibody toward ddk or FLAG) and any bound proteins. Mass-spec analysis 
could be used to determine any differences in proteins bound by the two versions of 
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dcp1, which would indicate whether dcp1 phosphorylation is important for binding or 
recruiting interacting proteins. Decapping assays could be performed with lysates from 
mock-infected cells and RSV-infected cells to determine whether RSV-mediated dcp1 
phosphorylation is important for decapping functions. 
Future Directions: RSV N biomimicry project 
Chapter 3 discussed our investigation into RSV's relationship with cellular p54. These 
studies provide a cautionary tale against interpreting colocalization results, since two 
separate antibodies were able to recognize RSV proteins. In addition, they provide 
evidence for two antigenically-separate populations of N, and a possible role for N in 
mimicking p54. 
Future studies are needed to identify how the N populations differ. As discussed earlier, 
it is possible that the two forms of N differ in their post-translational modifications. 
lmmunoprecipitation experiments could be performed in which RSV N pulled down with 
the polyclonal antibody toward RSV could be compared to RSV N pulled down with the 
polyclonal antibody toward p54 using mass-spectometry analysis. 
Additional studies are also needed to determine whether RSV N mimics cellular p54. 
Structural analysis using bioinformatics may reveal important similarities between the 
proteins that could provide clues as to the functional significance of such similarity. 
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Overarching theme: stress responses as part of a cellular antiviral 
campaign 
While the studies discussed in Chapters 1, 2, and 3 are fairly distinct, a unifying theme is 
that viruses and eukaryotes have co-evolved to establish a complex equilibrium between 
cellular stress-response structures and proteins involved in mediating antiviral responses 
and virus strategies for evading, manipulating, and combating these responses. Stress 
granules have the potential to limit viral infection by regulating translation, RNP 
structures, and/or targeting mRNAs to p-bodies for degradation. It is therefore not 
surprising that RSV has evolved to prevent stress granules from assembling during 
infection. Similarly, p-bodies and p-body-associated proteins have obvious potential for 
interfering with virus replication by either regulating viral RNAs or by regulating factors 
such as cytokines and chemokines involved in antiviral defenses. Finally, p54, which is 
associated with both stress granules and p-bodies, is linked to translational repression, 
mRNP remodeling, and p-body assembly - all of which could be important during RSV 
replication. 
Model 
Our studies have helped to characterize the complex relationships among RSV, stress 
granules, p-bodies, and some of their associated proteins. We propose a model in 
which RSV subverts the deleterious effects of stress responses by interfering with 
stress-granule formation, possibly by Tr-region-dependent sequestration of p38, OGN, 
or other SG-associated proteins. In addition , we believe that p-body protein dcp1 is 
phosphorylated during RSV infection as part of a host-response to regulate immune 
factors and the nature of immune responses. We posit that phosphorylated dcp1 is 
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necessary for interacting with dcp2 in the decapping complex, and that the dcp1-dcp2 
complex is important for regulating mRNAs, including those that encode cytokines 
involved in combating RSV infection. Finally, we propose that RSV N protein may mimic 
p54 to interfere with stress-granule and/or p-body antiviral activities. For example, N 
may mimic p54 in order to interfere with potential p54-mediated recruitment of viral 
mRNAs top-bodies, and thereby prevent viral transcript degradation. Together, our data 
provide evidence that RSV has evolved to interact with and, in some cases, subvert, 
elements of host-cell stress responses, and establish a foundation for future studies 
regarding RSV interactions with host-cell RNA-processing structures and proteins. 
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